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Abstract 
 
Among marine organism, Porifera have proven to be a rich source of new 
metabolites. Sponge are sessile organisms, therefore lacking any physical defence 
against predators. To make up to this lack, they produce species-specific molecules, 
known as secondary metabolites, which may play a key role in interspecific 
competition, defense against predators and reproduction processes. Secondary 
metabolites of marine origins are interesting molecules, often characterised by 
complex and unusual structures, which have shown to have a broad spectrum of 
pharmacological activities, such as anti-inflammatory, antiviral, antibiotic and 
anticancer. These compounds are hence considered promising lead compounds in 
drug discovery. Recently, many marine natural products have been approved, and 
others are in clinical trials. Due to the small amount isolated from the marine source, 
the evaluation of the biological activity of these compounds is often limited. Many 
alternatives have been considered to solve this issue. The total or semi-synthesis of 
these compound represents a valide alternative to provide greater amounts of the 
metabolites of interest, allowing to gain a better insight in their biological activity. 
Currently, the number of synthetic or semi-synthetic drugs is indeed strongly 
increasing.  
This research field forms the backdrop to my PhD work, aimed to the identification 
and structural elucidation of new bioactive marine natural products and to the 
synthesis of analogues with improved biological activities. The main topic of my 
reseach activity was the total synthesis of hybrid peptide/polyketide compounds of 
marine origins. Simultaneously, I was involved in the analysis of the chemical 
II 
 
content of the Caribbean sponge Smenospongia conulosa and the Mediterranean 
sponge Geodia cydonium. 
The analysis of the lipofilic extract of the Caribbean sponge S. aurea led to the 
isolation, in 2013, of two hybrid peptide/polyketide compounds: smenamide A and 
B. Although both compounds possess a cytotoxic activity at nanomolar levels, 
smenamide A resulted more active blocking the cell proliferation through a pro-
aapoptotic mechanism. Therefore the total synthesis of smenamide A and its 
analogues was undertaken in order to provide greater amount of the compounds 
needed to confirm the structure of the compound, determine the absolute 
configuration at C-16, that remained undetermined until the end of the synthetic 
project, and to further investigate the cytotoxic activity. The total synthesis resulted 
in the preparation of 16-epi- and ent-smenamide A, two synthetic analogues of 
smenamide A. 
In order to investigate the role of the structural determining-features of smenamides 
family, eight shorter-chain analogues of the synthetic 16-epi-smenamide A have 
been designed and prepared. The evaluation of the antiproliferative activity of 16-
epi-smenamide A, together with its analogues, is now in progress. 
On the other hand, the analysis of the organic extracts of the Caribbean sponge 
Smenospongia conulosa and the Mediterranean sponge Geodia cydonium led to the 
identification of two new hybrid peptide/polyketide compounds, conulothiazole A 
and B, and an active fraction, respectively.  
The evaluation of the biological activity of conulothiazoles could not be carried out 
because of the low amount isolated from the marine source.  
As for G. cydonium active fraction, it showed an antiproliferative activity on three 
humar cancer breast cell lines (MCF-7, MDA-MB-231 and MDA-MB-468). The 
III 
 
use of LC-HRMS, LC-HRMS/MS coupled with a bioinformatic techniques, e.g. 
Molecular Networking, as a novel dereplication strategy allowed to identify most 
of the metabolites contained in this fraction. In addition, the evaluation of the 
metabolomic profiling and the cytokine levels of the three cancer cell lines after 
treatment with the active fraction showed that the latter participates in the 
modulation of several metabolites in pro- or anti-tumor processes. Further studies 
are necessary in order to understand the mechanism of action of each compound 
contained in this fraction, as well as the evaluation of the possible synergistic effect 
of a pool of compounds. 
 
 
 
  
 INTRODUCTION 
 
Since the dawn of time natural products have been used as a remedy to relieve their 
pains. The first humans nourished themselves not only with meat, but also roots, 
berries, herbs and wild fruits. By eating them, they accidentally discovered their 
healing benefits. Ancient apothecaries learned several techniques in order to 
prepare, store and make use of medicinal herbs. They used them as a panacea, only 
basing their uses on empirical evidences. 
Extremely relevant is the example of aloe species, widely described by the Greek 
physician Dioscoride, in his play De materia medica. Among the remarkable 
benefits of these plants, it is possible to cite: healing of plagues and wounds, 
protection and relief towards burns, itching and cutaneous inflammation. In 
addition, it is worth to mention nettle, also known as "green gold", which is a potent 
anti-inflammatory, stimulator of microcirculation, with antiseptic and elasticising 
properties especially when used in combination with olive oil.  
However, it is only in eighteenth century that, through the manipulation of the 
organic extracts from natural sources, scientists isolated the first chemical pure 
compounds. With the introduction of new isolation and purification techniques an 
increasing number of these compounds have been identified, prompting researchers 
to study cells and organisms from which they derive from, identifying similarities 
and differences.  
Primary metabolism is the ensemble of chemical reactions by which some 
substances, known as primary metabolites, are produced. Carbohydrates, amino 
acids, nucleic acids and fatty acids are primary metabolites. They are essential for 
cell survival. Secondary metabolites, on the other hand, regulate other functions and 
2 
 
they vary from species to species. They are part of specialised characteristics of a 
cell, and participate in interspecific competition, defense against predators and 
promotion of reproduction processes. 
Secondary metabolites are characterised by peculiar and complex structure, which 
brings about several different biological activities. 
Currently, about 42% of compounds used in therapy are natural substances or their 
derivatives. Among them, it is worth to cite some molecules with anti-inflammatory 
(e.g. acetylsalicylic acid), bronchodilator (e.g ephedrine), cardiotonic (e.g digoxin 
and digitoxin) and anticancer (e.g vincristine, vinblastine, taxol) activities. 
Therefore, modern pharmaceutical discovery programs owe much to natural 
products. Pharmaceutical companies are always looking for new drugs for the 
treatment of life-threatening diseases, in particular cancer. Despite the cancer death 
rate has significantly dropped since 1991,1 cancer still is the leading cause of death 
in 21 States. In particular, because of the increasing of drug resistance against 
common anticancer therapies, new chemotherapeutic agents are urgently required. 
Moreover, the incidence of new types of cancer, such as glioblastoma, increases 
rapidly2. In the latest 50 years, thanks to advances in technologies (in particular 
scuba diving) researchers have quickly turned their attention to the marine 
environment, thus beginning the “blue chemistry Age". Marine natural products 
(MNPs)3 are interesting molecules characterised by complex and unusual molecular 
skeletons, as well as a great structural diversity. Due to the greater genetic 
heterogeneity of marine organisms, this structural variability results in a variety of 
biological activities. 
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As reported recently,3 a wide range of molecules with cytotoxic, antimicrobial and 
antiviral activities have been isolated. Therefore, MNPs are largely recognized as 
one of the most prolific source of therapeutics. 
From a practical point of view, there are many problems concerning the isolation 
of new MNPs. The main difficulty of developing drugs from a marine source 
resides in the sustainable supply from the natural source.4 
For instance, Porifera and Tunicates, source of many bioactive compounds, are 
sessile organisms, the collection of which can only be performed by hand using 
scuba diving or with the aid of submarines equipped with robotic arms. In addition, 
the chemical composition of organic extracts can deeply vary within samples of the 
same species when collected in different places or at different moments. Moreover, 
due to the exiguous amounts of these compounds isolated from the marine source, 
the study of their biological activity is more complicated. Nevertheless, the interest 
for this kind of molecules remains high, pushing the researchers to find solutions 
for the supply. Among the alternatives, of great importance are aquaculture 
(massive growth of the organisms in a controlled area) and production of 
metabolites of interest through cell cultures. Recent studies have shown that 
secondary metabolites are often produced by the microbial symbionts of the 
sponges.5 Since the microbial fauna is largely unculturable, chemical synthesis 
represents a valid alternative. 
Organic synthesists aim to the construction of natural or designed molecules whose 
primary element is carbon with the purpose of synthetising in the laboratory natural 
products occurring from the living world.6 Organic synthesis sinks its roots in 1828, 
when German chemist Friedrich Wöhler performed the serendipitous synthesis of 
urea from ammonium isocyanate.7  
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Chemical synthesis is fundamental to provide larger quantities of the desired natural 
compound needed to further investigate its biological activity. Several to hundred 
grams are instead required for preclinical and clinical development of a drug. 
Synthesis is also extremely useful to determine the absolute stereochemistry of 
stereogenic centers when this cannot be achieved by spectroscopical tools or 
derivatization methods such as Marfey’s method.8 Moreover, synthetic analogues 
can be prepared in order to perform SAR (structure–activity relationship) studies 
aiming to improve the bioactivity and reduce the toxic side effects.  
Although most of the drugs currently approved are natural products, the number of 
synthetic or semi-synthetic drugs is increasing thanks to their production cost, time 
effectiveness and easy quality control. 
Among drugs of marine origins currently produced via synthesis, it is worth to 
mention Trabectedin (Yondelis®), a tetrahydroisoquinoline alkaloid isolated from 
the Caribbean tunicate Ecteinascidia turbinata.9 It has been approved as anti-
neoplastic drug for the treatment of soft tissue sarcoma and, in combination with 
pegylated liposomal doxorubicin, for patients with platinum-refractory ovarian 
cancer. Trabectedin is now produced synthetically. 
Ziconotide (Prialt®) is a synthetic non-opioid analgesic drug, equivalent of the 25-
amino acid peptide -conotoxin MVIIA, originally isolated from the venom of the 
marine snail Conus magus.10 It is used in symptomatic management of severe 
chronic pain in patients with cancer or AIDS, for whom intrathecal (IT) therapy is 
warranted, and who are intolerant of or refractory to treatment with morphine and 
systemic analgesics.  
Brentuximab vedotin (ADCETRIS®)11 is a cysteine-linked antibody-drug conjugate 
(ADC) in which the chimeric monoclonal anti-CD30 antibody (obtained by 
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recombinant DNA technology), is covalently linked to the monomethylauristatin E 
(MMAE). The latter is a semi-synthetic analogue of the marine cytotoxic peptide 
dolastatin-10, isolated from the mollusk Dolabella auricularia. ADCETRIS® is 
actually used in the treatment of Hodgkin’s lymphoma (HL) and systemic 
anaplastic large cell lymphoma (ALCL).  
The present research project is focused on the study of Caribbean and 
Mediterranean marine sponges in order to discover novel anticancer lead molecules 
and to design and prepare their synthetic or semi-synthetic analogues. 
More precisely, during my PhD I was involved in the study of the chemical 
composition of the organic extracts of the Caribbean sponges Smenospongia aurea 
and conulosa and the Mediterranean sponge Geodia cydonium. 
Four hybrid polyketide/peptide (PKS/NRPS) compounds have been previously 
isolated by our group from the organic extract of S. aurea.12,13 Among these 
compounds, smenamide A showed a potent cytotoxic activity at nanomolar 
concentrations on a non-small-cell lung cancer (NSCLC) cell line, known as Calu-
1. As part of my PhD project,  a strategy to prepare synthetic derivatives has been 
set up. The stereoselective total synthesis resulted in the preparation of two 
analogues of smenamide A: 16-epi- and ent-smenamide A.14 
A different approach was instead used for the study of the chemical content of the 
Mediterranean sponge G. cydonium. A bioguided fractionation of the cytotoxic 
organic extract of the sponge was performed. This procedure allowed the 
identification of one antiproliferative fraction acting with an apoptotic mechanism 
against MCF-7, MDA-MB231, and MDA-MB468 breast cancer cell lines.15 
Interestingly, no activity was observed on the normal breast cell line (MCF-10A) 
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used as control. Such a result opens up the possibility of using this fraction for 
therapeutic purposes. 
The results obtained during my PhD have been divided in two sections: 
 The main project of my research activity, which resulted in the total 
synthesis of 16-epi- and ent-smenamide A, two new hybrid PKS/NRPS 
compounds. 
 Simultaneously, I analysed the chemical composition of two marine 
sponges, S. conulosa and G. cydonium.  
 
  
7 
 
The results achieved during my Ph.D. have been reported in four publications on 
peer-rewied journals. 
 
1. A. Caso, A. Mangoni, G. Piccialli, V. Costantino, and V. Piccialli, Studies 
toward the Synthesis of Smenamide A, an Antiproliferative Metabolite from 
Smenospongia aurea: Total Synthesis of ent-Smenamide A and 16-epi-
Smenamide A, ACS Omega, 2017, 2(4), 1477–1488. Impact Factor: * 
2. G. Esposito, G. Della Sala, R. Teta, A. Caso, M.L. Bouguet-Kondracki, J.R. 
Pawlik, A. Mangoni, V. Costantino, Chlorinated thiazole containing 
polyketide-peptides from the Caribbean sponge Smenospongia conulosa: 
structure elucidation on microgram scale. Eur. J. Org. Chem. 2016, 16, 
2871–2875. Impact Factor: 2.834 (2016). 
3. S. Costantini, E. Guerriero, R. Teta, F. Capone, Caso, A. Sorice, G. 
Romano, A. Ianora, N. Ruocco, A. Budillon, V. Costantino, M. Costantini, 
Evaluating the effects of an organic extract from the mediterranean sponge 
Geodia cydonium on human breast cancer cell lines, Int J Mol Sci.,2017, 
18(10). pii: E2112. Impact Factor:3.226 (2016).  
4. A. Caso, I. Laurenzana, D. Lamorte, S. Trino, G. Esposito, V. Piccialli , and 
V. Costantino, Smenamide-A-analogues: a case-example of the application 
of the functional-analogues strategy to design and study complex natural 
lead compounds, Mar. Drugs, 2018, accepted. Impact Factor:3.503 (2016).  
 
* The first volume of this paper was published in December 2015. The value of its impact factor 
has not yet been disclosed. 
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 Chapter 1 
Structural elucidation techniques 
Before the introduction of spectroscopy, structural determination of new chemical 
compounds was carried out through degradative methods and/or derivatisation of 
functional groups. The main problem of degradative techniques is the total loss of 
the sample. As regards derivatisation methods, these can change sample 
composition, may not be quantitative or give by-products, and reduce amount of 
the analyte. Considering that natural products are often isolated in very exiguous 
amounts, these techniques are evidently unsuitable for structural elucidation of 
micrograms of compounds.  
The introduction of highly sensitive and non-degradative methodologies marks a 
turning point in the field of structural determination, allowing the elucidation of 
submilligrams samples.  
Structural elucidation of each molecule described in thesis has been accomplished 
through spectroscopic techniques, mostly NMR spectroscopy and mass 
spectrometry (MS), but also IR and CD spectroscopy. The absolute stereochemistry 
of amino acids has been established by using Marfey’s method. The specific 
rotation of each chiral compound has been determined by measuring the optical 
rotation at the sodium D line (589 nm). 
 
1.1 Nuclear Magnetic Resonance 
Nuclear Magnetic Resonance (NMR) spectroscopy is a powerful, high sensitive 
and non-destructive analytical tool used for the identification of the carbon-
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hydrogen framework of an organic compound. It allows structure elucidation, 
qualitative and quantitative analysis of single molecules or mixtures of compounds.   
NMR experiments involve the nuclei of atoms: the chemical environment of a 
specific nucleus is determined getting information about that nucleus. When the 
sample is placed in a magnetic field, it is excited by radio waves. Therefore, the 
nuclei get into nuclear magnetic resonance, and it is detected with sensitive 
detectors (Figure 1). 
 
Figure 1.1. Scheme of a NMR spectrometer. 
 
Subatomic particles (protons, neutrons and electrons) can be imagined as spinning 
around their axes. In some cases, these spins are paired against each other and the 
nucleus of the atom has no overall spin. However, in some atoms (such as 1H 
and 13C) the nucleus has an overall spin.  
The rules for determining the net spin of a nucleus are the following: 
1. If the number of neutrons and the number of protons are both even, then the 
nucleus has NO spin. 
2. If the number of neutrons plus the number of protons is odd, then the 
nucleus has a half-integer spin (i.e. 1/2, 3/2, 5/2) 
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3. If the number of neutrons and the number of protons are both odd, then the 
nucleus has an integer spin (i.e. 1, 2, 3) 
Therefore, what is important is the overall spin, I. Particularly useful isotopes 
are 1H, 13C, 19F and 31P, all of which have spin I = 1/2. 
A spinning charge generates a magnetic field (Figure 2). The resulting spin-magnet 
has a magnetic moment (μ) proportional to the spin.             
 
Figure 1.2. A spinning charged particule generate a magnetic field. 
 
Since spin I has have 2I + 1 possible orientations, a nucleus with spin 1/2 will have 
2 possible orientations. In the absence of an external magnetic field, these 
orientations are of equal energy. When a magnetic field is applied, these nuclei align 
themselves with or against the magnetic field (Bo) and the energy levels split. Each 
level is characterized by a magnetic quantum number, m (Figure 1.3).  
 
Figure 1.3. Spin energy states. 
 
In particular, irradiation with electromagnetic radiation allow the low energy state 
to flip over to the high-energy state. The difference in energy between the two spin 
states is dependent on the external magnetic field strength, and is always very 
small. The stronger is the magnetic field (Bo), the larger is the difference in energy 
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of the two energy states. For nuclei with spin 1/2 the energy difference between the 
two spin states at a given magnetic field strength is proportional to their magnetic 
moments. 
When the radiation cease, a free induction decay (FID) is produced because of the 
nuclei relaxation. The FID is transformed through the Fourier transform to give the 
peaks of the NMR spectrum. The Fourier transform is a mathematic transformation 
that allows to write a time-dependent function in the frequency domain. 
The use of mono and two-dimensional NMR experiments represented a 
fundamental tool for the structural determination of each compound described in 
this thesis. 
 
1.1.1 One-dimensional NMR experiments 
A single nucleus is analysed in a one-dimensional NMR esperiment. In a 1D NMR 
spectrum the intensity is expressed as a function of the frequency. It is a two-
dimesional chart but it is defined as one-dimensional because it involves only one 
dimension “frequency”.  
The most common one-dimensional NMR experiments concern 1H and 13C.  
As for 1H spectra, since protons all have the same magnetic moment we might 
expect no difference in their resonance signals. Fortunately, they behave differently 
in the NMR experiment. This phenomenon can be explained by electrons shelding. 
Electrons are indeed charged particles, hence they response to the external magnetic 
field (Bo) generating a secondary field. The latter, opposing to Bo, shields the 
nucleus from the applied magnetic field. Therefore, to achieve resonance and then 
absorption of rf energy, Bo must be increased. 
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Based on its chemical environment, each proton resonates at a specific chemical 
shift (expressed in parts per million, ppm). This means that it is differently located 
in the proton spectrum. 
Although the 1H NMR spectroscopy is a powerful tool in the field of structural 
determination, it can not provide information for those molecules composed by big 
portions lacking carbon-hydrogen bonds.  
13C NMR experiments can provide the missing information. It is worth noting that 
13C isotope is only 1.1% abundant and the nucleus is fifty-fold less sensitive than a 
proton in a NMR experiment. For these reasons high concentrated samples are 
required. Moreover, the spectra are complicated by the large one-bond coupling 
between and 1H. Protons bonded to a 13C atom split its NMR signals from 130 to 
270 Hz, further complicating the spectrum. The issue has been solved thanks to the 
use of the high-field pulse technology in combination with broad-
band heteronuclear decoupling of all protons. Several acquisitions are accumulated 
in each experiment in order to provide a stronger signal. Also, thanks to the 
decoupling irradiation the sensitivity of carbon nuclei bonded to protons is 
enhanced.  
 
1.1.2 Two-dimensional NMR experiments 
In addition to 1D experiments, two-dimensional experiments have been recorded 
and analysed in order to complete the resonance assignment of each molecule.  
A two-dimensional NMR spectrum is a three-dimensional chart in which two 
frequencies are expressed as function of the intensity.  
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Considering that, in a NMR experiment, frequencies derive from the Fourier 
transformation of a time-dependent function, the simultaneous acquisition of two 
temporal functions is required to obtain a 2D spectrum.  
Although the nuclei resonate in crowded regions of the spectra, a remarkably easier 
interpretation characterises 2D spectra (signals’ superimposition is much less 
frequent in two dimensions than in one). Their easier interpretation and shorter 
acquisition times make 2D experiments superior than the one-dimensionals. 
Two kinds of two-dimensional experiments can be mentioned: homonuclear and 
heteronuclear experiments. A 2D experiment is defined as homonuclear if the two 
frequencies refer to the same nucleus. Vice versa, in a heteronuclear experiment the 
correlation peaks between two different nuclei are observed. 
The COSY (Correlation SpettroscopY) experiment was the first two-dimensional 
NMR experiment invented. It is simple and still widely used today in its various 
versions (COSY, DQF-COSY, COSY-b, COSY-90). The analysis of a COSY 
spectrum provides information about homonuclear correlations of protons between 
them to 2 or 3 bonds (scalar spin-spin coupling). 
The HSQC (Heteronuclear Single Quantum Coherence)1 experiment is a 2D 
heteronuclear correlation experiment detecting correlation peaks between 13C and 
1H nuclei directly bonded each other through the direct coupling constant 1J C-H. 
The HMBC (Heteronuclear Multiple Bond Correlation)2 experiment is a long-range 
heteronuclear experiment acquired in reverse detection. In a HMBC spectrum 
correlations between 1H and 13C through two (2JCH) or three bonds (3JCH) are 
visible. This experiment allows the identification of the correlations between 
quaternary carbons (not visible in the HSQC spectrum) with protons close to them. 
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However, not all of the correlation peaks expected from the structure of a molecule 
are present in many HMBC spectra. Since 2,3JCH can very different to each other, 
the optimization of the experiment for each type of coupling is required. 
 
1.2. Methods for the determination of relative/absolute configurations 
Since most of the natural compounds have one or more chiral centers, the 
determination of their relative and absolute configuration is fundamental for their 
structural characterization. The knowledge of the stereochemistry of a molecule 
allows to trace back to its three-dimensional structure and its role in the interaction 
with the biological systems, e.g. the SAR studies of synthetic molecules which are 
designed and prepared in order to improve the drug-receptor interaction and, then, 
their biological activity in comparison with the natural lead compounds. 
The determination of the relative configuration of the chiral centers can be achieved 
evaluating NMR data such as the values of chemical shifts (δ), coupling constants 
(J) and NOE effects.  
The chemical environment of a proton influences its chemical shift, hence protons 
of two diastereomers show different values. 
Many information about the relative stereochemistry of an organic molecule can be 
obtained studying the coupling constants values (JH-H). The application of Karplus 
law The application of Karplus law allows to calculate both homonuclear, 3JH-H, 
and heteronuclear, 3JC-H constants values. These values depend on the dihedral 
angle θ between the coupled atoms.3 When θ is approximately 90°, the 3JH-H values 
are very small, about 0-1.5 Hz, whereas the values increase considerably when θ is 
between 0° or 180°. In addition, the axial-axial relationship between two protons of 
a six terms cycle (3Ja-a~ 9-13 Hz) can be distinguished in comparison with the axial-
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equatorial (3Ja-e ~ 5-8 Hz) and the equatorial-equatorial (
3Je-e ~ 2.5 Hz). As a 
consequence, the cis-trans relationship between the protons of a double bond (3Jcis 
~ 6-12 Hz, 3Jtrans ~ 14-20 Hz) can be determined. 
Moreover, the study of homonuclear couplings between neighboring protons 
(dipolar couplings) can provide further information about the relative configuration 
of a chiral center. Dipolar coupling involves nuclei which are close in space, and 
not coupled through bonds, as in scalar coupling.  
Exploiting the dipolar coupling, the spatial relationship between the substituents of 
a molecule can be established through the evaluation of the NOE effect (Nuclear 
Overhauser Enchancements)4.  
When a proton HA, nearby located to another, HB, undergo irradiation, a variation 
of the signal intensity of HB can be observed. This phenomenon is known as NOE 
effect. Generally, an increasing of the signal intensity (positive NOE) is observed 
for small organic molecules, while a decreasing is observed for macromolecules 
(negative NOE). Since the increase in intensity is small, normally the NOE is 
measured using the difference spectra (NOE difference): two spectra are recorded 
with and without irradiation. In the difference spectrum, deriving from the two 
original spectra, only the protons showing NOE effect, can be detected. 
Since this experiment involves a pair of protons at a time, nowadays it is often 
replaced by a single two-dimensional experiment, called NOESY (Nuclear 
Overhauser Effect SpectroscopY). The latter is a 2D NMR homonuclear correlation 
experiment which is able to provide information about dipolar couplings of each of 
the pairs of protons of the molecule at the same time. It shows the presence of a 
NOE effect between two protons, suggesting hence that they are close in space. 
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In addition to NOESY, the ROESY (Rotating-frame Overhauser SpectroscopY) 
experiment can be performed: it detects the ROE effect. Since the latter is related 
to dipolar coupling between nuclei, and depends on the geometric distance between 
the nuclei, it is similar to NOE. But while NOE effect can be positive or negative, 
depending on the size of the molecules, ROE effect is always positive. For this 
reason, the ROESY experiment is particularly useful in the analysis of medium-
sized molecules, which would show a NOE effect close to zero.  
 
1.3 Mass spectrometry 
Mass spectrometry (MS) is a powerful analytical technique used to identify 
unknown compounds, elucidate their structure and chemical properties, and also to 
quantify known materials within a sample.  
The principle underlying a MS experiment is the conversion of a sample into 
gaseous ions, each of which is characterised by a specific mass-to-charge ratio (m/z 
ratio) and relative abundance. The ions that arise from the ionisation process are 
then separated on the basis of their m/z ratio and revealed by a detector. 
A molecule is converted in ions losing an electron: a radical cation is formed 
(molecule ion). The latter is subjected to fragmentation giving in part molecules 
and/or neutral radicals (not detected by the instrument), and in part cations and/or 
cations radicals (fragment ions). 
The ionisation of the sample is then the key step of the whole experiment. The 
sam0ple, which can be solid, liquid or gaseous, is introduced into a vacuum 
chamber through an appropriate introduction system. The molecules may already 
exist in solution as ions, or they can undergo ionization in situ after volatilization 
or by other methods in the ion source. According to their m/z ratio, the gaseous ions 
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obtained are separated in the analyzer and collected by the detector. An electrical 
signal, proportional to the number of ions present, is generated. It is recorded as a 
function of the m/z ratio by the data processing system records and converted into 
the mass spectrum. 
As result of the experiment a graph, named as mass spectrum, is obtained in which 
is the representation of the relative abundance of the ions according to their m/z 
ratio.  
Mass spectrometry is a high sensitive tool allowing the determination of the 
molecular mass of compound and its molecular formula, even if only sub-
milligrams of the molecule are available. 
A mass spectrometer is composed by an ion source, (in which the sample is 
ionized), a mass analyser (where ions are separated on the basis of their m/z ratio) 
and a detector. Many types of ion sources, mass analysers and detectors exist. 
Hereinafter only the methods used for the realisation of this thesis work will be 
described. 
Each molecule described in this thesis have been analyzed by ESI (Electrospray 
Ionization) mass spectrometry (Figure 1.4) through an Orbitrap system. 
 
Figure 1.4. ESI mass spectrometry. 
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A solution of the sample, dissolved in a polar and volatile solvent such as H2O, 
CH3OH and CH3CN, is nebulized at atmospheric pressure inside the ionization 
chamber through a needle held at high electrical potential. 
Therefore, a spray of droplets is formed. The droplets are positively charged 
because of the presence of an electric field. Once the ions are created, it is the role 
of the “ion lens” (which consists of a capillary maintained under vacuum and in a 
negative potential) to extract ions from the source efficiently and focus them as they 
pass through the mass spectrometer accelerating them towards the analyser. 
It is worth to mention a kind of mass spectrometry known as tandem mass (MS/MS) 
spectrometry. During or after ionization, the molecules may indeed undergo 
fragmentation. If the fragmentation does not occur spontaneously, this can be 
induced letting the ions to collide with gas molecules. Since each molecule has a 
specific fragmentation pattern, the analysis of the fragments provides information 
about its the structure. In this case, a second analyzer is used to measure the mass 
of the fragments.  
In some cases, the formation of multiple-charged ions can be observed. This 
happens for molecules with high molecular weight such as proteins. The formation 
of multiple-charged ions facilitates the analysis of this kind of molecules because 
the m/z ratio of the ions is reduced, and therefore easier to measure. 
The mass spectrometer used for the experiments performed in this project was 
equipped with an Orbitrap analyzer, a new type of mass analyzer introduced by 
Makarov.5 The LTQ Orbitrap XL™ Hybrid Ion Trap-Orbitrap Mass Spectrometer 
is a Fourier Transform Mass Spectrometer (FTMS) in which the most advanced Ion 
Trap and Fourier Transform technologies are combined.  
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Figure 1.5. Ion trajectories in an Orbitrap mass spectrometer. 
 
In a Orbitrap analyzer (Figure 1.5) a central electrode, and a pair of bell-shaped 
external electrodes which surrounded it, generate electric fields in order to capture 
and confine the ions. The ions orbit around the central electrode and oscillate back 
and forth down the center axis with periodic motion. Through a Fast Fourier 
Transformation (FFT), the device receives the frequencies of these axial oscillations 
and, therefore, the m/z relations of the ions. 
 
 
1.4. Infrared Spectroscopy 
Infrared spectroscopy is a conservative analytical technique based on the interaction 
between the matter and the infrared light. The most interesting region of IR 
radiations have a wavelength range from 4000 and 400 cm-1. However, near 
(14290-4000 cm-1) and far (700-200 cm-1) infrared regions are also considered 
suitable to contribute to the determination of the structure of a molecule. 
As a consequence of the hitting of a molecule by IR radiations, an absorption of 
energy, converted in vibrational energy, is observed. Therefore, such a technique 
can be defined as a vibrational spectroscopy. 
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Molecular vibrations can be classified in fundamental and non-fundamental. Two 
kinds of fundamental vibration can essentially be observed in a molecule:  
stretching and bending vibrations. The stretching vibration involves the continuous 
change, in terms of interatomic distance, along the axis of the bond between two 
atoms. The bending vibration concerns indeed the variation of the angle between 
two bonds. Stretching vibrations can be symmetric and asymmetric, whereas four 
different bending vibrations can be observed: scissoring and rocking (in-plane 
bendings), wagging and twisting (out of the plane bendings).  
Non-fundamental vibrations appears as a consequence of fundamental vibrations. 
Generally, IR spectroscopy is not sufficient to reveal the structure of a molecule, 
but it can provide useful information to be used in combination with other 
spectroscopic data. Although the IR spectrum is characteristic of each molecule, 
certain functional groups show typical bands in specific regions of the spectrum, 
independently from the whole structure of the molecule.  
The infrared spectrum is a graph in which the absorption bands of the functional 
groups are represented as a function of the wavelength. 
 
1.5. Circular Dichroism 
Circular dichroism (CD) is the physical phenomenon whereby a chiral molecule 
can differently absorb both components, left- and right-handed, of circularly 
polarised light at a given wavelength. Circular dichroism ΔA is then the difference in 
terms of absorbance of the left (AL) and right (AR) circularly polarised light: 
ΔA = AL - AR 
CD spectroscopy is a spectroscopic technique, which measures the CD of the 
molecules over a range of wavelengths. It is widely used to determine the three-
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dimensional structure of chiral organic molecules of all types and sizes, but mostly 
of macromolecules such as proteins. Such a technique can provide information about 
absolute configurations, conformations, reaction mechanisms, etc. 
The presence of at least one chromophore in the structure of the molecule is required 
to observe a differential absorbance. If the molecule does not have a chromophore, this 
can be introduced through derivatisation methods. 
A CD spectrum is a graph in which circular dichroism (ΔA) is represented as a function 
of wavelength. A circular dichroism signal can be positive or negative.  
Since asymmetric electromagnetic radiations are used, CD spectroscopy can 
distinguish between enantiomers. The CD of pure enantiomers differs in sign, but not 
in magnitude. Any relation between the absolute configuration of an enantiomer and 
the sign of its electronic circular dichroism (ECD) can be established: CD depends on 
details of the electronic and geometric molecular structure. However, nowadays the 
ECD can be predicted through electronic structure calculations allowing the assignment 
of the absolute configuration by simply comparison of experimental and computed CD 
spectra. 
 
1.6. Marfey’s Method 
Marfey’s method6 is one of the most used analytical approaches for determining the 
regiochemistry of enantiomeric amino acid residues in natural products. This is a 
derivative method, whereby the natural compound undergo acid hydrolysis to 
deliver the amino acid residues, the configuration of which is undetermined. The 
amino acid residues are then derivatised with a chiral reactive, the 1-fluoro-2,4-
dinitrophenyl-5-L-alaninammide (L-FDAA) (Figure 1.6) and analysed by LC-MS 
analysis. The LC-MS retention times of the derivatised amino acids deriving from 
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the peptide are compared with retention times of the corresponding standards D and 
L amino acid derivatised with the same reagent. 
When the standard amino acids are commercially available, the analysis is quite 
easy and consists of the following steps: 
 Hydrolysis of the peptide with 6N HCl 
 Derivatization of hydrolysed amino acids with L-FDAA 
 Derivatization of both D and L standards amino acids with L-FDAA. If the 
steric D series standard is not commercially available, or is too expensive, the L-
aminoacid under study can be derivatised with L and D-FDAA. 
 LC/MS analysis of derivatised samples and comparison of respective 
retention times. 
  
Figure 1.6. L-FDAA structure. 
 
For non-proteinogenic amino acids, for which the corresponding commercially 
standards are not available, a modified Marfey’s method, known as "Method of 
Marfey Advanced", has been set up.7 
This method, based on the elution order of the L-FDAA-amino acids, was tested on 
a series of proteinogenic and non-proteinogenic amino acids showing that the L-
FDAA-L-amino acid is almost invariably eluted through a C18 column before its 
corresponding L-FDAA-D-enantiomer. 
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Several NMR and UV measurements allowed to understand the mechanism of 
elution of the L-FDAA-derivatised amino acids of L and D steric series through a 
C18 column. 
The more hydrophobic substituents present at the α-carbon of non-proteinogenic 
amino acids were observed to form cis or trans rearrangements with the substituent 
at the α-carbon of L-FDAA. For D-(amino acid)-L-FDAA stereoisomers essentially 
cis rearrangements have been observed. This makes them more hydrophobic and 
then strongly retained by the C18 phase. They show indeed greater retention times 
compared to the less hydrophobic L-(aminoacid)-L-FDAA stereoisomers, which 
are preferentially involved in trans type rearrangements (Figure 1.7).  
 
 
 
  
Figure 1.7. Plausible conformations of the L- and D-amminoacids derivatives during separation 
by Marfey’s method. 
 
This method, overcoming the limits of Marfey’s method, allowed to establish the 
configuration at α-carbon of unconventional amino acids. 
In conclusion, the configuration of a non-proteinogenic amino acid can be 
determined as described below: 
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 An aliquot of amino acid is derivatised with L-FDAA 
 An aliquot of amino acid is derivatised with D-FDAA 
 Analysis of the LC/MS retention times. 
 
1.7 Conclusion 
In this chapter, the main techniques used for the structural determination of the 
molecules described in my thesis have been discussed. 
Among the spectroscopic techniques, NMR and MS provided valuable data about 
the isolated and synthesised compounds. 
The determination of absolute configuration of amino acids in PK/NRP compounds 
was carried out by using Marfey’s method. 
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PART 1 
 
Total synthesis of new hybrid PKS/NRPS 
compounds, in the frame of the anticancer 
drug discovery 
 
 Chapter 2 
Total synthesis of 16-epi- and ent-smenamide A, 
two analogues of the cytotoxic smenamide A 
 
2.1 Cancer and bioactive natural products 
Cancer is a generic term to define a group of diseases involving abnormal cell 
growth. Such a disease, also know as malignant tumour or neoplasm, arises without 
obvious causes from pre-existing body cells. It has no purposeful function, and it 
has the tendency to independent and uncontrolled growth.  
Compared with benign tumours, in which the mass of abnormal tissue remains 
confined to its original location, a malignant tumour invades adjoining parts of the 
body and spreads to other organs, through the cardiovascular system and other 
channels. The latter process is known as metastasizing.  
Cancer cells are defined as abnormal because they have undergone one or more of 
the following alterations: 
 hypertrophy:  the increase in size of individual cells; 
 hyperplasia: the increase in number of the cells; 
 anaplasia: the regression of the cells towards a more primitive or 
undifferentiated type. 
Neoplasms arises from the transformation of normal cells into cancer cells through 
a multistage process which, starting as a pre-cancerous lesion, leads to a malignant 
tumour. Only in 5–10% of cases the development of tumours can be attributed to 
genetic defects,1 whereas the remaining 90–95% sink their roots in external causes, 
such as the environmental factors and lifestyle. Environmental factors do not only 
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include pollution, but every causative factor which is not genetically inherited.2 
Three categories of external factor can be cited: physical carcinogens (e.g. 
ultraviolet and ionizing radiation), chemical carcinogens [e.g. asbestos, components 
of tobacco, aflatoxin (a food contaminant), and arsenic (a drinking water 
contaminant)] and biological carcinogens (e.g. infections caused by viruses, 
bacteria, or parasites).  
In normal tissues, there is a delicate balance between the cell growth and 
proliferation and the replacing of dead or damaged cells. The body must continually 
regulate this balance to support own proper development and maintain healthy 
homeostasis of mature tissues. 
In malignant tumours the regulation of the balance is compromised: a continuous 
proliferation of cells occurs, whereas apoptosis processes fail. This phenomenon 
can be traced back to the occurrence of genetic alterations. The incidence of several 
genetic mutations causes the accumulation of many errors which can give birth to 
a cancerogenic process. Some of these mutations are hereditary, while others are 
caused by external factors. 
The genetic events underlying these mutations are essentially two: 
 activation of proto-oncogenes into oncogenes. Proto-oncogenes positively 
control the cell cycle through the regulation of cell division, apoptosis and 
differentiation. When they become oncogenes, normal cell division is 
disrupted and malignant changes occurs.  
 inactivation of tumour suppressor genes. In normal conditions, cells possess 
genes which have the ability to suppress malignant alterations (tumor 
suppressor). Mutations in these genes can trigger the carcinogenic process. 
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As for therapeutical approaches, many treatments are used in the fight against 
cancer. The choice of a specific treatment depends on the type of cancer and its 
stage of development. Among the most common anti-cancer approaches it is worth 
to cite surgery, chemotherapy, and radiotherapy. The surgery is a medical procedure 
by which a surgeon removes and/or examines the tumor mass. Radiation therapy is 
a treatment in which high doses of radiation are used in order to kill cancer cells 
and shrink tumours. Chemotherapy is indeed a treatment involving the use of drugs 
to kill the cancer. Some patients with cancer undergo only one treatment, but most 
patients have a combination of treatments such as surgery with chemotherapy 
and/or radiation therapy.  
The efficacy of chemotherapy depends on the selectivity of the drug against cancer 
cells. The greater the biological differences between healthy and tumor cells are, 
the more the effectiveness of the treatment is.  As these differences are minimal, 
there is no anticancer drug which does not cause serious toxic side effects. 
Therefore, the anticancer chemotherapy is severely limited by the drugs toxicity.  
One of the most daunting features of cancer is its biological diversity which occurs 
not only in different types of tumours but also in the same population. Moreover, 
cancer cells develop very fast cells resistance against common anticancer therapies. 
Despite this seemingly catastrophic scenario, the chances of cancer survival have 
significantly increased in the last decade thanks to the early diagnosis and the 
efficiency of the therapies currently available.  
Since cancer is a constantly evolving disease, the research of safe and effective 
chemotherapeutic agents is a formidable challenge.  
31 
 
 
In the frame of the constant anticancer research, natural products, with their unusual 
and often complex structures, have shown a broad spectrum of pharmacological 
activities. 
Among natural anticancer molecules it is worth to mention vinca alkaloids derived 
from the periwinkle plant Catharanthus roseus, also known as Vinca Rosea. The 
cytotoxic effect of this class of compounds is due to their capability to bind to 
tubulin.3 Tubulin is a cytoplasmic protein which plays a key role during cell 
division: its polymerised form constitutes the “spindle fibers”, also called 
microtubules. The formation of microtubules is a crucial step during cellular 
mitosis, because it provides cells with both the structure and flexibility needed for 
division and replication. Without microtubules, cells cannot divide. The vinca 
alkaloids mechanism exert their mechanism by blocking tubulin polymerisation and 
then the assembly of microtubules. Since the mitotic spindle can not be created, the 
cell consequently stops in metaphase during mitosis.  
The taxanes represent another class of anticancer natural products. Compared with 
vinca alkaloids, they show the opposite mechanism of action: they prevent from the 
disassembly of the microtubules and the mitotic spindle. Paclitaxel, the progenitor 
of taxanes family, was isolated for the first time from the bark of Taxus brevifolia4. 
It is a promoter of tubulin polymerisation. In particular, it bonds the tubulin which 
constitutes the microtubules, stabilising them and preventing them from 
disassembly. Therefore, a morphological alteration is created that leads the tumor 
cell to undergo apoptosis (programmed cell death mechanism). Docetaxel, the 
semi-synthetic analogue of Paclitaxel, was shown to have a slightly different 
mechanism of action. It binds to tubulin, giving rise to different-size microtubules 
in comparison with those induced by Paclitaxel. Moreover, it shows a much longer 
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residence time in the cell. Cabazitaxel is another antineoplastic drug belonging to 
taxanes family, the action of which is based on the breaking of the microtubular 
network. It binds to tubulin and facilitates its polimerisation, stabilizing at the same 
time the microtubules. This process leads to the inhibition of their disassembly, and 
consequentially to the block of both mitosis and interphase cellular functions. 
Although plants are still the main source of bioactive compounds, marine organisms 
and their symbiont microorganisms represent a new prolific source of new bioactive 
molecules.  
In 2007 trabectedin has been approved the first marine anticancer drug with the 
name of Yondelis®. Three years later, auristatin E, a semi-synthetic derivative of 
the cytotoxic marine depsipeptide dolastatin-10, was approved, in combination with 
a monoclonal antibody, for the treatment of Hodgkin's lymphoma.5,6 
Among marine organisms it is worth to cite marine sponges, from which the most 
part of the MNPs have been isolated. An example is the nucleoside analogue Ara-
C, approved since 1969 as anticancer drugs. The latter is a synthetic derivative of a 
compound isolated from the Caribbean sponge Cryptotethia crypta. Recently, 
Eribuline mesylate, a synthetic analogue of halichondrin B (isolated from the 
Japanese sponge Halichondria okadai), has been approved for the treatment of 
metastatic breast cancer.  
My thesis work perfectly matches with this wide research line aiming to the 
isolation and structural determination of new molecules to be used as lead 
compounds in the anticancer drug discovery. Several new hybrid 
peptide/polyketide compounds isolated by my research group.7,8,9 In addition, many 
synthetic analogues have been designed and prepared in order to detected the 
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pharmacophore of this class of compound and further investigate their biological 
activity.10,11 
 
2.2 Smenamides A and B, two cytotoxic secondary metabolites from the 
marine sponge Smenospongia aurea 
Marine sponges are considered one of the most productive sources of novel 
scaffolds to be used as leads in the anticancer drug research. The analysis of the 
organic extract of the Caribbean sponge S. aurea (order Dictyoceratida, family 
Thorectidae) led to the isolation of two new hybrid peptide/polyketide compounds, 
namely smenamide A and B (Figure 2.1).7 
 
Figure 2.1. Structures of smenamide A (1) and B (2). 
 
Although smenamides have no structural analogues in the field of marine natural 
products, they share some structural features with several compounds of 
cyanobacterial origin. The unusual N-methylacetamido function and the 
dolapyrrolidone terminus are typical of dolastatins-15,12 while the chlorovinyl 
moiety is common in some cyanobacterial metabolites, such as jamaicamides, 
isolated from Lyngbia majuscula.13 
Smenamides only differ in the configuration of the C-13 double bond, which was 
determined as E in smenamide A. Both compounds were shown to have a potent 
cytotoxic activity at nanomolar concentrations on the Calu-1 lung cancer cell line 
(Figure 2.2).  
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Figure 2.2. MTT assay of smenamides A and B. Evaluation by MTT assay of Calu-1 cell viability 
after 72 h of treatment with (A) compound 1 and (B) compound 2. ** P < 0.0005. 
 
In particular, smenamide A exerts its cytotoxic activity through a clear pro-
apoptotic mechanism in a dose-dependent way (Figure 2.3). 
 
 
Figure 2.3. Evaluation of pro-apoptotic activity of smenamides using the Annexin-V FITC/PI assay. 
(A) The percentage of apoptosis for cells treated for 72 h with compound 1 at 1, 10, 50, and 100 nM 
was, respectively, 4%, 4%, 40%, and 80%; the remaining cells remained viable. (B) The percentage 
of apoptosis for cells treated for 72 h with compound 2 at 1, 10, 50, and 100 nM was, respectively, 
6%, 6%, 23%, 40%; the remaining cells remained viable except at concentration of 100 nM, where 
47% of cells were necrotic. ** P < 0.0005, * P < 0.001. 
  
In lights of the promising biological activity of smenamide A, a flexible synthetic 
route was planned in order to prepare synthetic analogues aiming to confirm its 
structure, determine the configuration at C-16 -which was undetermined before the 
synthetic project was carried out- and further investigate the cytotoxic activity. 
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2.3. Towards the synthesis of smenamide A: total synthesis of 16-epi- and ent-
smenamide A 
Smenamides are two intriguing molecules belonging to the class of hybrid 
peptide/polyketide compounds. The latter are mixed biogenesis molecules, 
biosynthetically derived from amino acids and short carboxylic acids, showing 
many biological activities (antibiotic, immunosuppressive, antifungal and 
cytotoxic). The skeleton of this class of molecules consists of two main building 
blocks: a peptide and a polyketide moiety. Once the disconnection between the two 
moieties has been identified, the asymmetric total synthesis of these compounds 
can be achieved through the parallel synthesis of the two fragments and their final 
coupling. 
The total synthesis of 16-epi- and ent-smenamide A is a case-example of the 
synthetic approach to this class of compounds. 
 
2.4 Previous stereochemical studies on smenamide A 
Despite the small amount of smenamide A isolated from the natural source, it was 
nevertheless possible to determine its structure using spectrometric and one- and 
two-dimensional spectroscopic techniques. The chemical shifts of the carbon nuclei 
were obtained from the two-dimensional NMR spectra, therefore the one-
dimensional 13C NMR spectra were not recorded. 
The positive ion mode high-resolution ESI mass spectrum of smenamide A (Figure 
2.4) showed the presence of the [M + H]+ and [M + Na]+ pseudomolecular ion peaks 
at m/z 501.2508 and 523.2326, respectively. Both ions show an isotopic peak M + 
2, whose intensity is about 32%, suggesting the presence in the molecule of a 
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chlorine atom, then confirmed by the peak at m/z 487.2557 corresponding to [M-
HCl+Na]+ ion peak. 
 
Figura 2.4. High-resolution ESI mass spectrum of smenamide A. 
 
The molecular formula C28H37ClN2O4 is in perfect agreement with these data. 
The analysis of the proton spectrum (Figure 2.5) showed the presence of five 
aromatic protons (belonging to a mono-substituted benzene), three olefinic protons, 
an amino acidic -proton and five methyl signals (one O-methyl, one N-methyl, 
one acetyl methyl, one olefinic methyl, and one aliphatic methyl). 
 
 
Figura 2.5. 1H NMR spectrum of smenamide A (1) (CD3OD, 700 MHz). 
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Smenamide A possess two double bonds, whose configurations have been 
determined through the analysis of the ROESY spectrum (Figure 2.6). 
 
 
Figure 2.6. 2D ROESY spectrum of smenamide A (CD3OD, 700 MHz).  
 
The presence of the correlation peak between protons H3-14 and H-16, and the 
absence of a correlation peak between H3-14 and H-15, showed the E configuration 
of the double bond between C-13 and C-15 (Figure 2.7). At the same time, the 
presence of the correlation peak between the protons H-21 and H-19a and the 
absence of a correlation peak between H-21 and H2-22 allowed to determine as Z 
the configuration of the double bond between C-20 and C-21. 
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Figure 2.7. Main correlation peaks provided ROESY 2D NMR spectrum of smenamide A 
allowing the assignment of the configuration of the two double bonds of the molecule. 
 
Smenamide A contains two chiral centers, at C-8 and C-16. The absolute 
configuration of C-8 carbon was determined by using Marfey’s method (Figure 
2.8).14 A small amount of smenamide A (5 μg) was suspended in 300 μL of ozone-
saturated CH3OH at -78 ° C for 5 minutes.  
The sample was dried under N2 stream to remove ozone, then treated with 6N HCl 
and heated in a sealed glass tube at 180 ° C for 2 hours. The residual HCl fumes 
were removed under vacuum. The hydrolysate was then dissolved in (CH3CH2)3N 
/acetone (2: 3, 100 μL) and the solution was treated with 100 μL of 1% 1-fluoro-
2,4-dinitrophenyl-5-L-alaninamide (L-FDAA ) in CH3CN/acetone (1: 2). The vial 
was heated to 50 ° C for 1 hour. The mixture was dried, and the resulting L-FDAA-
Phe derivative was re-dissolved in CH3CN/H2O (5:95, 500 μL) for LC-MS analysis. 
An authentic L-Phe standard was treated with L-FDAA and D-FDAA, as described 
above, to give respectively the L-FDAA-L-Phe and D-FDAA-L-Phe standards used 
in the subsequent LC-MS analysis.  
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Figure 2.8. Ozonolysis, hydrolysis and detivatisation of smenamide A with L-FDAA. 
 
Marfey’s derivatives were analyzed by high-resolution LC-MS. A 5 μm Kinetex 
C18 column (50 × 2.10 mm), maintained at 25 ° C, was eluted at 200 μL min-1 with 
H2O and CH3CN, using the following elution gradient: CH3CN 5% for 3 minutes, 
from 5 to 60% CH3CN over 20 minutes and CH3CN 90% 5 minutes. The retention 
times of the L-FDAA-L-Phe and D-FDAA-L-Phe standards were determined as 
17.32 and 18.60 minutes, respectively, on the basis of the extracted-ion 
chromatograms at m/z 418.1357. The retention time (17.36 min), measured in the 
same way, of L-FDAA-Phe sample deriving from smenamide A, allowed to 
determine as L the absolute configuration of the phenylalanine residue of 
smenamide A (figure 2.9). 
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Figure 2.9. High resolution LC-MS analysis of Marfey’s derivative from smenamide A. Extracted-
ion chromatograms at m/z 418.1357 of authentic 1-fluoro-2,4-dinitrophenyl-5-alanine amide L-
phenilalanine (L-FDAA-L-Phe), authentic D-FDAA-L-Phe and L-FDAA-Phe from smenamide A. 
 
As for the absolute configuration at the C-16, the spectrometric and spectroscopic 
tools available were not sufficient to determine it. Therefore, this configuration 
remained undetermined until the end of the synthetic project. 
In conclusion, the total synthesis of smenamide A was planned to solve the problem 
of the scarce amount of natural product isolated from S. aurea, with the aim of 
deepening the knowledge about its mechanism of action, the pharmacological 
activity, the structure-activity relationships and the stereochemistry. 
 
2.5. Synthetic strategy 
2.5.1 Retrosynthetic analysis 
Smenamide A is a small but densely functionalised molecule in which a N-
methylacetamido western terminus, a chlorovinyl moiety and a pyrrolinone subunit 
are present.  
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From a retrosynthetic point of view, the molecule can be disconnected in two 
building blocks: the acid (3) and the pyrrolinone moiety (4), corresponding to the 
polyketide and to the peptide portions of the molecule, respectively (Figure 2.10).  
 
 
Figure 2.10. Retrosynthetic analysis of smenamide A 
 
Fragment 3 can be further simplified by the cleavage of the two carbon-carbon 
double bonds and the C-24/N bond, leading to the fully protected triol 5 (C-15/C-
24). The protecting groups were chosen so as that the timing of their removal 
coincided with that of the introduction of the three main functionalities of the 
molecule. The presence, in compound 5, of a methyl at position 16 suggests a 
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further disconnection between the C-20 and the C-22, revealing the aldehyde 6 (C-
15/C-20) which can be easily traced back to citronellene. As the configuration at C-
16 was unknown, the S enantiomer of citronellene was arbitrarily chosen. The 
protected bromalcohol 7 was recognized as the functionalized form of the 
remaining C-22/C-24 structural fragment. The entire carbon backbone of the 
polyketidic moiety 3 was eventually build up through two Wittig reactions, one of 
which is E-selective (generating the E C-13/C-15 double bond), and a Grignard 
reaction (generating the C-20/C-21 bond). 
As for the synthesis of the dolapyrrolidinone unit, a racemisation free approach was 
used in order to avoid the racemisation at C-8.15 It is indeed known that this 
stereogenic center is prone to racemisation.16 Fragment 4 was synthesised from 
Meldrum acid and Boc-L-phenylalanine acid. The final coupling was accomplished 
via activation of 3 as pentafluorophenyl ester (Andrus’ protocol) and its couling 
with fragment 4. 
 
2.5.2 Synthesis of the polyketide moiety 
The S enantiomer of the commercially available citronellene, was selected as the 
chiral precursor for the synthesis of the polyketide moiety (3). S-citronellene, 
suitably degraded and functionalised, provided the C15/C20 portion of the 
molecule. 
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Figure 2.11. Preparation of the fully protected triol 5. 
 
 The chemoselective epoxidation of the tri-substituted double bond, followed by an 
acid-catalyzed opening of the resulting epoxide and the subsequent benzoylation of 
the secondary alcohol function afforded benzoate 8, as a 1: 1 mixture of two 
diastereomers (82 % over three steps). The terminal double bond underwent 
dihydroxylation with OsO4 (cat.)/NMO,
17 and the resulting diol was cleaved with 
sodium periodate to give the C-15 aldehyde. The latter was reduced with sodium 
borohydride and the corresponding primary alcohol was protected with the TBDPS 
group18 affording silylether 9 (50% over four steps). Aldehyde 10 was prepared 
through removal of the benzoate under reductive conditions with lithium aluminum 
hydride and cleavage of the resulting diol. Aldehyde 10 was then reacted with 
Grignard reactive 11, previously prepared from the commercially available 
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bromoalcohol 7, affording secondary alcohol 12 as a mixture of two diastereomers 
in a 1:1 ratio (72% over three steps). The latter allowed the extension of the skeleton 
of the molecule from C-20 to C-24 the extension of the skeleton of the molecule 
from C-20 to C-24. The conversion of alcohol 12 into the corresponding benzyl 
ether, using sodium hydride, benzyl bromide and tetrabutylammonium iodide 
(TBAI) as the catalyst, resulted in the fully protected triol 5 (Figure 2.11). 
The choice of protecting groups required particular attention. A protecting group is 
introduced into a molecule to mask a functionality in order to make it inactive in 
the subsequent reactions. In this case it was necessary to choose orthogonal 
protecting groups, which can be installed or removed under different conditions, 
without interfering with each other. The selected groups are benzoyl (Bz), benzyl 
(Bn), terzbutildimethylsilyl (TBS) and terzbutildiphenylsilyl (TBDPS). 
The introduction of the N-methylacetamido function was carried out in three steps 
(Figure 2.12). The removal of the TBS group with CH3COOH/THF/H2O (3: 1: 1), 
followed by tosylation of the delivered alcohol with TsCl and treatment of tosyl 
derivative with an excess of methylamine (40% solution in water)19 afforded 
secondary amine 13. The latter was left to react with AcCl/triethylamine giving the 
desired amide (14) as a 1: 1 mixture of two rotamers (53% over four steps). The 
hydrogenolysis of the benzylether 14 (H2/Pd(OH)), followed by oxidation of the 
secondary alcohol with the TPAP(cat.)/NMO system, according to Ley’s method,20 
provided ketone 15 required for the following Wittig olefination (79% over two 
steps). 
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Figure 2.12 Installation of the N-methylacetamido function. 
 
A crucial issue of the whole synthetic plan was the installation of the Z-chlorovinyl 
function. Some synthetic procedures have been reported for the construction of that 
function in related substances,21 but relatively few methods have been described for 
the stereoselective preparation of chloroolefins. Paige et al.22 exploited the 
palladium-mediated regio- and stereospecific silylstannation of a terminal alkyne23 
to ensure the stereoselectivity of the process. Unfortunately, this strategy, although 
very elegant, resulted in a moderate yield (42%), and similar results were obtained 
by others (45−51% yields).24 Therefore, we envisioned that this approach could 
neither provide any advantage in terms of the overall efficiency of the synthesis nor 
reduce the necessity of chromatographic purifications. The Wittig olefination, on 
the other hand, has been reported as a good, easy, and efficient method to generate 
a chlorovinyl function. 21a 
Therefore, the Wittig reaction was first tested on the model compound 16 (Figure 
2.13) obtained from the catalytic oxidation of alcohol 12 under Ley’s conditions 
(90%). The phosphonium salt 17 was prepared by reaction of iodochloromethane 
and triphenylphosphine.21a 
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Figure 2.13. Installation of the chlorovinyl moiety. 
 
As reported in literature, the Wittig olefination was conducted with nBuLi as the 
base in THF at -78 °C.21c,d Despite the mass recovery was satisfactory, in addition 
to the expected chlorovinyl derivatives 18 (1: 1 mixture of geometric isomers), this 
process also afforded a large amount of product 19, with a methylene function 
instead of the chlorovinyl moiety (Figure 2.13). The use of a slightly modified 
procedure, involving the use of potassium tert-butoxide as the base,21a  in a range of 
temperature between 0 and 25 °C, led to the desired products both in the reaction 
on the model  ketone 16 (18, 76%), and the intermediate 15 (20 and 21, in a 3: 2 
ratio in favor of the desired Z isomer, 83%). It is worth highlighting that only traces 
of the by-product with the methylene function are obtained with this procedure. 
Compounds 20 and 21 were easily separated by column chromatography. The 
analysis of the data provided by the ROESY spectrum allowed the assignment of 
configuration of the double bond in each isomer.  
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Finally, the introduction of the α,β-unsaturated acid function was addressed (Figure 
2.14). The removal of the TBDPS group in compound 20 with tetrabutylammonium 
fluoride (TBAF) in THF, followed by the oxidation of alcohol 22 with 
TPAP(cat.)/NMO, afforded aldehyde 23, which was applied for  the subsequent E-
selective Wittig olefination without further purification. Thus, aldehyde 23 was 
reacted with Ph3P=CH(Me)CO2Et leading to the synthesis of the α,β-unsaturated 
ester 24, which was eventually hydrolyzed to acid 3 by treatment with hydrated 
lithium hydroxide (53% over four steps). 
 
 
Figure 2.14. Preparation of the α,β-unsaturated ester 24. 
 
2.5.3 Preparation of the peptide moiety and final coupling 
The synthesis of the pyrrolidinone portion 4 (57% overall yield) is depicted in 
Figure 2.15. The reaction of (S)-Boc-Phenylalanine with Meldrum acid, followed 
by reflux of the crude in ethyl acetate over 30 minutes, gave the Boc-protected 
tetramic acid 25. The latter was methylated according to Mitsunobu conditions,25 
and the removal of the protecting group Boc gave the desired compound 4. 
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 The optical rotation measured for this product is in perfect agreement with the 
value reported in the literature ([α]D = -62.3; lit. -63);26 this confirmed its high 
enantiomeric purity. 
 
 
Figure 2.15. Synthesis of the pyrrolidinone unit 24. 
 
Finally, the two building blocks 3 and 4 were coupled by using Andrus protocol27 
(Figure 20). The acid portion 3 was activated as pentafluorophenil ester 26 by 
reaction with C6F5OH/DCC (82%). Intermediate 26 was coupled with an excess of 
the lithium imidate, deriving by reaction from pyrrolinone 4 with nBuLi. The 
reaction proceeded smoothly, affording product 27  in 91% yield. 
 
 
49 
 
 
Figure 2.16. Final coupling. 
 
Unfortunately, the proton spectrum of 27 did not match that of natural smenamide 
A. In particular, the shape and value of the chemical shifts of H-15 vinyl proton 
signals, adjacent to the C-16 stereogenic center, were different (Figure 2.16). This 
suggested that compound 27 was the epimer at C-16 of smenamide A and, 
consequently, the natural smenamide A should possess the R configuration at C-16. 
 
 
Figure 2.17. 1H NMR spectra of 16-epi-smenamide A and natural smenamide A. 
 
At this point, in order to confirm the structure of smenamide A the synthesis of the 
ent-smenamide A was carried out (figure 2.17). Two enantiomers show the same 
NMR spectrum, therefore the proton spectra of 29 and natural smenamide A should 
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perfectly match. Starting from (R)-Boc-phenylalanine, (R)-pirrolinone 28 (47%) 
was obtained. The latter was coupled, following the Andrus method, with 
pentafluorophenilester 26 to give ent-smenamide A 29 (88%). 
 
Figure 2.18. Synthesis of ent-smenamide A. 
The comparison between the proton spectra of both compounds, which perfectly 
match, confirmed the R absolute configuration at C-16 (Figure 2.18). Furthermore, 
as expected, natural smenamide A and ent-smenamide A show specular CD spectra 
(for more details see Experimental section). 
 
Figure 2.19. 1H NMR spectra of ent-smenamide A and natural smenamide A. 
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2.6. Conclusions 
The total syntheses of ent- and 16-epi-smenamide A was accomplished with a 2.6% 
and 2.5% overall yield, respectively, in 23 steps. The total synthesis of these two 
compounds confirmed the structure of natural smenamide A, and the assignment of 
the R absolute configuration to the C-16 carbon, which remained undetermined 
before the synthetic project was carried out. The evaluation of the antiproliferative 
activity of ent- and 16-epi-smenamide A is in progress in collaboration with the 
IRCCS CROB (Scientific Institute of Hospitalization and Care- Basilicata 
Oncological Center) of Rionero in Vulture (PZ). 
 
2.7. Experimental section 
2.7.1 Generals  
All reagents and anhydrous solvents were purchased (Aldrich and Fluka) at the 
highest commercial quality and used without further purification. Where necessary, 
flame-dried and argon-charged glassware was used. Reactions were monitored by 
thin-layer chromatography carried out on precoated silica gel plates (Merck 60, 
F254, 0.25 mm thick). Merck silica gel (Kieselgel 40, particle size 0.063-0.200 mm) 
was used for column chromatography. MgSO4 was used as a drying agent for 
aqueous work-up. NMR experiments were performed on a Varian Unity Inova 
spectrometers at 400, 500 and 700 MHz spectrometers in CDCl3. Proton chemical 
shifts were referenced to the residual CHCl3 signal (7.26 ppm). 
13C-NMR chemical 
shifts were referenced to the solvent (77.0 ppm). Abbreviations for signal coupling 
are as follows: s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet, b=broad. IR 
spectra were recorded neat on Perkin Elmer spectrum 100R spectrophotometer and 
are reported in cm-1. Optical rotations were measured using a Jasco P-2000 
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polarimeter at the sodium D line. ECD spectra were recorded using a Jasco J-710 
spectropolarimeter. HRMS spectra were recorded by infusion on Thermo LTQ 
Orbitrap XL mass spectrometer equipped with an Electrospray source in the 
positive mode using MeOH as the solvent. 
 
2.7.2 Experimental procedures 
Determination of the absolute coinfiguration at C-8 of smenamide A by using 
Marfey’s method. 
 
Figure 2.20. Ozonolysis, hydrolysis and derivatization of smenamide A with l-enantiomer of 
Marfey’s reagent. 
A small amount of smenamide A (5 µg) was suspended in ozone-saturated MeOH 
(300 μL) at -78 °C for 5 min (Figure 2.20). The sample was dried under a N2 stream 
to remove ozone, then treated with 6N HCl and heated in a sealed glass tube at 180 
°C for 2 h. The residual HCl fumes were removed in vacuo. 
The hydrolysate was dissolved in Et3N/acetone (2:3, 100 µL) and the solution was 
treated with 100 µL of 1% 1-fluoro-2,4-dinitrophenyl-5-l-alaninamide (L-FDAA) 
in CH3CN/acetone (1:2). The vial was heated at 50 °C for 1 h. The mixture was 
53 
 
 
dried, and the resulting L-FDAA-Phe derivative was redissolved in CH3CN/H2O 
(5:95, 500 μL) for LC-MS analysis. An authentic L-Phe standard was treated with 
L-FDAA and D-FDAA as described above to give, respectively, the L-FDAA-L-Phe 
and D-FDAA-L-Phe standards used in the subsequent LC-MS analysis. 
Marfey’s derivatives were analyzed by LC-HRESIMS. A 5 μm Kinetex C18 
column (50 × 2.10 mm), maintained at 25 °C, was eluted at 200 μL min−1 with H2O 
and CH3CN, using a gradient elution. The gradient program was as follows: 5% 
CH3CN 3 min, 5-60% CH3CN over 20 min, 90% CH3CN 5 min. Mass spectra were 
acquired in positive ion detection mode and the data were analyzed using the suite 
of programs Xcalibur. The retention times of L-FDAA-L-Phe and D-FDAA-L-Phe 
standards were determined as 17.32 min and 18.60 min, respectively, on the basis 
of the extracted-ion chromatograms at m/z 418.1357. The retention time, measured 
in the same way for the L-FDAA-Phe sample obtained from smenamide A, was 
17.36 min, and was indicative of the L configuration of Phe residue in smenamide 
A (Figure 2.21). 
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Figure 2.21. HR-ESI-MS-HPLC analysis of Marfey’s derivative from smenamide A. Extracted-ion 
chromatograms at m/z 418.1357 of authentic 1-fluoro-2,4-dinitrophenyl-5-alanine amide L-
phenilalanine (L-FDAA-L-Phe), authentic D-FDAA-L-Phe and L-FDAA-Phe from smenamide A. 
 
Benzoate 8 
 
According to a literature procedure,28 commercially available (Sigma Aldrich, e.e. 
≥ 98.5 %) β-citronellene (10 mL, 7.6 g, 54.9 mmol) was converted into the 
corresponding 6,7-epoxide (8.44 g, 100%), a smelling colourless oil. To a flask 
containing the crude epoxide in 1,4-dioxane-H2O (34 mL, 2:1), conc. H2SO4 (3 
drops) was added. After 1h solid NaHCO3 was added portionwise until the 
effervescence cheased. The mixture was concentrated in vacuo and partitioned 
between water and EtOAc (3 x 20 mL). The organic phase was dried and evaporated 
in vacuo to give diol 30 (8.22 g, 87%) as a colourless oil. An analytically pure 
sample of this compound was obtained by chromatography over silica gel 
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(hexane/EtOAc, 7:3) for characterization. Mixture of two diastereomers, IR (neat) 
max: 3410,  2957,  2927,  2858, 1699, 1640, 1454, 1378, 1271, 1167, 1069, 995, 
911, 713 cm-1; 1H-NMR (400 MHz, CDCl3):  5.76-5.61 (2H, m, 2 x H-15), 4.97 
(2H, bd, J= 18.0, vinyl proton), 4.93, (2H, bd, J= 11.0, vinyl proton), 3.35 (2H, bt, 
J=9.2, 2 x H-20), 2.14 (2H, m, 2 x H-16), 1.89 (bs, 2 x OH), 1.204, 1.203, 1.153, 
1.147 (3H each, all s, 2 x C(CH3)2), 1.02, 1.01 (3H each, both d, J=6.7, 2 x H3-17); 
13C-NMR (100 MHz, CDCl3):  144.5, 144.3, 113.0, 112.8, 78.9, 78.5, 73.4, 73.3, 
38.0, 37.8, 33.7, 33.4, 29.4, 29.2, 26.5, 23.1, 20.6, 20.2; HRMS (ESI) m/z calcd for 
C10H20NaO2 [M+Na]+ 195.1361, found 195.1348. 
To a stirred solution of diol 30 (7.34 g, 42.6 mmol) in pyridine (20 mL), benzoyl 
chloride (0.052, 6 mL) was added. After 2.5 h water (8 mL) was added and the 
mixture stirred for 15 min in a water bath and then taken to dryness. The residue 
was taken up in CHCl3 (50 mL) and washed with a satd. aq. NaHCO3 solution and 
water. The organic phase was dried, filtered and evaporated in vacuo. Purification 
over silica gel (hexane/EtOAc, 9:1) gave benzoate 8 (11.0 g, 94%), mixture of two 
diastereomers. IR (neat) max: 3482, 2974, 2929, 1718, 1704, 1452, 1275, 1177, 
1113, 1070, 1027, 711 cm-1; 1H-NMR: (400 MHz, CDCl3):  8.07 (4H, d, J=7.1, 
ArH), 7.57 (2H, t, J=7.5, ArH), 7.46 (4H, t, J=7.6, ArH), 5.71-5.55 (2H, m, 2xH-
15), 5.12-5.02 (2H, m), 5.01-4.87 (4H, m),2.22-2.04 (2H, m), 1.94 (2H, bs, 2xOH), 
1.85-1.58 (4H, m), 1.43-1.29 (4H, m), 1.26 (12H, s, 2 x C(CH3)2), 0.96 (6H, d, 
J=6.9, H3-17); 13C-NMR (100 MHz, CDCl3):  166.63, 166.60, 144.2, 144.0, 133.0, 
130.1, 129.6, 128.4, 113.2, 112.9, 80.7, 80.3, 72.7, 37.8, 37.6, 33.0, 32.7, 27.4, 27.2, 
26.5, 25.1, 20.6, 20.0; HRMS (ESI) m/z calcd for C17H25O3 [M+H]+ 277.1798, 
found 277.1788. 
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Silylether 9 
 
To a stirred solution of benzoate 8 (7.93 g, 28.7 mmol) in acetone/water (120 mL, 
5:1) OsO4 (369 mg, 14.5 mmol, 5 mol%) was added. After 2 hours the reaction was 
quenced by addition of solid Na2S2O5 (720 mg, 2.9 mmol) and the reaction mixture 
was stirred for further 30 min. Acetone was evaporated under reduced pressure and 
the resulting aqueous suspension was extracted with EtOAc (3 x 50 mL). The 
organic phase was dried and evaporated in vacuo to give diol 31 (8.71 g) as a 
colourless oil. An analytically pure sample of this compound was obtained by 
chromatography over silica gel (CHCl3/CH3OH, 9:1) for characterization. Mixture 
of four diastereomers, IR (neat) max: 3400, 2971, 2932, 1716, 1701, 1452, 1278, 
1177, 1115, 1071, 1017, 712 cm-1; 1H-NMR: (400 MHz, CDCl3):  8.05 (4H, d, 
J=7.5, ArH), 7.57 (2H, t, J=7.8, ArH), 7.44 (4H, t, J=7.6, ArH), 5.05 (2H, m, 2xH-
20), 3.77-3.37 (6H, overlapped m’s), 2.55 (bs, OH’s), 1.26, 1.25 (6H each, both s, 
2x C(CH3)2), 0.89, 0.88, 0.863, 0.858 (3H each, d’s, J=6.7, 4 x H3-17); 13C-NMR 
(100 MHz, CDCl3): δ 167.0, 166.9, 166.76, 166.73, 133.2, 133.1, 130.02, 129.99, 
129.94, 129.91, 129.68, 129.67, 128.48, 128.47, 80.8, 80.5, 80.3, 80.2, 76.0, 75.6, 
75.3, 74.9, 72.65, 72.62, 72.5, 65.0, 64.6, 64.50, 64.46, 35.7, 35.4, 35.3, 35.1, 29.7, 
29.3, 29.2, 28.6, 27.0, 26.9, 26.8, 26.7, 26.0, 25.95, 25.88, 25.84, 25.73, 25.66, 
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25.62, 25.57, 15.5, 15.3, 14.6, 14.5; HRMS (ESI) m/z calcd for C17H26NaO5 
[M+Na]+ 333.1678, found 333.1663. 
To a stirred solution of diol 31 (8.69 g, 29.0 mmol) in acetone/water (180 mL, 5:1) 
at 0°C, sodium periodate (12.35 g, 58.0 mmol) was added. After a few minutes a 
large amount of a white solid precipitated. After 4 h the reaction mixture was 
filtered under vacuum and the precipitate was carefully washed with acetone. The 
solvent was evaporated in vacuo and the aqueous suspension was extracted with 
EtOAc (3 x 30 mL). The organic layer was dried and concentrated in vacuo to give 
aldehyde 32 as a colourless oil (5.54 g) that was applied to next step without further 
purification. 
To a stirred solution of aldehyde 32 (5.52 g, 20.0 mmol) in methanol (70 mL) at 
0°C, NaBH4 (376 mg, 9.9 mmol) was added in portions. After 1h the reaction was 
quenched by dropwise addition of CH3COOH (3.5 mL). Then, the reaction mixture 
was concentrated in vacuo, treated with a satd. aq. solution of NaHCO3 (30 mL) 
and extracted with EtOAc (3 x 30 mL). The organic phase was dried and evaporated 
under reduced pressure to to give crude 33 (5.29 g). An analytically pure sample of 
this compound was obtained by chromatography over silica gel (CHCl3/CH3OH, 
9:1) for characterization. Mixture of two diastereomers, IR (neat) max: 3400, 2972, 
2930, 1716, 1699, 1451, 1277, 1177, 1113, 1070, 1027, 711 cm-1; 1H-NMR: (400 
MHz, CDCl3):  8.07 (4H, d, J=7.1, ArH), 7.57 (2H, t, J=7.5, ArH), 7.46 (4H, t, 
J=7.6, ArH), 5.11-5.04 (2H, m, 2xH-20), 3.53-3.36 (4H, m, 2 x H2-15), 1.91-1.11 
(10H, m), 1.28 (12H, s, 2 x C(CH3)2), 0.92, 0.90 (3H each, both d, J=6.9, 2 x H3-
17); 13C-NMR (100 MHz, CDCl3):  166.8, 166.7, 133.06, 133.08, 130.0, 129.6, 
128.4, 80.7, 80.4, 72.64, 72.57, 67.9, 67.6, 35.43, 35.39, 29.7, 29.4, 26.9, 26.1, 
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25.43, 25.39, 16.7, 16.3; HRMS (ESI) m/z calcd for C16H24NaO4 [M+Na]+ 
303.1572, found 303.1561. 
To a stirred solution of alcohol 33 (5.29 g, 19.0 mmol) in DMF (19 mL) were 
sequentially added imidazole (1.56 g, 23 mmol) and tert-butyldiphenylsilyl 
chloride (6.32 g, 5.88 mL, 23 mmol), at rt. After 40 min, DMF was evaporated in 
vacuo and the residue was taken up in CHCl3 and washed with brine. The organic 
phase was dried, concentrated in vacuo and purified by chromatography over silica 
gel (hexane/EtOAc, 95:5) to give TBDPS ether 9 (7.54 g, 50% over four steps). 
Mixture two diastereomers, IR (neat) max : 3485, 2960, 2931, 2858, 1715, 1602, 
1588, 1472, 1452, 1428, 1275, 1112, 1071, 824, 806, 741, 703 cm-1; 1H-NMR: (400 
MHz, CDCl3):  8.07 (4H, d, J=7.1, ArH), 7.67-7.29 (26H, overlapped m’s, ArH), 
5.07 (2H, d, J=8.7, 2 x H-20), 3.44 (4H, m, 2 x H2-15), 2.00-1.46 (10H, m), 1.27, 
1.26 (6H each, both s, 2 x C(CH3)2), 1.00, 0.97 (9H each, both s, 2 x C(CH3)3), 0.91 
(6H, d, J=6.5, 2 x H3-17); 13C-NMR (100 MHz, CDCl3):  166.6, 135.6, 133.9, 
133.0, 130.1, 129.7, 129.5, 128.4, 127.5, 80.8, 80.6, 72.7, 68.7, 68.4, 35.7, 35.5, 
29.8, 29.6, 27.3, 27.0, 26.8, 26.7, 26.6, 26.5, 25.16, 25.11, 19.23, 19.18, 17.0, 16.6; 
HRMS (ESI) m/z calcd for C32H42NaO4Si [M+Na]+ 541.2750, found 541.2733. 
Aldehyde 10 
 
 
To a stirred solution of silyl ether 9 (7.54 g, 14.5 mmol) in dry Et2O (50 mL) at 0°C, 
LAlH4 (762 mg, 20.1 mmol) was added in portions. The mixture was allowed to 
warm to room temperature over 1h and then quenched by dropwise addition of wet 
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ethyl ether and then water. After all inorganic materials were precipitated, the solid 
was filtered and washed with EtOAc (3 x 20 mL). The organic phase was dried, 
concentrated in vacuo and purified by chromatography on silica gel (hexane 
/EtOAc, 85/15) to give diol 34 (5.71 g, 95%) as a colourless oil. Mixture of two 
diastereomers, IR (neat) max : 3412, 2958, 2931, 2858, 1472, 1461, 1428, 1388, 
1112, 1075, 702 cm-1; 1H-NMR: (400 MHz, CDCl3):  7.66 (8H, d, J=6.5, ArH), 
7.45-7.33 (12H, m, ArH), 3.57 (4H, m), 3.42 (2H, m), 1.75-1.61 (4H, m), 1.19, 1.18, 
1.14, 1.12 (3H each, all s, 2 x C(CH3)2), 0.95, 0.92 (3H each, both d, J=6.7, 2 x H3-
17), 13C-NMR (100 MHz, CDCl3):  135.6, 134.0, 129.5, 127.6, 79.1, 78.7, 73.1, 
68.9, 68.5, 35.7, 35.6, 30.4, 30.3, 29.07, 29.02, 26.9, 26.49, 26.45, 23.17, 23.15, 
19.3, 17.1, 16.8; HRMS (ESI) m/z calcd for C25H38NaO3Si [M+Na]+ 437.2488, 
found 437.2473. 
To a stirred solution of diol 34 (4.83 g, 11.6 mmol) in acetone/water 5:1 (57 mL) at 
0°C, sodium periodate (4.98 g, 23.2 mmol) was added. After a few minutes a large 
amount of a white solid precipitated. After 4 h the reaction mixture was filtrated 
under vacuum and the precipitate was carefully washed with acetone. The solvent 
was evaporated in vacuo and the aqueous suspension was extracted with EtOAc (3 
x 30 mL). The organic layer was dried and concentrated in vacuo to give aldehyde 
10 as a colourless oil (4.34 g) that was applied to the next step without further 
purification. 1H-NMR (400 MHz, CDCl3):  9.74 (1H, s, CHO), 7.66 4H, d, J=7.1, 
ArH), 7.46-7.34 (6H, m, ArH), 3.50 (2H, m, H2-15), 2.47-2.31 (2H, m, H2-19), 1.87-
1.75 (1H, m), 1.75-1.61 (1H, m), 1.55-1.43 (1H, m), 1.06 (9H, s, C(CH3)3), 0.92 
(3H, d, J=6.7, H3-17). 
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Alcohol 12 
 
To a suspension of magnesium turnings (583 mg, 24.0 mmol) in anhydrous THF 
(30 mL) a catalytic amount of iodine was added. After 10 min (3-bromopropoxy)-
tert-butyldimethylsilane (4.56 g, 4.17 mL, 18.0 mmol) in THF (20 mL) was slowly 
added at rt, under argon. During the addition, the temperature was maintained at 
30-35 °C. After the addition was completed, the reaction mixture was stirred at 
40°C for 1h. To the above solution, crude aldehyde 10 (4.34 g, 12.2 mmol) in THF 
(10 mL) was dropwise added. After the addition was completed, the reaction 
mixture was stirred for 1h at room temperature. Then, the reaction mixture was 
treated with a satd. aq. NH4Cl solution (50 mL) and extracted with EtOAc. The 
organic phase was washed with brine, dried, concentrated in vacuo and purified by 
chromatography on silica gel (hexane-EtOAc, 95:5) to give alcohol 12 (4.83 g, 75 
%) as a colourless oil. Mixture of two diastereomers, IR (neat) max: 3420, 2954, 
2930, 2858, 1472, 1464, 1428, 1389, 1256, 1111, 1007, 835, 777, 740, 702 cm-1; 
1H-NMR: (400 MHz, CDCl3):  7.70 (8H, d, J=7.0, ArH), 7.47-7.35 (12H, m, ArH), 
3.69 (4H, bt, J=5.2), 3.63-3.53 (4H, m), 3.53-3.45 (2H, m, H-20), 2.45 (2H, bs, 
2xOH), 1.77-1.54 (8H, m), 1.54-1.34 (8H, m), 1.34-1.13 (2H, m), 1.09, 0.94 (18H 
each, both s, 2 x C(CH3)3), 0.970 (3H, d, J=6.6, H3-17), 0.965 (3H, d, J=6.6, H3-
17); 13C-NMR (100 MHz, CDCl3): δ 135.6, 134.0, 129.4, 127.5, 71.73, 71.66, 68.8, 
68.7, 63.5, 35.8, 34.8, 34.7, 34.6, 34.4, 29.2, 29.15, 29.09, 29.07, 26.8, 25.9, 19.3, 
18.2, 16.9, -5.4; HRMS (ESI) m/z calcd for C31H53O3Si2 [M+H]+ 529.3528, found 
529.3506. 
 
61 
 
 
Fully protected triol 5 
 
To a stirred solution of alcohol 12 (1.93 g, 3.66 mmol) in anhydrous THF (40 mL), 
under argon, sodium hydride (60% dispersion in mineral oil, 292.8 mg, 7.32 mmol) 
was added. After stirring at reflux for 5 min, benzyl bromide (0.790 mL, 6.59 mmol) 
was added, followed by TBAI (20 mol%, 271 mg, 0.732 mmol). The reaction was 
stirred at at 50 °C for 24 h. After cooling to room temperature, the reaction mixture 
was diluted with EtOAc (50 mL) and quenched by carfeul addition of a satd. aq. 
NaHCO3 solution (50 mL). Phases were separated and the aqueous layer was 
extracted with EtOAc (2 x 50 mL). The combined organic phases were washed with 
water (50 mL) and brine (50 mL), dried, and concentrated in vacuo. Purification by 
column chromatography on silica gel (hexane-EtOAc, 95:5) gave fully protected 
triol 5 (2.05 g, 91%) as a colourless oil. Mixture of two diastereomers, IR (neat) 
max: 2955, 2929, 2858, 1472, 1473, 1463, 1428, 1388, 1255, 1112, 1095, 835, 776, 
738, 701 cm-1; 1H-NMR: (400 MHz, CDCl3):  7.67 (8H, d, J=7.3, ArH), 7.45-7.28 
(22H, m, ArH), 4.48 (4H, d, J = 3.3, OCH2Ph), 3.60 (4H, bt, J= 6.0,2 x H2-24), 3.52 
(2H, m, 2 x Ha-15), 3.45 (2H, m, 2 x Hb-15), 3.36 (2H, m, 2 x H-20), 1.71-1.10 
(18H, overlapped m’s), 1.05 (18H, s, 2 x C(CH3)3), 0.93 (6H, bd, J=6.6, 2 x H3-17), 
0.05 (12H, s, 2 x Si(CH3)2); 13C-NMR (100 MHz, CDCl3):  139.0, 135.6, 134.0, 
129.5, 128.3, 127.7, 127.5, 127.3, 79.1, 70.73, 70.68, 68.8, 63.3, 35.95, 35.91, 31.3, 
31.2, 30.0, 29.9, 28.82, 28.80, 28.61, 28.56, 26.9, 26.0, 19.3, 18.3, 16.9, -5.3; 
HRMS (ESI) m/z calcd for C38H58NaO3Si2 [M+Na]+ 641.3822, found 641.3804. 
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Amine 13 
 
To a flask containing compound 5 (2.05 g, 3.32 mmol) at rt, a premixed solution of 
AcOH/THF/H2O (3:1:1, 34 mL) was added. After 4 h the reaction was quenced 
with a satd. aq. NaHCO3 solution (20 mL) and extracted with EtOAc. The organic 
phase was washed with water, dried, filtered and concentrated in vacuo. Purification 
by column chromatography over silica gel (hexane-EtOAc, 9:1) afforded alcohol 
35 (1.52 g, 91%) as a colourless oil. Mixture of two diastereomers, IR (neat) max: 
3400, 2930, 2857, 1455, 1428, 1389, 1112, 1066, 824, 739, 701 cm-1; 1H-NMR: 
(400 MHz, CDCl3),  7.67 (8H, d, J=6.8, ArH), 7.44-7.30 (12H, m, ArH), 7.32 
(10H, m, ArH), 4.51 (2H, m, OCH2Ph), 4.47 (2H, m, OCH2Ph), 3.62 (4H, t, J=5.2, 
OCH2), 3.55-3.43 (4H, m), 3.43-3.36 (2H, m, 2 x H-20), 1.90 (2H, bs, 2 x OH), 
1.70-1.40 (16H, overlapped m’s, 8 x CH2), 1.28-1.09 (2H, m), 1.06, (18H each, s, 
2 x C(CH3)3), 0.93 (6H, bd, J=6.6, 2 x H3-17); 13C-NMR (100 MHz, CDCl3):  
138.6, 135.6, 134.0, 129.5, 128.3, 127.8, 127.6, 79.11, 79.06, 70.86, 70.82, 68.78, 
68.74, 63.1. 35.9, 35.8, 30.9, 30.7, 30.25, 30.16, 28.7, 28.5; 26.9, 19.3, 16.88, 16.83; 
HRMS (ESI) m/z calcd for C32H44NaO3Si [M+Na]+ 527.2957, found 527.2953. 
To a stirred solution of alcohol 35 (763 mg, 1.51 mmol) in dry CH2Cl2 (12 mL) at 
0 °C DMAP (111 mg, 0.906 mmol), p-toluensulfonyl chloride (345 mg, 1.81 mmol) 
and triethylamine (230.8 mg, 0. 318 mL, 1.51 mmol) were added in sequence. After 
4.5 h the suspension was diluted with Et2O (30 mL) and stirred for 30 min. Then 
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the precipitate was removed by filtration. The organic phase was washed with a 
10% CuSO4 solution (2 x 100 mL), a 10% NaHCO3 solution (2 x 100 mL) and brine 
(100 mL). The combined organic phases were dried, filtered and concentrated in 
vacuo to give tosylate 36 (946 mg) as a colourless oil. An analytically pure sample 
of this compound was obtained by chromatography over silica gel (hexane/EtOAc, 
7:3) for characterization. Mixture of two diastereomers, IR (neat) max: 2960, 2929, 
2857, 1455, 1428, 1361, 1261, 1176, 1111, 1028, 814, 740, 702, 664 cm-1; 1H-NMR: 
(400 MHz, CDCl3):  7.83 (4H, d, J =7.9, ArH), 7.74 (8H, d, J =7.9, ArH), 7.50-
7.39, 7.39-7.27 (overall 26H, m’s, ArH), 4.52 (2H, A part of an apparent AB system 
further coupled, dd, J = 11.5, 3.7, OCH2Ph), 4.43 (2H, B part of an apparent AB 
system further coupled, bd, J = 11.5,), 4.08 (4H, bd, J=5.9), 3.56 (4H, m), 3.37 (2H, 
bs, 2 x H-20), 2.45 (6H, s, 2 x CH3PhSO3-), 1.90-1.10 (18H, overlapped m’s), 1.13 
(18H, s, 2 x C(CH3)3), 0.99 (6H, d, J=6.7, 2 x H3-17); 13C-NMR (100 MHz, CDCl3): 
 144.7, 138.8, 135.7, 134.0, 133.3, 129.9, 129.6, 128.4, 127.9, 127.76, 127.70, 
78.3, 77.5, 70.92, 70.90, 70.86, 70.82, 68.8, 36.00, 35.9, 31.1, 31.0, 29.7, 29.6, 28.7, 
28.6, 27.0, 24.92, 24.88, 21.6, 19.4, 17.0; HRMS (ESI) m/z calcd for 
C39H50NaO5SSi [M+Na]+ 681.3046, found 681.3037. 
To a solution of tosylate 36 (946 mg, 1.43 mmol) in CHCl3 (22.8 mL) methylamine 
(40% solution in water, 22.8  mL) was added. The mixture was vigorously stirred 
for 2 days at room temperature and then poured into a separatory funnel. The 
organic phase was separated and the water phase was extracted with CHCl3 (2 x 50 
mL). The combined organic phases were dried and concentrated in vacuo. 
Purification by silica gel chromatography (CHCl3/CH3OH, 8:2) gave amine 13 (562 
mg, 72% over two steps) as a colourless oil. Mixture of two diastereomers, IR (neat) 
max: 2959, 2928, 2855, 1456, 1428, 1261, 1112, 800, 740, 702, 667 cm-1; 1H-NMR 
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(400 MHz, CDCl3):  7.68 (8H, d, J =7.8, ArH), 7.45-7.35 (12H, m, ArH), 7.33 
(10H, m, ArH), 4.51 (2H, apparent dd, J=11.5, 4.7, OCH2Ph), 4.49 (2H, apparent 
dd, J=11.5, 1.9, OCH2Ph), 3.56-3.43 (4H, m, OCH2TBDPS), 3.37 (2H, bs, 2 x H-
20), 2.58 (4H, bs, 2 x H2-24), 2.43 (6H, s, 2 x H3-27), 1.71-1.08 (18H, overlapped 
m’s), 1.07 (18H, s, 2 x C(CH3)3), 0.94 (6H, d, J=6.5, 2 x H3-17); 13C-NMR (100 
MHz, CDCl3):  138.9, 135.5, 134.0, 129.4, 128.2, 127.7, 127.5, 127.3, 79.0, 70.8, 
70.7, 68.8, 52.1, 36.3, 35.9, 35.8, 31.45, 31.36, 31.1, 31.0, 28.7, 28.6, 26.8, 25.6, 
25.5, 19.2, 16.8; HRMS (ESI) m/z calcd for C33H48NO2Si [M+H]+ 518.3449, found 
518.3434. 
Amide 14 
 
To a stirred solution of amine 13 (526 mg, 1.02 mmol) in CH2Cl2 (3.5 mL) at 0 °C, 
excess Et3N (0.720 mL, 5.15 mmol) was added, followed by dropwise addition of 
acetyl chloride (160 mg, 0.15 mL, 2.04 mmol). After 30 min the reaction mixture 
was diluted with CH2Cl2 and a few drops of water were added. The reaction mixture 
was washed with a satd. aq. NaHCO3 solution and brine. The combined organic 
phases were dried and concentrated in vacuo to give amide 14 (511.7 mg, 90 %) as 
a colourless oil. An analytically pure sample of this compound was obtained by 
chromatography over silica gel (CHCl3/CH3OH, 95:5) for characterization. Mixture 
of two diastereomers, IR (neat) max2955, 2925, 2858, 1632, 1465, 1455, 1261, 
1112, 803, 739, 701 cm-1; 1H-NMR (400 MHz, CDCl3, mixture of rotamers):  7.67 
(8H, d, J=7.1, ArH), 7.46-7.23 (12H, m, ArH), 4.58-4.39 (4H, m, OCH2Ph), 3.57-
3.43 (m), 3.42-3.32 (m), 3.23 (2H, t, J=7.1, H2-24), 2.93 (1.5 H, s, H3-27), 2.89 (1.5 
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H, s, H3-27), 2.06 (1.5 H, s, H3-26), 2.05 (1.5 H, s, H3-26), 1.74-0.98 (18H, 
overlapped m’s), 1.07 (18H, s, 2 x C(CH3)3), 0.94 (6H, bd, J=6.4, 2 x H3-17); 13C-
NMR (100 MHz, CDCl3):  170.3, 138.9, 138.6, 135.5, 133.93, 133.88, 129.45, 
129.41, 128.3, 128.2, 127.6, 127.5, 127.3, 78.89, 78.87, 78.68, 78.62, 70.92, 70.86, 
70.82, 68.73, 68.67, 68.65, 50.8, 47.3, 35.87, 35.85, 35.81, 35.77, 33.0, 31.2, 31.1, 
31.0, 30.9, 30.81, 30.78, 30.69, 28.70, 28.66, 28.58, 28.56, 26.8, 24.15, 24.11, 23.0, 
22.9, 21.8, 21.2, 19.2, 16.8; HRMS (ESI) m/z calcd for C35H49NNaO3Si [M+Na]+ 
582.3379, found 582.3369. 
Alcohol 37 
 
Amide 14 (511 mg, 0.91 mmol) and Pd(OH)2/C (274 mg 20% w/w) were suspended 
in EtOH (14 mL). The mixture was hydrogenated at atmospheric pressure for 2 
days. Then, the reaction mixture was filtered over celite and the filtrate was dried 
under reduced pressure to give alcohol 37 (371 mg, 87%) a a colourless oil. An 
analytically pure sample of this compound was obtained by chromatography over 
silica gel (CHCl3/CH3OH, 98:2) for characterization. Mixture of two diastereomers, 
IR (neat) max: 3416, 2931, 2858, 1631, 1472, 1456, 1428, 1261, 1112, 824, 741, 
703 cm-1; 1H-NMR (400 MHz, CDCl3, mixture of rotamers):  7.66 (8H, d, J=6.9, 
ArH), 7.46-7.31 (12H, m, ArH), 3.59-3.39 (6H, m, 2x H-20 and 2 x H2-15), 3.25 
(4H, bt, J=7.6, 2 x H2-24), 2.95 (1.5H, s, H3-27), 2.89 (1.5H, s, H3-27), 2.07 (1.5H, 
s, H3-26), 2.04 (1.5H, s, H3-26), 1.80-1.08 (18H, overlapped multiplets, 8 x CH2 
and 2 x CH), 1.05 (18H, s, 2 x C(CH3)3), 0.92 (3H, d, J=6.4, H3-16), 0.91 (3H, d, J 
= 6.4, H3-17); 13C-NMR (100 MHz, CDCl3):  170.6, 170.4, 135.5, 133.95, 133.90, 
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129.5, 129.4, 127.5, 71.7, 71.6, 71.5, 68.8, 68.7, 68.6, 50.8, 47.4, 36.0, 35.73, 35.68, 
35.6, 35.0, 34.1, 33.9, 33.8, 33.1, 29.07, 29.02, 26.8, 24.55, 24.50, 23.46, 23.43, 
21.8, 21.2, 19.2, 16.85, 16.79, 16.76; HRMS (ESI) m/z calcd for C28H44NO3Si 
[M+H]+ 470.3085, found 470.3067. 
Ketone 15 
 
To a stirred solution of alcohol 37 (368 mg, 0.79 mmol) in CH2Cl2 (55 mL), N-
methylmorpholine-N-oxide (138 mg, 1.18 mmol) and powdered 4Å molecular 
sieves (392 mg) were added under argon. After 10 min TPAP (13.8 mg, 0.039 mmol, 
5 mol %) was added. After 2.5 h, the reaction mixture was filtered through a short 
silica gel plug (CHCl3/EtOAc, 8:2) and the filtrate was concentrated under reduced 
pressure. Purification by column chromatography over silica gel (hexane-EtOAc, 
6:4) afforded ketone 15 (335 mg, 91%) as a colourless oil. [α]D 20 =+2.7 (c=1.0, 
CHCl3); IR (neat) max: 2958, 2924, 2854, 1715, 1651, 1462, 1367, 1261, 1111, 800, 
704 cm-1; 1H-NMR (400 MHz, CDCl3, mixture of rotamers):  7.65 (8H, d, J=7.2, 
ArH), 7.46-7.33 (12H, m, ArH), 3.52-3.40 (4H, m, 2 x H2-15), 3.34 (0.6 H, t, J=7.1, 
H2-24), 3.24 (0.4 H, t, J=7.4, H2-24), 2.96 (1.8 H, s, H3-27), 2.90 (1.2 H, s, H3-27), 
2.48-2.28 (8H, m, H2-22 and H2-19), 2.08 (1.2 H, s, H3-26), 2.05 (1.8 H, s, H3-26), 
1.86-1.20 (18H, overlapped multiplets, 8 x CH2 and 2 x CH), 1.05 (18H, s, 2 x 
C(CH3)3), 0.90 (6H, bd, J = 6.5, 2 x H3-17); 13C-NMR (100 MHz, CDCl3):  210.5, 
209.7, 170.6, 170.4, 135.5, 133.8, 129.51, 129.48, 127.5, 68.43, 68.39, 49.8, 46.6, 
40.5, 40.4, 39.5, 38.6, 35.8, 35.2, 33.0, 27.1, 27.0, 26.8, 21.9, 21.7, 21.1, 19.2, 
16.6HRMS (ESI) m/z calcd for C28H42NO3Si [M+H]+ 468.2928, found 468.2913. 
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Ketone 16 
 
To a stirred solution of alcohol 12 (102.3 mg, 0.194 mmol) in CH2Cl2 (0.5 mL) N-
methylmorpholine-N-oxide (34 mg, 0.291 mmol) and powdered 4 Å molecular 
sieves (94 mg) were added under argon. After 10 min stirring, TPAP (3.4 mg, 0.0097 
mmol, 5 mol %) was added. After 2.5 hours, the reaction mixture was filtered 
through a short silica gel plug eluting with CH2Cl2/EtOAc (8:2) and concentrated 
in vacuo. Purification by preparative TLC (hexane-EtOAc, 8:2) afforded ketone 16 
(91.8 mg, 90%) as a colourless oil. [α]D 20 = –1.8 (c=1.0, CHCl3); IR (neat) max: 
2957, 2930, 2858, 1717, 1472, 1464, 1428, 1389, 1257, 1112, 836, 777, 740, 702 
cm-1; 1H-NMR (400 MHz, CDCl3):  7.68 (8H, d, J=6.6, ArH), 7.47-7.36 (12H, m, 
ArH), 3.63 (4H, bt, J=6.3), 3.51 (4H, m), 2.47 (2H, t, J=7.3), 2.41 (2H, m), 1.08 
(9H, s, C(CH3)3), 0.94 (3H, d, J=6.7, H3-17), 0.91 (9H, s, C(CH3)3), 0.06 (6H, s, 
Si(CH3)2);  13C-NMR (100 MHz, CDCl3):  211.0, 135.6, 133.8, 129.5, 127.6, 68.5, 
62.2, 40.5, 38.9, 35.3, 27.2, 26.86, 26.82, 25.9, 19.3, 18.3, 16.7, -5.4; HRMS (ESI) 
m/z calcd for C31H51O3Si2 [M+H]+ 527.3371, found 527.3379. 
Phosphonium salt 17 
 
(Chloromethyl)triphenylphosphonium iodide 17 was prepared by a modification of 
the reported procedure,21 starting from triphenylphosphine (31.44 g, 120 mmol) and 
chloroiodomethane (25 g, 10.3 mL, 142 mmol). In particular, the Widmer condenser 
was replaced by a double jacketed condenser. After 4h the process was stopped by 
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filtering the reaction mixture under argon to give compound 17 (14.23 g, 27%) as a 
light yellow powder. This compound could be stored in a dessiccator without 
decomposition for several months. Crystallization from ethanol gave 12.55 g (24%) 
of 17 as white crystals. Mp 186-187 (dec.) [lit. 185-187 (dec.)2]; 1H-NMR: (400 
MHz, DMSO-d6)  8.01-7.75 (15H, m, ArH), 6.08 (2H, d, J=6.8); 13C-NMR (100 
MHz, DMSO-d6):  135.6, 134.0 (d, J=10.2), 130.3 (d, J=12.6), 116.1 (d, J=88.2), 
32.0 (d, J=55.4). 
Wittig reaction on model ketone 16 using nBuLi as the base 
 
To a stirred suspension of (chloromethyl)triphenylphosphonium iodide (338 mg, 
0.772 mmol) in THF (10 mL), at -78°C, under argon, nBuLi (0.362 mL, 0.579 
mmol, 1.0 M sol. in hexane) was added dropwise. The white suspension became a 
red-orange solution. After one hour at -78°C, a solution of ketone 16 (101.4 mg, 
0.193 mmol) in dry THF (1.3 mL) was added via cannula, and the mixture was 
allowed to reach room temperature. After 2h the reaction was quenched with a satd. 
aq. NH4Cl solution (10 mL) and extracted with EtOAc (3 x 15 mL). The organic 
phase was washed with brine, dried and evaporated under reduced pressure to give 
a mixture of compounds 18 and 19 (171.5 mg, 18:19, 1:1, 1H-NMR analysis), as a 
colourless oil. 
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Wittig reaction on model ketone 16 using tert-BuOK as the base 
To a stirred suspension of (chloromethyl)triphenylphosphonium iodide (137 mg, 
0.31 mmol) in THF (3.5 mL), at 0°C, under argon, tert-BuOK (0.314 mL, 0.314 
mmol, 1.0 M sol. in THF) was added dropwise.21 The solution became immediately 
yellow. After 30 min at 0°C, a solution of ketone 16 (82.8 mg, 0.157 mmol) in dry 
THF (1.0 mL plus 0.2 mL rinse) was added and the mixture was allowed to reach 
room temperature. After 4h, the reaction was quenched with a satd. aq. NH4Cl 
solution (10 mL) and extracted with Et2O (3 x 15 mL). The organic phase was 
washed with brine, dried and evaporated under reduced pressure. Purification by 
preparative TLC (hexane/EtOAc, 8:2) gave compounds 18 (66.5 mg, 76%, 1.8:1 
mixture of diastereomers, 1H-NMR analysis), as a colourless oil. 1H-NMR (400 
MHz, CDCl3): mixture of two diastereomers,  7.72 -7.27 (ArH), 5.78, 5.74 (both 
s, vinyl proton), 3.63 -3.55, 3.52-3.45 (both m, 2 x OCH2), 2.29-2.04 (m, H2-19 and 
H2-22), 1.71-1.51 (m), 1.06, 0.89 (both s, 2 x C(CH3)3), 0.041 (m, (CH3)2Si); HRMS 
(ESI) m/z calcd for 559.3189 [M+H]+, found 559.3178. 
Chlorovinyl derivative 20 
 
 
To a stirred suspension of (chloromethyl)triphenylphosphonium iodide (128 mg, 
0.292 mmol) in THF (5 mL), at 0°C, under argon, tert-BuOK (0.281 mL, 0.7281 
mmol, 1.0 M sol. in THF) was added dropwise.21 The solution became immediately 
yellow. After 30 min at 0°C, a solution of ketone 15 (45.5 mg, 0.097 mmol) in dry 
THF (1.0 mL plus 1.0 mL rinse) was added and the mixture was allowed to reach 
room temperature. After 4h, the reaction was quenched with a satd. aq. NH4Cl 
solution (10 mL) and extracted with Et2O (3 x 20 mL). The organic phase was 
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washed with brine, dried and evaporated under reduced pressure. Separation by 
column chromatography over silica gel (hexane-EtOAc, 8:2) gave compounds 20 
(19.6 mg, 40.4%) and 21 (20.5 mg, 42.3%) as colourless oils. Compound 20. [α]D 
20 = –1.6 (c= 0.23, CHCl3); IR (neat) max: 2955, 2930, 2858, 1652, 1428, 1112, 
824, 798, 741, 703 cm-1; 1H-NMR: (400 MHz, CDCl3, mixture of rotamers):  7.65 
(4H, d, J=6.9, ArH), 7.45-7.34 (6H, m, ArH), 5.81 (0.5H, s, vinyl proton), 5.75 
(0.5H, s, vinyl proton), 3.48 (2H, bt, J=5.6, H2-15), 3.37, 3.25 (1H each, both t, 
J=7.6, H2-24), 2.97 (1.5H, s, H3-27), 2.90 (1.5H, s, H3-27), 2.24-2.13 (2H, m), 2.13-
1.95 (5H, overlapped signals including a singlet at 2.07 for H3-26), 1.77-1.53 (4H, 
m), 1.34-1.13 (1H, m), 1.06 (9H, s, C(CH3)3), 0.91 (3H, d, J=6.6, H3-17); 13C-NMR 
(100 MHz, CDCl3):  170.4, 170.3, 142.1, 141.4, 135.6, 133.89, 133.81, 129.59, 
129.54, 127.6, 113.0, 112.3, 68.5, 68.4, 50.5, 47.1, 36.0, 35.2, 33.1, 32.25, 32.22, 
31.05, 30.99, 27.5, 27.3, 26.9, 25.8, 24.7, 21.9, 21.2, 19.3, 16.6; HRMS (ESI) m/z 
calcd for C29H42ClNNaO2Si [M+Na]+ 522.2566, found 522.2541. Compound 21. 
[α]D20 = –1.4 (c=0.6, CHCl3); IR (neat) max: 2958, 2931, 2858, 1627, 1428, 1112, 
823, 802, 742, 703 cm-1; 1H-NMR (400 MHz, CDCl3): mixture of rotamers,  7.66 
(4H, d, J=7.5, ArH), 7.45-7.34 (6H, m, ArH), 5.80 (1H, s, vinyl proton), 3.50 (2H, 
m, H2-15), 3.32 (0.6 H, t, J=7.7, H2-24), 3.21 (0.4 H, t, J=7.7, H2-24), 2.94 (1.8 H, 
s, H3-27), 2.89 (1.2 H, s, H3-27), 2.21 (2H, m), 2.10-2.02 (5H, overlapped signals 
including a singlet at 2.06 for H3-26), 1.77-1.56 (4H, m), 1.31-1.15 (1H, m), 1.05 
(9H, s, C(CH3)3), 0.95 (3H, d, J=6.6, H3-17); 13C-NMR (100 MHz, CDCl3):  170.4, 
170.3, 142.05, 141.5, 135.6, 134.0, 133.9, 129.5, 127.6, 112.9, 112.3, 68.6, 68.5, 
50.2, 47.2, 36.1, 35.7, 33.1, 32.0, 31.7, 30.3, 27.7, 27.5, 26.9, 26.2, 25.2, 21.9, 21.2, 
19.3, 16.6; HRMS (ESI) m/z calcd for C29H42ClNNaO2Si [M+Na]+ 522.2566, found 
522.2562. 
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Alcohol 22 
 
To a solution of 20 (47.2 mg, 0.094 mmol) in THF (6.7 mL), TBAF (0.142 mL, 
0.142 mmol, 1.0 M solution in THF) was added dropwise, at 0°C. The reaction 
mixture was allowed to reach room temperature and stirred for 1h. Then, the 
reaction was quenced with a satd. aq. solution of NH4Cl (2 mL). The phases were 
separated and the aqueous layer was extracted with EtOAc (3 x 20 mL). The 
combined organic phases were dried and evaporated in vacuo. Purification by 
column chromathography over silica gel (CHCl3/CH3OH, 99:1) gave alcohol 22 
(21.4 mg, 87%) as colourless oil. [α]D20 = –63.4 (c=1.5, CHCl3); IR (neat) max: 
3410, 2953, 2927, 2858, 1634, 1489, 1456, 1404, 1046, 795 cm-1; 1H-NMR: (400 
MHz, CDCl3, mixture of rotamers):  5.86 (0.4H, s, vinyl proton), 5.82 (0.6H, s, 
vinyl proton), 3.46 (2H, t, J=5.3), 3.42-3.24 (2H, m’s), 2.99 (1.8 H, s, H3-27), 2.89 
(1.2 H, s, H3-27), 2.27-2.02 (7H, overlapped signals including two singlets at 2.09 
and 2.07 for H3-26), 1.78-1.52 (4H, m), 1.30-1.15 (1H, m), 0.93, 0.91 (overall 3H, 
overlapped d’s, both J=6.0, H3-17); 13C-NMR (100 MHz, CDCl3):  170.6, 170.4, 
142.0, 141.3, 113.2, 112.6, 67.8, 67.7, 50.5, 47.3, 36.1, 35.2, 33.2, 32.3, 32.2, 31.1, 
31.0, 27.4, 27.3, 25.8, 24.6, 21.9, 21.2, 16.44, 16.38; HRMS (ESI) m/z calcd for 
C13H25ClNO2 [M+H]+ 262.1568, found 262.1564. 
Aldehyde 23 
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To a stirred solution of alcohol 22 (16.2 mg, 0.062 mmol) in CH2Cl2 (0.3 mL) N-
methylmorpholine-N-oxide (10.87 mg, 0.093 mmol) and powdered 4 Å molecular 
sieves (31 mg) were added under argon. After 10 min, TPAP (1.1 mg, 0.003 mmol, 
5 mol %) was added. After 2 h the reaction mixture was filtrated through a short 
silica gel plug eluting with CHCl3/EtOAc (8:2) and concentrated under reduced 
pressure to yield aldehyde 23 (13.7 mg) as a colourless oil, that was applied to the 
next step without further purification. 
Ethyl ester 24 
 
To a stirred solution of the aldehyde 23 (13.7, 0.053 mmol) in anhydrous toluene 
(0.4 mL), at 80° C, under argon, (carboethoxyethylidene)triphenylphosphorane 
(40.8 mg, 0.106 mmol) was added all at once. After 6 h, the reaction mixture was 
concentrated under reduced pressure. Purification by column chromatography over 
silica gel (CHCl3/CH3OH, 95:5) afforded ethyl ester 24 (16.3 mg, 76% over two 
steps) as a colorless oil. [α]D20 = +127.4 (c=0.5, CHCl3); IR (neat) max: 2957, 2927, 
2858, 1707, 1651, 1596, 1459, 1424, 1373, 1262, 1122 cm-1; 1H-NMR (400 MHz, 
CDCl3, mixture of rotamers):  6.49 (1H, d, J=10.1, H-15), 5.82 (0.5H, s, vinyl 
proton), 5.76 (0.5H, s, vinyl proton), 4.18 (2H, q, J=7.0, OCH2CH3), 3.37, 3.27 (1H 
each, both t, J=7.6, H2-24), 2.99 (1.5H, s, H3-27), 2.91 (1.5H, s, H3-27), 2.46 (1H, 
m, H-16), 2.18 (2H, m), 2.09 (1.5H, s, H3-26), 2.08 (1.5H, s, H3-26), 2.01 (2H, t, 
J=8.6), 1.83 (1.5H, d, J=1.2, H3-14), 1.82 (1.5H, d, J=1.2, H3-14), 1.30 (3H, t, J=7.0, 
OCH2CH3), 1.02 (1.5H, d, J=6.6, H3-17), 1.00 (1.5H, d, J=6.6, H3-17); 13C-NMR 
(100 MHz, CDCl3)  170.5, 170.3, 168.3, 168.2, 146.9, 146.6, 141.6, 140.8, 132.1, 
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132.0, 131.94, 131.91, 128.5, 128.4, 127.2, 127.0, 113.4, 112.7, 60.6, 60.5, 50.4, 
47.1, 36.0, 34.7, 34.6, 33.1, 32.7, 27.4, 27.3, 25.7, 24.6, 21.9, 21.3, 20.01, 19.98, 
14.3, 12.63, 12.61; HRMS (ESI) m/z calcd for C18H30ClNNaO3 [M+Na]+ 366.1812, 
found 366.1802. 
Pentafluorophenyl ester 26. 
 
To a solution of 3 (4.5 mg, 0.014 mmol) in EtOAc (0.130 mL), at 0°C, 
pentafluorophenol (4.0 mg, 0.022 mmol) and DCC (4.5 mg, 0.22 mmol) were 
added. The reaction mixture was stirred for 1 hour at 0°C and 3h at rt, and 
evaporated under reduced pressure. Purification by preparative TLC 
(CHCl3/CH3OH, 95:5) gave pentafluorophenyl ester 26 (5.5 mg, 82%) as a 
colourless oil. IR (neat) max: 2962, 2917, 2949, 1683, 1626, 1521, 1261, 
1096,1022, 801, 760 cm-1; 1H-NMR: (400 MHz, CDCl3, mixture of rotamers):  
6.85 (1H, d, J=10.1, H-15), 5.86 (0.5H, s, vinyl proton), 5.80 (0.5H, s, vinyl proton), 
3.39, 3.29 (1H each, both t, J=7.7, H2-24), 3.00 (1.5H, s, H3-27), 2.92 (1.5H, s, H3-
27), 2.58 (1H, m, H-16), 2.20 (2H, m), 2.09 (1.5H, s, H3-26), 2.08 (1.5H, s, H3-26), 
2.07 (2H, t, J=8.5), 1.97 (1.5H, d, J=1.2, H3-14), 1.96 (1.5H, d, J=1.2, H3-14), 1.10 
(1.5H, d, J=6.8, H3-17), 1.08 (1.5H, d, J=6.8, H3-17); 13C-NMR (100 MHz, CDCl3): 
 152.4, 152.0, 141.3, 140.6, 124.4, 124.2, 113.7, 113.0, 50.4, 49.1, 47.1, 36.0, 34.5, 
34.4, 33.9, 33.3, 33.1, 32.74, 32.68, 27.31, 27.29, 25.8, 25.6, 24.9, 24.6, 21.9, 21.3, 
19.67, 19.64, 12.7; HRMS (ESI) m/z calcd for C22H26ClF5NO3 [M+H]+ 482.1516, 
found 482.1499. 
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Pyrrolinone 25 
 
To a stirred solution of Meldrum’s acid (1.60 g, 11.1 mmol) and DMAP (1.57 g, 
12.9 mmol) in CH2Cl2 (60 mL), at 0° C, Boc-(L)-Phe-OH (2.44 g, 9.21 mmol) was 
added followed by EDC·HCl (1.76 g, 11.1 mmol). The yellow mixture was stirred 
overnight at rt, then poured into EtOAc (200 mL) and sequentially washed with 
brine (2 x 100 mL), 5% citric acid solution (3 x 300 mL) and again brine (1 x 300 
mL). The organic phase was refluxed for 1 h. and evaporated under reduced 
pressure to gave compound 25 (2.69 g) that was applied to the next step without 
further purification. 
Pyrrolinone 4 
 
To a stirred solution of pyrrolinone 25 (1.0 g, 3.46 mmol) and triphenylphospine 
(1.36 g, 5.19 mmol) in CH2Cl2 (20 mL), at 0° C, under argon, CH3OH (0.21 mL, 
5.19 mmol) and DIAD (1.0 mL, 5.19 mmol) were added. The reaction mixture was 
allowed to warm to rt and after 6 h concentrated in vacuo. Purification by column 
chromatography over silica gel (hexane/EtOAc, 6:4) gave Boc-protected 
pyrrolinone 38 (621 mg, 57% over three steps) as a colourless oil. [α]D20 = +203.3 
(c=1.0, CH3OH); IR (neat) max: 2980, 2940, 1779, 1733, 1705, 1634, 1456, 1319, 
1246, 1152, 1094, 1073, 981, 848, 808, 757, 701, 667 cm-1; 1H-NMR: (400 MHz, 
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CDCl3):  7.11-7.00 (3H, m, ArH), 6.87 (2H, d, J=7.1, ArH), 4.66 (1H, s, H-10), 
4.52 (1H, bdd, J=5.0, 3.0, H-8), 3.62 (3H, s, OCH3), 3.31 (1H, dd, J=13.8, 5.1, Ha-
7), 2.98 (1H, dd, J=13.8, 3.0, Hb-7), 1.48 (9H, s, C(CH3)3); 13C-NMR (100 MHz, 
CDCl3)  175.6, 168.0, 148.8, 133.5, 128.9, 127.6, 126.4, 94.5, 81.8, 59.5, 57.7, 
34.7, 27.6. HRMS (ESI) m/z calcd for C17H22NO4 [M+H]+ 304.1543, found 
304.1532. 
To a stirred solution of 38 (212 mg, 0.66 mmol) in CH2Cl2 (2.5 mL) TFA (2.5 mL) 
was added. After 30 min the reaction mixture was evaporated in vacuo. Residual 
TFA was removed by evaporation with toluene (3 x 1.5 mL) to give pyrrolinone 4 
(144 mg, quant.) as a white waxy solid. Mp 84-85 (EtOAc/hexane) [lit. 103-1043]; 
[α]D20 = –62.3 (c=1.0, CHCl3) [lit. -63.0 (c=1.0, CHCl3)26]; IR (neat) max: 3238, 
3030, 2939, 2848, 1683, 1623, 1497, 1455, 1365, 1344, 1232, 989, 806, 700 cm-1; 
1H-NMR: (400 MHz, CDCl3):  7.32-7.20 (3H, m, ArH), 7.14 (2H, d, J=7.1, ArH), 
5.6 (br s, NH), 5.04 (1H, s, H-10), 4.33 (1H, m, H-8), 3.83 (3H, s, OCH3), 3.17 (1H, 
dd, J=13.7, 3.4, Ha-7), 2.78 (1H, dd, J=13.7, 7.6, Hb-7); 13C-NMR (100 MHz, 
CDCl3)  177.2, 173.7, 136.3, 129.1, 128.4, 126.8, 94.0, 58.4, 58.1, 38.3. HRMS 
(ESI) m/z calcd for C12H14NO2 [M+H]+ 204.1019, found 204.1011. 
16-epi-smenamide 27 
 
To a stirred solution of pyrrolinone 4 (9.9 mg, 0.049 mmol) in THF (0.1 mL) at -
78°C, nBuLi (0.020 mL, 0.033 mmol, 1.6 M sol. in hexane) was added dropwise. 
After 15 min, a solution of pentafluorophenyl ester 26 (1.5 mg, 0.0031 mmol) in 
THF (0.1 mL) was added via syringe. After 2h, the reaction was quenced with a 
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satd. aq. NH4Cl solution (1 mL) and extracted with EtOAc (3 x 10 mL). The organic 
phase was washed with water (6 mL) and brine (6 mL), dried and concentrated in 
vacuo. The crude was subjected to reversed-phase HPLC separation [column Luna 
(Phenomenex) C18, 250 × 4.6 mm, 5 μm; eluent A: H2O; eluent B: CH3CN; 
gradient: 50→100% B, over 35 min, flow rate 1 mL min–1], to give 16-epi-
smenamide A (tR=17.5 min, 1.3 mg, 84%) as a colourless oil. [α]D 20 = 86.9 (c=0.1, 
CHCl3); IR (neat) νmax: 2958,  2928,  2857,  1731, 1631, 1455, 1308, 1245, 
1197,1024, 965, 807, 753,708 cm-1; 1H-NMR: (400 MHz, CD3OD, mixture of 
rotamers):  7.26-7.20 (3H, m, H-3, H-4, H-5), 6.99 (2H, m, H-2, H-6), 6.00 (0.5H, 
s, H-21), 5.97 (0.5H, s, H-21), 5.41 (1H, bdd, J=10.0, 1.5, H-15), 5.40 (1H, bdd, 
J=10.0, 1.5, H-15), 5.03 (0.5H, s, H-10), 5.02 (0.5H, s, H-10), 5.00 (1H, m, H-8), 
3.96 (3H, s, OCH3), 3.46-3.33 (3H, overlapped m’s), 3.19 (1H, dd, J=14.0, 2.4), 
3.03 (1.5H, s, H3-27), 2.89 (1.5H, s, H3-27), 2.44 (1H, m), 2.32-2.13 (3H, 
overlapped m’s), 2.13-2.02 (4H, overlapped signals including a singlet at 2.07 for 
H3-26), 1.81-1.60 (5H, overlapped signals including two doublets for H3-14 at 
1.714 and 1.708, both J=1.3), 1.60-1.50 (1H, m), 1.39-1.27 (1H, m), 0.99 (1.5H, d, 
J=7.1, H3-17), 0.98 (1.5H, d, J=7.1, H3-17); 13C NMR (126 MHz, CD3OD) δ 180.0, 
143.2, 143.0, 142.6, 142.2, 135.6, 133.2, 130.9, 129.2, 128.2, 114.2, 114.0, 95.4, 
60.6, 59.5, 51.5, 36.6, 36.2, 36.1, 34.7, 33.6, 33.4, 33.22 33.17, 28.2, 28.0, 26.6, 
25.7, 21.7, 21.1, 20.3, 20.2, 14.3, 14.2; HRMS (ESI) m/z calcd for C28H38ClN2O4 
[M+H]+ 501.2515, found 501.2493. 
ent-smenamide 29 
 
77 
 
 
To a stirred solution of pyrrolinone 28 (9.9 mg, 0.049 mmol) in THF (0.1 mL) at -
78°C, nBuLi (0.20 mL, 0.033 mmol, 1.6 M sol. in hexane) was added dropwise. 
After 15 min, a solution of pentafluorophenyl ester 26 (1.5 mg, 0.0031 mmol) in 
THF (0.1 mL) was added via syringe. After 2h, the reaction was quenced with a 
satd. aq. NH4Cl solution (1 mL) and extracted with EtOAc (3 x 10 mL). The organic 
phase was washed with water (6 mL) and brine (6 mL), dried and concentrated in 
vacuo. The crude was subjected to reversed-phase HPLC separation [column Luna 
(Phenomenex) C18, 250 × 4.6 mm, 5 μm; eluent A: H2O; eluent B: CH3CN; 
gradient: 50→100% B, over 35 min, flow rate1 mL min–1], to give ent-smenamide 
A 29 (tR = 18.5 min, 1.4 mg, 88%) as a colourless oil. [α]D 20 = –9.8 (c=0.1, CHCl3); 
IR (neat) max: 2958, 2923, 2853, 1729, 1631, 1455, 1306, 1205, 1132, 1026, 802 
cm-1; 1H- and 13C-NMR see Table 1. HRMS (ESI) m/z calcd for C28H38ClN2O4 
[M+H]+ 501.2515, found 501.2495.  
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2.8 Supplementary spectroscopic data 
 
 
Figure 2.22. 1H NMR spectrum of compound 30 (CDCl3, 400 MHz) 
 
 
Figure 2.23. 13C NMR spectrum of compound 30 (CDCl3, 100 MHz) 
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Figure 2.24. 1H NMR spectrum of compound 8 (CDCl3, 400 MHz) 
 
 
Figure 2.25. 13C NMR spectrum of compound 8 (CDCl3, 100 MHz) 
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Figure 2.26. 1H NMR spectrum of compound 31 (CDCl3, 400 MHz) 
 
 
 
Figure 2.27. 13C NMR spectrum of compound 31 (CDCl3, 100 MHz) 
 
 
81 
 
 
 
Figure 2.28. 1H NMR spectrum of compound 33 (CDCl3, 400 MHz) 
 
 
 
Figure 2.29. 13C NMR spectrum of compound 33 (CDCl3, 100 MHz) 
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Figure 2.30. 1H NMR spectrum of compound 9 (CDCl3, 400 MHz) 
 
 
 
 
Figure 2.31. 13C NMR spectrum of compound 9 (CDCl3, 100 MHz) 
 
83 
 
 
 
 
 
Figure 2.32. 1H NMR spectrum of compound 34 (CDCl3, 400 MHz) 
 
 
 
 
Figure 2.33. 13C NMR spectrum of compound 34 (CDCl3, 100 MHz) 
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Figure 2.34. 1H NMR spectrum of compound 10 (CDCl3, 400 MHz) 
 
 
 
 
 
 
 
85 
 
 
 
  
 
Figure 2.35. 1H NMR spectrum of compound 12 (CDCl3, 400 MHz) 
 
 
 
Figure 2.36. 13C NMR spectrum of compound 12 (CDCl3, 100 MHz) 
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Figure 2.37. 1H NMR spectrum of compound 5 (CDCl3, 400 MHz) 
 
 
 
 
 
 
Figure 2.38. 13C NMR spectrum of compound 5 (CDCl3, 100 MHz) 
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Figure 2.39. 1H NMR spectrum of compound 35 (CDCl3, 400 MHz) 
 
 
 
 
 
Figure 2.40. 13C NMR spectrum of compound 35 (CDCl3, 100 MHz) 
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Figure 2.41. 1H NMR spectrum of compound 36 (CDCl3, 400 MHz) 
 
 
 
 
Figure 2.42. 13C NMR spectrum of compound 36 (CDCl3, 100 MHz) 
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Figure 2.43. 1H NMR spectrum of compound 13 (CDCl3, 400 MHz) 
 
 
 
Figure 2.44. 13C NMR spectrum of compound 13 (CDCl3, 100 MHz) 
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Figure 2.45. 1H NMR spectrum of compound 14 (CDCl3, 400 MHz) 
 
 
 
Figure 2.46. 13C NMR spectrum of compound 14 (CDCl3, 100 MHz) 
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Figure 2.47. 1H NMR spectrum of compound 37 (CDCl3, 400 MHz) 
 
 
 
Figure 2.48. 13C NMR spectrum of compound 37 (CDCl3, 100 MHz) 
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Figure 2.49. 1H NMR spectrum of compound 15 (CDCl3, 400 MHz) 
 
 
 
 
Figure 2.50. 13C NMR spectrum of compound 15 (CDCl3, 100 MHz) 
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Figure 2.51. 1H NMR spectrum of compound 16 (CDCl3, 400 MHz) 
 
 
 
 
Figure 2.52. 13C NMR spectrum of compound 16 (CDCl3, 100 MHz) 
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Figure 2.53. 1H NMR spectrum of compound 17 (DMSO, 400 MHz) 
 
 
 
 
 
Figure 2.54. 13C NMR spectrum of compound 17 (DMSO, 100 MHz) 
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Figure 2.55. 1H NMR spectrum of compounds 18 (CDCl3, 400 MHz) 
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 Figure 2.56. 1H NMR spectrum of compound 20 (CDCl3, 400 MHz) 
 
 
 
 
Figure 2.57. 13C NMR spectrum of compound 20 (CDCl3, 100 MHz) 
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Figure 2.58. 1H NMR spectrum of compound 21 (CDCl3, 400 MHz) 
 
 
 
 
 
Figure 2.59. 13C NMR spectrum of compound 21 (CDCl3, 100 MHz) 
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Figure 2.60. 1H NMR spectrum of compound 22 (CDCl3, 400 MHz) 
 
 
 
 
 
Figure 2.61. 13C NMR spectrum of compound 22 (CDCl3, 100 MHz) 
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Figure 2.62. 1H NMR spectrum of compound 24 (CDCl3, 400 MHz) 
 
 
 
Figure 2.63. 13C NMR spectrum of compound 24 (CDCl3, 100 MHz) 
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Figure 2.64. 1H NMR spectrum of compound 26 (CDCl3, 400 MHz) 
 
 
 
 
Figure 2.65. 13C NMR spectrum of compound 26 (CDCl3, 400 MHz) 
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Figure 2.66. 1H NMR spectrum of compound 4 (CDCl3, 400 MHz) 
 
 
 
 
Figure 2.67. 13C NMR spectrum of compound 4 (CDCl3, 100 MHz) 
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Figure 2.68. 1H NMR spectrum of compound 27 (CD3OD, 500 MHz) 
 
 
 
 
Figure 2.69. 13C NMR spectrum of compound 27 (CD3OD, 125 MHz) 
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Figure 2.70. 1H NMR spectrum of compound 29 (CD3OD, 700 MHz) 
 
 
 
Figure 2.71. 13C NMR spectrum of compound 29 (CD3OD, 175 MHz) 
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Figure 2.72. ECD spectra of natural smenamide A (solid red line) and ent-smenamide A (29) 
(dashed blue line). 
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Table 2.1. NMR data of natural smenamide A and ent-smenamide A. 
 
 
  
 T
ab
le
 1
. N
M
R
 d
at
a 
of
 n
at
ur
al
 s
m
en
am
id
e 
A
 (
1)
 a
nd
 e
nt
-s
m
en
am
id
e 
A
 (
29
) 
(7
00
 M
H
z,
 C
D
3O
D
).
 
 
 
sm
en
am
id
e 
A
 
Z
-C
on
fo
rm
er
 
 
E
-C
on
fo
rm
er
 
 
 
 
Z
-C
on
fo
rm
er
 
en
t-
sm
en
am
id
e 
A
 
 
E
-C
on
fo
rm
er
 
  
P
os
it
io
n
 
 
 H
 [
M
u
lt
., 
J 
(H
z)
] 
 C
 [
M
u
lt
.]
 
 H
 [
M
u
lt
., 
J 
(H
z)
] 
 C
 [
M
u
lt
.]
 
P
os
it
io
n
 
 
 H
 [
M
u
lt
., 
J 
(H
z)
] 
 C
 [
M
u
lt
.]
 
 H
 [
M
u
lt
., 
J 
(H
z)
] 
 C
 [
M
u
lt
.]
 
1 
 
−
 
13
5.
6 
(C
) 
−
 
13
5.
6 
(C
) 
1 
 
−
 
13
5.
7 
(C
) 
−
 
13
5.
7 
(C
) 
2/
6 
 
6.
99
 (
m
) 
13
0.
8 
(C
H
) 
6.
99
 (
m
) 
13
0.
8 
(C
H
) 
2/
6 
 
6.
90
 (
m
) 
13
0.
9 
(C
H
) 
6.
90
 (
m
) 
13
0.
9 
(C
H
) 
3/
5 
 
7.
23
 (
ov
l)
 
12
9.
4 
(C
H
) 
7.
23
 (
ov
l)
 
12
9.
4 
(C
H
) 
3/
5 
 
7.
23
 (
ov
l)
 
12
9.
3 
(C
H
) 
7.
23
 (
ov
l)
 
12
9.
3 
(C
H
) 
4 
 
7.
23
 (
ov
l)
 
12
8.
3 
(C
H
) 
7.
23
 (
ov
l)
 
12
8.
3 
(C
H
) 
4 
 
7.
23
 (
ov
l)
 
12
8.
2 
(C
H
) 
7.
23
 (
ov
l)
 
12
8.
2 
(C
H
) 
7 
a 
3.
37
 (
ov
l)
 
34
.8
 (
C
H
2)
 
3.
37
 (
ov
l)
 
34
.8
 (
C
H
2)
 
7 
a 
3.
36
 (
ov
l)
 
34
.7
 (
C
H
2)
 
3.
36
 (
ov
l)
 
34
.7
 (
C
H
2)
 
 
b 
3.
19
 (
m
) 
 
3.
19
 (
m
) 
 
 
b 
3.
20
 (
m
) 
 
3.
20
 (
m
) 
 
8 
 
5.
02
 (
ov
l)
 
60
.5
 (
C
H
) 
5.
02
 (
ov
l)
 
60
.5
 (
C
H
) 
8 
 
5.
02
 (
ov
l)
 
60
.5
 (
C
H
) 
5.
02
 (
ov
l)
 
60
.5
 (
C
H
) 
9 
 
−
 
17
9.
5 
(C
) 
−
 
17
9.
5 
(C
) 
9 
 
−
 
17
9.
8 
(C
) 
 
−
 
17
9.
8 
(C
) 
10
 
 
5.
04
 (
br
. s
) 
95
.5
 (
C
H
) 
5.
02
 (
br
. s
) 
95
.5
 (
C
H
) 
10
 
 
5.
04
 (
br
. s
) 
95
.5
 (
C
H
) 
5.
02
 (
br
. s
) 
95
.5
 (
C
H
) 
11
 
 
−
 
17
0.
7 
(C
) 
−
 
17
0.
7 
(C
) 
11
 
 
−
 
17
1.
1 
(C
) 
−
 
17
1.
1 
(C
) 
12
 
 
−
 
17
2.
3 
(C
) 
−
 
17
2.
2 
(C
) 
12
 
 
−
 
17
2.
7 
(C
) 
−
 
17
2.
7 
(C
) 
13
 
 
−
 
13
2.
1 
(C
) 
−
 
13
2.
1 
(C
) 
13
 
 
−
 
13
2.
1 
(C
) 
−
 
13
2.
1 
(C
) 
14
 
 
1.
77
 (
d,
 1
.5
) 
13
.7
 (
C
H
3)
 
1.
78
 (
d,
 1
.5
) 
13
.7
 (
C
H
3)
 
14
 
 
1.
77
 (
d,
 1
.4
) 
13
.7
 (
C
H
3)
 
1.
78
 (
d,
 1
.4
) 
13
.7
 (
C
H
3)
 
15
 
 
5.
36
 (
br
. d
, 1
0.
2)
 
14
4.
1 
(C
H
) 
5.
36
 (
br
. d
, 1
0.
2)
  
14
4.
1 
(C
H
) 
15
 
 
5.
36
 (
br
. d
, 1
0.
1)
 
14
4.
1 
(C
H
) 
5.
36
 (
br
. d
, 1
0.
1)
  
14
4.
1 
(C
H
) 
16
 
 
2.
45
 (
m
) 
33
.4
 (
C
H
) 
2.
48
 (
m
) 
33
.4
 (
C
H
) 
16
 
 
2.
45
 (
m
) 
33
.4
 (
C
H
) 
2.
48
 (
m
) 
33
.5
 (
C
H
) 
17
 
 
0.
98
 (
d,
 6
.5
) 
20
.4
 (
C
H
3)
 
1.
00
 (
d,
 6
.5
) 
20
.6
 (
C
H
3)
 
17
 
 
0.
98
 (
d,
 6
.5
) 
20
.6
 (
C
H
3)
 
1.
00
 (
d,
 6
.5
) 
20
.7
 (
C
H
3)
 
18
 
a 
1.
51
 (
ov
l)
 
36
.1
 (
C
H
2)
 
1.
52
 (
ov
l)
 
35
.9
 (
C
H
2)
 
18
 
a 
1.
51
 (
ov
l)
 
36
.4
 (
C
H
2)
 
1.
51
 (
ov
l)
 
36
.2
 (
C
H
2)
 
 
b 
1.
28
 (
ov
l)
 
 
1.
30
 (
ov
l)
 
 
 
b 
1.
29
 (
ov
l)
 
 
1.
29
 (
ov
l)
 
 
19
 
a 
2.
19
 (
ov
l)
 
33
.2
 (
C
H
2)
 
2.
23
 (
ov
l)
 
33
.2
 (
C
H
2)
 
19
 
a 
2.
19
 (
ov
l)
 
33
.2
 (
C
H
2)
 
2.
23
 (
ov
l)
 
33
.3
 (
C
H
2)
 
 
b 
2.
06
 (
ov
l)
 
 
2.
05
 (
ov
l)
 
 
 
b 
2.
05
 (
ov
l)
 
 
2.
05
 (
ov
l)
 
 
20
 
 
−
 
14
3.
1 
(C
) 
−
 
14
2.
8 
(C
) 
20
 
 
−
 
14
3.
4 
(C
) 
−
 
14
3.
2 
(C
) 
21
 
 
5.
93
 (
br
. s
) 
11
3.
9 
(C
H
) 
5.
97
 (
br
. s
) 
11
4.
1 
(C
H
) 
21
 
 
5.
92
 (
br
. s
) 
11
3.
9 
(C
H
) 
5.
96
 (
br
. s
) 
11
4.
1 
(C
H
) 
22
 
a 
2.
22
 (
m
) 
28
.1
 (
C
H
2)
 
2.
26
 (
m
) 
28
.0
 (
C
H
2)
 
22
 
a 
2.
22
 (
m
) 
28
.1
 (
C
H
2)
 
2.
26
 (
m
) 
27
.9
 (
C
H
2)
 
 
b 
2.
15
 (
m
) 
 
2.
18
 (
m
) 
 
 
b 
2.
15
 (
m
) 
 
2.
18
 (
m
) 
 
23
 
 
1.
64
 (
m
) 
25
.9
 (
C
H
2)
 
1.
70
 (
m
) 
26
.6
 (
C
H
2)
 
23
 
 
1.
65
 (
m
) 
25
.7
 (
C
H
2)
 
1.
70
 (
m
) 
26
.6
 (
C
H
2)
 
24
 
 
3.
36
 (
ov
l)
 
48
.6
 (
C
H
2)
 
3.
33
 (
ov
l)
 
51
.5
 (
C
H
2)
 
24
 
 
3.
36
 (
ov
l)
 
48
.4
 (
C
H
2)
 
3.
34
 (
ov
l)
 
51
.6
 (
C
H
2)
 
25
 
 
−
 
17
2.
9 
(C
) 
−
 
17
2.
7 
(C
) 
25
 
 
−
 
17
2.
7 
(C
) 
−
 
17
2.
7 
(C
) 
26
 
 
2.
08
 (
s)
 
21
.7
 (
C
H
3)
 
2.
07
 (
s)
 
21
.1
 (
C
H
3)
 
26
 
 
2.
08
 (
s)
 
21
.7
 (
C
H
3)
 
2.
07
 (
s)
 
21
.0
 (
C
H
3)
 
27
 
 
3.
03
 (
s)
 
36
.6
 (
C
H
3)
 
2.
88
 (
s)
 
33
.7
 (
C
H
3)
 
27
 
 
3.
03
 (
s)
 
36
.6
 (
C
H
3)
 
2.
88
 (
s)
 
33
.7
 (
C
H
3)
 
O
M
e 
 
3.
97
 (
s)
 
59
.7
 (
C
H
3)
 
3.
97
 (
s)
 
59
.7
 (
C
H
3)
 
O
M
e 
 
3.
95
 (
s)
 
59
.6
 (
C
H
3)
 
3.
95
 (
s)
 
59
.6
 (
C
H
3)
 
 
106 
 
 
References
1 Anand, P.; Kunnumakara, A.B.; Sundaram, C.; Harikumar, K.B.; Tharakan, S.T.; Lai, O. S.; Sung, 
B.; Aggarwal, Bharat B. Pharm. Res. 2008, 25, 2097-2116.  
2 Kravchenko, J.; Akushevich, I.; Manton, K.G.; Cancer mortality and morbidity patterns in the U. 
S. population: an interdisciplinary approach Berlin, Springer, 2009. 
3 Moudi, M.: Go, R.; Yong Seok Yien, C.; Nazre, M. Int. J. Prev. Med. 2013, 4(11), 1231-1235. 
4 Wani, M.C.; Taylor, H.L.; Wall, M.E. et al. J Am Chem Soc 1971; 93: 2325-7. 
5 Newman, D.J.; Cragg, G.M. Mar. Drugs 2014, 12, 255-278.  
6 Newman, D.J.; Giddings, L.A. Phytochem. Rev. 2013, 12, 293-304. 
7 R. Teta, E. Irollo, G. Della Sala, G. Pirozzi, A. Mangoni, V. Costantino, Marine Drugs, 2013, 11 
(11), 4451-4463. 
8 Esposito G., Teta R., Miceli R., Ceccarelli L., Della Sala G., Camerlingo R., Irollo E., Mangoni 
A., Pirozzi G., Costantino V., Mar. Drugs 2015, 13, 444-459. 
9 G. Esposito, G. Della Sala, R. Teta, A. Caso, M.L. Bouguet-Kondracki, J.R. Pawlik, A. Mangoni, 
V. Costantino, Eur. J. Org. Chem.  2016, 16, 2871–2875. 
10 A. Caso, A. Mangoni, G. Piccialli, V. Costantino, V. Piccialli, ACS Omega, 2017, 2, 1477−1488. 
11 A. Caso, I. Laurenzana, D. Lamorte, S. Trino, G. Esposito, V. Piccialli, and V. Costantino, Mar. 
Drugs, 2018, accepted. 
12 Pettit, G. R.; Kamano, Y.; Dufresne, C.; Cerny, R. L.; Herald, C. L.; Schmidt, J. M. J. Org. Chem. 
1989, 54, 6005−6006. 
13 Edwards, D. J.; Marquez, B. L.; Nogle, L. M.; McPhail, K.; Goeger, D. E.; Roberts, M. A.; 
Gerwick, W. H. Chem. Biol. 2004, 11, 817−833. 
14 Marfey, P. Carlsberg Res. Commun. 1984, 49, 591-596. 
15 Hosseini, M.; Kringelum, H.; Murray, A.; Tønder, J. E. Org. Lett. 2006, 8, 2103-2106. (b) 
Conroy, T.; Guo, J. T.; Linington, R. G.; Hunt, N. H.; Payne, R. J. Chem. Eur. J. 2011, 17, 
13544-13552.  
16 Hosseini, M.; Tanner, D.; Murray, A.; Tønder, J. E. Org. Biomol. Chem. 2007, 5, 3486-3494. 
17 a) Sharpless, K. B.; Ojima, I. VCH publishers. 1993. b) Kolb, H.C.; VanNienwenhze, M. S.; 
Sharpless, K. B. Chem. Rev. 1994, 94, 2483-2557. 
                                                          
107 
 
 
                                                                                                                                                               
18 Kocienski, P. J. Ed. G. Thieme. 1994, 38. 
19 Yi, C. S.; Martinelli, L. C.; DeWitt Blanton, C. Jr. J. Org. Chem. 1978, 43, 405-409. 
20 (a) Ley, S. V.; Norman, J.; Griffith, W. P.; Marsden, S. P. Synthesis. 1994, 639-666. (b) Piccialli, 
V. Molecules. 2014, 19, 6534-6582. 
21 (a) Miyano, S.; Izumi, Y.; Fujii, K.; Ohno, Y.; Hashimoto, H. Bull. Chem. Soc. Jpn. 1979, 52, 
1197−1202. (b) Kahnberg, P.; Sterner, O. Tetrahedron, 2001, 57, 7181−7184. (c) Kahnberg, P.; 
Lee, C. W.; Grubbs, R. H.; Sterner, O. Tetrahedron, 2002, 58, 5203−5208. (d) Chen, J.; Shi, Z.-
F.; Zhou, L.; Xie, A.-L.; Cao, X.-P. Tetrahedron, 2010, 66, 3499−3507. (e) Zhang, J.-T.; Qi, X.-
L.; Chen, J.; Li, B.-S.; Zhou, Y.-B.; Cao, X.-P. J. Org. Chem. 2011, 76, 3946−3959. (f) Esmieu, 
W. R.; Worden, S. M.; Catterick, D.; Wilson, C.; Hayes, C. J. Org. Lett. 2008, 10, 3045−3048. 
22 Graf, K. M.; Tabor, M. G.; Brown, M. L.; Paige, M. Org. Lett. 2009, 11, 5382−5385. 
23 Mitchell, T. N.; Killing, H.; Dicke, R.; Wickenkamp, R Chem. Commun. 1985, 354−355. 
24 (a) Erver, F.; Hilt, G. J. Org. Chem. 2012, 77, 5215−5219. (b) Kigoshi, H.; Kita, M.; Ogawa, S.; 
Itoh, M.; Uemura, D. Org. Lett. 2003, 5, 957−960. 
25 Mitsunobu, O.; Yamada, M.; Mukaiyama, T. Bull. Chem. Soc. Jpn. 1967, 40, 10, 2380–2382. 
26 Lan, H.-Q.; Ye, J.-L.; Wang, A.-E.; Ruan, Y.-P.; Huang, P.-Q. Chem. Eur. J. 2011, 17, 958-968. 
27 (a) Andrus, M. B.; Li, W.; Keyes, R. F. J. Org. Chem. 1997, 62, 5542−5549. (b) Andrus, M. B.; 
Li, W.; Keyes, R. F. Tetrahedron Lett. 1998, 39, 5465−5468. 
28 Mori, K. Tetrahedron 2008, 64, 4060-4071. 
 
 Chapter 3 
Synthesis and biological activity of eight 
smenamide A-functional analogues 
 
As part of a broad research project focused on the study of the chemistry of marine 
natural products and their synthetic or semi-synthetic derivatives, a flexible 
synthetic route, aimed to the synthesis of new bioactive compounds, was planned. 
Smenamide A is a hybrid peptide/polyketide (PKS/NRPS) compound possessing a 
promising cytotoxic activity against the Calu-1 lung cancer cell line.1 Recently, two 
synthetic derivatives of the natural compound, namely 16-epi- and ent-smenamide 
A, were synthesised starting from the commercially available S-citronellene.2 With 
the aim of gaining a better insight into the cytotoxic activity of smenamides family, 
eight shorter-chain synthetic analogues of the 16-epi- series have been designed and 
prepared.3 
 
3.1 Synthesis of eight smenamide A-analogues of the 16-epi- series and their 
biological activity 
Smenamides are small but highly functionalised organic molecules, the structure of 
which contains a N-methylacetamido western function, a chlorovinyl moiety and a 
pyrrolinone eastern terminal. In order to investigate the role of the three main 
functionalities of the molecules in the biological activity, eight chorter-chain (8-15) 
analogues of 16-epi-smenamide A were designed and prepared (Figure 3.1). 
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Although they are simplified analogues, they retain the main structural features of 
the natural lead compound 1. They were indeed thought as "functional-analogues”. 
 
 
Figure 3.1. Structures of compounds 7-15.  
 
 
Compound 8, truncated in position 18, consists essentially of the dolapyrrolidinone 
subunit. It was prepared in order to probe the role of the pyrrolinone moiety, 
whereas compounds 9-15 were prepared to simulate the polyketide portion, and, 
more precisely, the role of the chlorine atom and the stereochemistry of C 20-21 
double bond. Thanks to the flexible synthetic approach, all eight functional 
analogues were easily prepared. The activation of 2,4-dimethyl-2-pentenoic acid as 
pentafluorophenyl ester (16) and its subsequent coupling with the 
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dolapyrrolidinone subunit (17), previously synthesized2 afforded derivative 8 
(Figure 3.2) in high yield (85 %). 
 
 
Figure 3.2. Preparation of dolapyrrolidinone derivative 8. 
 
As for compounds 9-15 they have been prepared according to the reported 
procedure,2 starting from the chiral S-citronellene, commercially available. S-
citronellene, properly oxidised and degraded, provided the carbon backbone of 
C15-C20 aldehyde, which was further manipulated affording ketone 18. The latter 
is a versatile intermediate, the modification of which allowed the introduction of 
the desired functionalities: the chlorovinyl and the methylene moieties, and the -
unsaturated ethyl ester function (Figure 3.3). 
 
Figure 3.3. Ketone18 as a versatile intermediate. 
 
Compounds 9-13 were prepared as depicted in Figure 3.4. For the installation of the 
chlorovinyl function, we took advantage of one of the most useful C-C formation 
reactions: the Wittig reaction. Ketone 18 was reacted with the proper phosphonium 
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salt, (chloromethyl)triphenylphosphonium iodide, previously synthesized,2 to get 
the chlorovinyl derivatives 9 and 10, possessing the opposite configuration of the 
double bond. Since an unstabilised ylide was used, the process afforded both 
stereoisomers Z and E in ratio 3:2, respectively. 9 and 10 were then acetylated in 
classic conditions (Ac2O/Pyr) to give the corresponding acetyl derivatives 11 and 
12. Moreover, a further modification of 9 through an oxidation under Ley’s 
conditions (TPAP(cat)/NMO) afforded the corresponding aldehyde 21, which was 
used in the subsequent Wittig reaction with the stabilized ylide, 
(carbethoxyethylidene)triphenylphosphorane, commercially available. The last 
reaction led to the synthesis of the -unsaturated ethyl ester 13, bearing the same 
C 13-15 double bond configuration of the natural smenamide A (1). 
 
 
Figure 3.4. Preparation of compounds 9-13. 
 
Finally, methylene derivative 14 was prepared by using the same procedure 
described above for compounds 9 and 10, using the proper phosphonium salt 
(Figure 3.5). Ketone 18 was let to react with methylenetriphenylphosphorane, 
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commercially available, to give compound 22, which was deprotected with TBAF 
affording compound 14. Finally, acetylation of 14 with Ac2O/Pyr afforded 
compound 15 (Figure 3.5). 
 
 
Figure 3.5. Preparation of compounds 14 and 15. 
 
3.2. In vitro evaluation of the antiproliferative activity  
Smenamide A was shown to have a cytotoxic activity against the Calu-1 lung cancer 
cell line, blocking the proliferation of the cancer cells through a clear pro-apoptotic 
mechanism.1 Therefore, the antiproliferative activity of 16-epi-smenamide A, 
together with its analogues (8-15), will be evaluated in collaboration with the 
IRCCS CROB (Scientific Institute of Hospitalization and Care- Basilicata 
Oncological Center) of Rionero in Vulture (PZ)3 by MTS cell viability assays on 
SKM-M1 and RPMI-8226 (multiple myeloma) cell lines. 
 
3.3 Conclusions 
Eight shorter-chain synthetic analogues (8-15) of 16-epi-smenamide A have been 
prepared in order to expand the knowledge on the antiproliferative activity of 
smenamides family. The evaluation of their antiproliferative activity is in progress. 
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3.4. Experimental section 
3.4.1 Generals  
All reagents and anhydrous solvents were purchased (Aldrich and Fluka) at the 
highest commercial quality and used without further purification. Where necessary, 
flame-dried and argon-charged glassware was used. The reactions were monitored 
using thinlayer chromatography (TLC) carried out on precoated silica gel plates 
(Merck 60, F254, 0.25 mm thick). Merck silica gel (Kieselgel 40, particle size 
0.063−0.200 mm) was used for the column chromatography. MgSO4 was used as a 
drying agent for aqueous workup. Nuclear magnetic resonance (NMR) experiments 
were performed using Varian Unity Inova spectrometers at 400, 500, and 700 MHz 
in CDCl3. Proton chemical shifts were referenced to the residual CHCl3 signal (7.26 
ppm). 13C NMR chemical shifts were referenced to the solvent (77.0 ppm). 
Abbreviations for signal coupling are as follows: s = singlet, d = doublet, t = triplet, 
q = quartet, m = multiplet, and b = broad. Optical rotations were measured using a 
JASCO P-2000 polarimeter at the sodium D line. HRMS spectra were recorded by 
infusion on a Thermo LTQ Orbitrap XL mass spectrometer equipped with an 
electrospray source in the positive mode using MeOH as the solvent. 
 
3.4.2 Experimental procedures 
 
 Compound 8. To a solution of 2,4-dimethyl-2-pentenoic acid (114 mg, 0.889 
mmol) in EtOAc (4.0 mL), pentafluorophenol (188.2 mg, 1.02 mmol) and DCC 
(210.5 mg, 1.02 mmol) were added at 0 °C. The reaction mixture was stirred for 1 
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h at 0 °C and 3 h at rt and evaporated under reduced pressure to give 16 (185,9 mg, 
0.632 mmol) that was used in the next step without further purification. 1H-NMR: 
(400 MHz, CDCl3):  6.90 (1H, d, J=9.75), 2.8-2.6 (1H, m), 1.95 (3H, s), 1.07 (6H, 
d, J=6.6). 
To a stirred solution of pyrrolinone 17 (126.6 mg, 0.624 mmol)5 in THF (5.0 mL), 
nBuLi (0.390 mL, 0.632 mmol, 1.6 M soln in hexane) was added dropwise at −78 
°C. After 15 min, a solution of pentafluorophenyl ester 16 (183.45 mg, 0.624 mmol) 
in THF (0.1 mL) was added via syringe. After 2 h, the reaction was quenched with 
a saturated aqueous NH4Cl solution (5 mL) and extracted with EtOAc (3 × 15 mL). 
The organic phase was washed with water (15 mL) and brine (15 mL), dried, and 
concentrated in vacuo. The crude was purified by preparative TLC (CHCl3/CH3OH, 
98:2) to give 8 (166.2 mg, 0.530 mmol, 85%) as a colourless oil. [α]D20 = –63.4 
(c=1.5, CHCl3); 
1H-NMR: (400 MHz, CDCl3):  7.23-7.17 (3H, m, ArH), 7.0-6.9 
(2H, m, ArH), 5.62 (1H, d, J=9.47), 5.01-4.96 (1H, m), 4.84 (1H, s), 3.87 (3H, s, 
OCH3),  3.39 (1H, dd, J=14.1, 5.4, Ha-7), 3.15 (1H, dd, J=14.1, 2.0, Hb-7), 2.68-
2.54 (1H, m), 1.8 (3H, s), 0.99 (6H, d, J=6.5); 13C-NMR (100 MHz, CDCl3):  
177.2, 171.3, 168.8, 145.2, 134.4, 129.8, 129.4, 128.1, 127.0, 94.8, 59.1, 58.3, 33.9, 
27.4, 21.9, 21.5, 13.3; HRMS (ESI) m/z calcd for C13H25ClNO2 [M+H]
+ 262.1568, 
found 262.1566. 
Compound 9 
 
A mixture of compounds 19 and 20 was prepared as previously described [4]. Pure 
19 and 20 were obtained by silica gel chromatography (hexane-EtOAc, 1:2). 
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Deprotection of 19, as reported [5] afforded alcohol 9 as a colourless oil. [α]D20 = –
63.4 (c=1.5, CHCl3); 
1H-NMR: (400 MHz, CDCl3, mixture of rotamers):  5.86 
(0.4H, s, vinyl proton), 5.82 (0.6H, s, vinyl proton), 3.46 (2H, t, J=5.3), 3.42-3.24 
(2H, m’s), 2.99 (1.8 H, s, H3-27), 2.89 (1.2 H, s, H3-27), 2.27-2.02 (7H, overlapped 
signals including two singlets at 2.09 and 2.07 for H3-26), 1.78-1.52 (4H, m), 1.30-
1.15 (1H, m), 0.93, 0.91 (overall 3H, overlapped d’s, both J=6.0, H3-17); 13C-NMR 
(100 MHz, CDCl3):  170.6, 170.4, 142.0, 141.3, 113.2, 112.6, 67.8, 67.7, 50.5, 
47.3, 36.1, 35.2, 33.2, 32.3, 32.2, 31.1, 31.0, 27.4, 27.3, 25.8, 24.6, 21.9, 21.2, 
16.44, 16.38; HRMS (ESI) m/z calcd for C13H25ClNO2 [M+H]
+ 262.1568, found 
262.1566. 
Compound 10 
 
To a solution of 20 (3.9 mg, 0.008 mmol) in THF (0.6 mL), TBAF (0.012 mL, 0.012 
mmol, 1.0 M solution in THF) was added dropwise at 0 °C. The reaction mixture 
was allowed to reach RT and stirred for 1 h. Then, the reaction was quenched with 
a saturated aqueous solution of NH4Cl (0.5 mL). The phases were separated, and 
the aqueous layer was extracted using EtOAc (3 × 3 mL). The combined organic 
phases were dried and evaporated in vacuo. The crude was subjected to HPLC 
separation [column Ascentis (Supelco) Si, 25 cm  4.6 mm, 5 µm; eluent: n-
hexane/isopropanol 7:3, flor rate 1 mL min-1] to give alcohol 10 (tR=14.5 min, 1.0 
mg, x %) as a colorless oil. [α]D20 = +12.13 (c = 0.13 ; CHCl3); 1H NMR (400 MHz, 
CDCl3, mixture of rotamers):  δ 5.83 (0.4H, s, vinyl proton), 5.81 (0.6H, s, vinyl 
proton), 3.50 (2H, bt, J=5.7), 3.34, 3.26 (1H each, both t, uno dei due non è proprio 
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un tripletto,  J=7.49, H2-24), 2.98 (1.8H, s, H3-27), 2.91 (1.2H, s, H3-27), 2.31-2.17 
(2H, m), 2.11-2.05 (-H, overlapped signals including a singlet at 2.08 for H3-26); 
1.75-1.53 (-H, questo segnale a circa 1.57 è l’acqua???); 1.29-1.19 (1H, m), 0.98, 
0.96 (overall 3H, overlapped doublets, both J=6.10, H3-17); 
13C NMR (100 MHz, 
CDCl3):  170.7, 170.5, 142.0, 141.4, 113.0, 112.5, 67.9, 50.2, 47.4, 35.7, 35.6, 
33.2, 32.2, 31.7, 30.33, 30.28, 27.6, 27.5, 26.2, 25.2, 21.9, 16.4; HRMS (ESI) m/z 
calcd for C13H25ClNO2 [M + H]
+ 262.1568; found 262.1566. 
Compound 11 
  
To a stirred solution of alcohol 9 (1.4 mg, 0.005 mmol) in pyridine (0.6 mL), excess 
acetic anhydride (0.4 mL) was added at rt. After 2h the reaction mixture was 
evaporated under reduced pressure. The crude was subjected to HPLC separation 
[column Ascentis Si (Supelco), 25 cm x 4.6 mm, 5 µm; eluent: n-
hexane/isopropanol 75:25, flow rate 1 mLmin-1] to give acetyl derivative 11 as a 
colourless oil (1.5 mg, 0.0047 mmol, 95%). [α]D20 = + 5.1 (c = 0.12, CHCl3); 1H-
NMR: (400 MHz, CDCl3, mixture of rotamers):  5.87 (0.4H, s, vinyl proton), 5.82 
(0.6H, s, vinyl proton), 3.98-3.85 (2H, m), 3.39 (1.2 H, t, J=6.7, H2-24), 3.29 (0.8 
H, t, J=6.7, H2-24), 3.00 (1.8 H, s, H3-27), 2.93 (1.2H, s, H3-27), 2.27-2.03 (10H, 
overlapped signals including singlets at 2.10, 2.09 and 2.07 for acetates), 1.80-1.54 
(4H, m), 1.57-1.47 (1H, m), 1.31-1.21 (1H, m), 0.95, 0.93 (overall 3H, overlapped 
d’s, both J=6.0, H3-17); 13C-NMR (100 MHz, CDCl3):  141.9, 141.7, 141.3, 141.0, 
113.5, 112.7, 68.92, 68.83, 50.5, 47.2, 36.0, 33.2, 32.12, 32.11, 32.09, 32.08, 31.31, 
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31.29, 31.27, 31.26, 27.45, 27.40, 27.38, 25.8, 24.7, 21.2, 20.9, 16.7; HRMS (ESI) 
m/z calcd for C15H27ClNO3 [M+H]
+ 304.1674, found 304.1669. 
Compound 12 
 
To a stirred solution of alcohol 10 (1.2 mg, 0.004 mmol) in pyridine (0.5 mL), 
excess acetic anhydride (0.4 mL) was added at rt. After 2h the reaction mixture was 
evaporated under reduced pressure. The crude was subjected to HPLC separation 
[column Ascentis Si (Supelco), 25 cm x 4.6 mm, 5 µm; eluent: n-
hexane/isopropanol 75:25, flow rate 1 mLmin-1] to give acetyl derivative 12 as a 
colourless oil (1.0 mg, 0.003 mmol, 75%). [α]D20 = +12.88 (c = 0.06 ; CHCl3); 1H-
NMR: (500 MHz, CDCl3, mixture of rotamers):  5.83 (0.4H, s, vinyl proton), 5.82 
(0.6H, s, vinyl proton), 3.99-3.88 (2H, m), 3.34 (1.2 H, t, J=7.6, H2-24), 3.26 (0.8 
H, t, J=7.6, H2-24), 2.98 (1.8 H, s, H3-27), 2.91 (1.2 H, s, H3-27), 2.27-2.20 (3H, 
m,), 2.10-2.03 (7H, overlapped signals including singlets at 2.08, 2.07 and 2.06 for 
acetates), 1.85-1.45 (5H, m), 1.32-1.23 (1H, m), 0.99, 0.98 (overall 3H, overlapped 
d’s, both J=6.0, H3-17); 13C-NMR (100 MHz, CDCl3):  171.4, 171.3, 170.6, 141.7, 
141.0, 113.24, 112.7, 112.6, 69.0, 68.9, 50.2, 47.2, 36.2, 33.2, 32.44, 32.40, 31.7, 
30.5, 27.5, 27.4, 26.1, 25.2, 22.0, 21.1 16.7; HRMS (ESI) m/z calcd for 
C15H27ClNO3 [M + H]
+ 304.1674; found 304.1671. 
Compound 13 
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Compound 13 was prepared from alcohol 9 as previously described [4]. [α]D20 = 
+127.4 (c = 0.5, CHCl3); IR (neat) νmax: 2957, 2927, 2858, 1707, 1651, 1596, 1459, 
1424, 1373, 1262, 1122 cm−1; 1H NMR (400 MHz, CDCl3, mixture of rotamers): δ 
6.49 (1H, d, J = 10.1, H-15), 5.82 (0.5H, s, vinyl proton), 5.76 (0.5H, s, vinyl 
proton), 4.18 (2H, q, J = 7.0, OCH2CH3), 3.37, 3.27 (1H each, both t, J = 7.6, H2-
24), 2.99 (1.5H, s, H3-27), 2.91 (1.5H, s, H3-27), 2.46 (1H, m, H-16), 2.18 (2H, m), 
2.09 (1.5H, s, H3-26), 2.08 (1.5H, s, H3-26), 2.01 (2H, t, J = 8.6), 1.83 (1.5H, d, J = 
1.2, H3-14), 1.82 (1.5H, d, J = 1.2, H3-14), 1.30 (3H, t, J = 7.0, OCH2CH3), 1.02 
(1.5H, d, J = 6.6, H3-17), 1.00 (1.5H, d, J = 6.6, H3-17); 
13C NMR (100 MHz, 
CDCl3) δ 170.5, 170.3, 168.3, 168.2, 146.9, 146.6, 141.6, 140.8, 132.1, 132.0, 
131.94, 131.91, 128.5, 128.4, 127.2, 127.0, 113.4, 112.7, 60.6, 60.5, 50.4, 47.1, 
36.0, 34.7, 34.6, 33.1, 32.7, 27.4, 27.3, 25.7, 24.6, 21.9, 21.3, 20.01, 19.98, 14.3, 
12.63, 12.61; HRMS (ESI) m/z calcd for C18H30ClNNaO3 [M + Na]
+ 366.1812; 
found 366.1802.  
Compound 22 
 
To a stirred suspension of methylenetriphenylphosphorane (6.6 mg, 0.024 mmol) 
in THF (0.5 mL), nBuLi (0.015 mL, 0.024 mmol, 1.6 M sol. in hexane) was added 
dropwise at 0 °C under argon. After 30 min at 0 °C, a solution of ketone 18 (5.5 
mg, 0.012 mmol) in dry THF (0.3 + 0.3 mL rinse) was added, and the mixture was 
allowed to reach rt. After 4 h, the reaction was quenched with a saturated aqueous 
NH4Cl solution (2 mL) and extracted using Et2O (3× 5 mL). The organic phase was 
washed with brine, dried, and evaporated under reduced pressure. The crude was 
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purified by preparative TLC (chloroform/methanol 95:5) affording compounds 22 
as a colourless oil. 1H NMR: δ 7.66 (4H, J=6.9, ArH), 7.44-7.35 (6H, m, ArH), 4.76 
(0.5H, s, methylene proton), 4.72 (0.5H, s, methylene proton), 4.71 (1H, s, 
methylene protons), 3.53-3.44 (2H, m), 3.34, 3.23 (1H each, both t, J=7.6, H2-24), 
2.96 (1.5H, s, H3-27), 2.90 (1.5H, s, H3-27), 2.07 (3H, s, H3-26), 2.05-1.92 (4H, m), 
1.74-1.56 (4H, m), 1.32-1.17 (1H, m), 1.05 (9H, s, C(CH3)3), 0.93 (3H, d, J=6.5, 
H3-17); 
13C NMR (100 MHz, CDCl3): δ 170.4, 149.2, 148.4, 135.6, 134.0, 133.9, 
129.52, 129.48, 109.5, 108.9, 68.8, 68.7, 50.5, 47.4, 36.1, 35.4, 33.45, 33.38, 33.2, 
32.8, 31.2, 29.7, 26.9, 26.1, 25.3, 21.9, 21.2, 19.3, 16.7; HRMS (ESI) m/z calcd for 
C29H43NO2Si [M + H]
+ 466.3136; found 466.3124. 
Compound 14 
 
To a solution of 22 (5.4 mg, 0.012 mmol) in THF (0.8 mL), TBAF (0.017 mL, 0.017 
mmol, 1.0 M solution in THF) was added at 0 °C. The reaction mixture was allowed 
to reach rt and stirred for 1 h. Then, the reaction was quenched with a satd. aq. 
solution of NH4Cl (1 mL). The phases were separated, and the aqueous layer was 
extracted with EtOAc (3 x 5 mL). The combined organic phases were dried and 
evaporated in vacuo. The crude was subjected to HPLC separation [column 
Ascentis Si (Supelco), 25 cm x 4.6 mm, 5 µm; eluent: ethyl acetate/isopropanol 9:1, 
flow rate 1 mLmin-1] to give alcohol 14 (1.9 mg, 0.008 mmol, 70%) as a colourless 
oil. [α]D20 = + 7.24 (c = 0.07 ; CHCl3); 1H NMR (400 MHz, CDCl3, mixture of 
rotamers): δ 4.79 (0.5 H, s, methylene proton), 4.75 (1.5H, bs, methylene protons), 
3.54-3.43 (2H, m), 3.41-3.30 (1H, m, H2-24), 3.27 (1H, t, J=7.4, H2-24), 2.99 (1.5H, 
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s, H3-27), 2.92 (1.5H, s, H3-27), 2.12 1.98 (overall 7H, including singlets at 2.09 
and 2.07 for H3-26), 1.75-1.50 (4H, m), 1.32-1.19 (1H, m), 0.95, 0.93 (overall 3H, 
overlapped d’s, J=6.5, H3-17); 13C NMR (100 MHz, CDCl3): δ 170.6, 150.8???, 
148.8, 148.3, 109.6, 109.2, 68.14, 68.10, 50.4, 47.5, 36.3, 35.4, 33.4, 33.2, 33.1, 
33.0, 32.1, 31.08, 31.03, 29.7, 26.0, 25.1, 21.3, 16.6, 16.5; HRMS (ESI) m/z calcd 
for C13H26NO2 [M + H]
+ 228.1958; found 228.1956. 
Compound 15 
 
To a stirred solution of alcohol 14 (1.5 mg, 0.006 mmol) in pyridine (0.2 mL), 
excess acetic anhydride (0.2 mL) was added at rt. After 2h the reaction mixture was 
evaporated under reduced pressure. The crude was subjected to HPLC separation 
[column Ascentis Si (Supelco), 25 cm x 4.6 mm, 5 µm; eluent: n-
hexane/isopropanol 75:25, flow rate 1 mLmin-1] to give acetyl derivative 15 as a 
colourless oil (1.0 mg, 0.004 mmol, 62%). [α]D20 = + 13.63 (c = 0.07 ; CHCl3); 1H 
NMR (400 MHz, CDCl3, mixture of rotamers): δ 4.78 (0.5H, s, methylene proton), 
4.75 (0.5H, s, methylene proton), 4.74 (1H, s, methylene protons), 3.99-3.84 (2H, 
m), 3.36, 3.26 (1H each, both t, J=7.6, H2-24), 2.98 (1.5H, s, H3-27), 2.92 (1.5H, s, 
H3-27), 2.12-1.96 (10H, overlapped signals including singlets at 2.09, 2.08 and 2.06 
for acetates) 1.82-1.60 (4H, m), 1.34-1.22 (1H, m), 0.95, 0.94 (overall 3H, 
overlapped d’s, J=6.5, H3-17); 13C NMR (175 MHz, CDCl3): δ 170.42, 171.36, 
170.6, 141.7, 141.05, 113.24, 112.6, 112,65, 69.0, 68.9, 50.2, 47.1, 36.2, 33.2, 
32.42, 32.40, 31.9, 31.7, 30.5, 27.45, 27.39, 26.1, 25.2, 22.0, 21.4, 21.0, 16.7;  
HRMS (ESI) m/z calcd for C15H27NO3 [M + H]
+ 270.2063; found 270.2061. 
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3.6 Supplementary spectroscopic data 
 
 
 
 
 
Figure 3.6. 1H NMR spectrum of compound 16 (CDCl3, 400 MHz). 
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Figure 3.7. 1H NMR spectrum of compound 8 (CDCl3, 400 MHz). 
 
 
Figure 3.8. 13C NMR spectrum of compound 8 (CDCl3, 100 MHz). 
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Figure 3.9. 1H NMR spectrum of compound 10 (CDCl3, 400 MHz). 
 
 
Figure 3.10. 13C NMR spectrum of compound 10 (CDCl3, 100 MHz). 
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Figure 3.11. 1H NMR spectrum of compound 11 (CDCl3, 400 MHz). 
 
 
Figure 3.12. 13C NMR spectrum of compound 11 (CDCl3, 100 MHz). 
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Figure 3.13. 1H NMR spectrum of compound 12 (CDCl3, 400 MHz) 
 
 
Figure 3.14. 13C NMR spectrum of compound 12 (CDCl3, 100 MHz) 
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Figure 3.15. 1H NMR spectrum of compound 22 (CDCl3, 400 MHz).  
 
Figure 3.16. 13C NMR spectrum of compound 22 (CDCl3, 100 MHz). 
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Figure 3.17. 1H NMR spectrum of compound 14 (CDCl3, 400 MHz). 
 
Figure 3.18. 13C NMR spectrum of compound 14 (CDCl3, 100 MHz). 
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Figure 3.19. 1H NMR spectrum of compound 15 (CDCl3, 400 MHz). 
 
 
Figure 3.20. 13C NMR spectrum of compound 15 (CDCl3, 100 MHz). 
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PART 2 
 
Isolation and structural determination of 
new bioactive metabolites from marine 
sources 
 
 Chapter 4 
Conulothiazoles A and B, two chlorinated 
peptide/polyketide metabolites from the marine 
sponge Smenospongia conulosa 
 
In an attempt to identify new bioactive metabolites to be used as lead compounds 
in the anticancer drug discovery, the study of the chemical composition of the 
Caribbean sponges of Smenospongia genus (Demospongiae, Dictyoceratida, 
Thorectidae), in particular S. aurea and conulosa, was carried out.  
    
Figure 4.1. Smenospongia aurea and conulosa sponges, respectively. 
 
The chemical analysis of the organic extract of S. aurea led to the isolation of four 
chlorinated PKS/NRPS compounds, namely smenamide A (1) and B (2), and 
smenothiazole A (3) and B (4), the structure of which is depicted in Figure 4.2. 
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Figure 4.2. Structures of smenamide A (1) and B (2), and smenothiazole A (3) and B (4). 
 
Both smenamides and smenothiazoles showed an interesting cytotoxic activity at 
nanomolar concentrations. More precisely, smenamides were shown to exert their 
cytotoxic activity against Calu-1 lung cancer cells,1 whereas smenothiazoles have 
shown a certain selectivity against ovarian cancer cells.2 
In lights of the captivating chemical content of S. aurea, its congeneric species, S. 
conulosa, was studied. The in-depth analysis revealed the presence in the organic 
extract of two additional chlorinated NRP/PK derivatives (Figure 4.3): 
conulothiazoles A (5) and B (6).3 
 
4.1 Isolation of conulothiazoles A and B 
A specimen of the sponge S. conulosa was collected by Scuba along the coasts of 
Little Inagua (Bahamas) in 2013, during one of Prof. J. Pawlik expeditions. After 
collection, it was immediately frozen and stored at −20 °C until it arrived to the 
Department of Pharmacy, in the laboratory of Prof. Costantino. The sample, 
properly homogenized, was subjected to several extractions using CH3OH, 
mixtures of CH3OH /CHCl3 and CHCl3. The methanol extract was partitioned 
between water and butanol with the aim of separating the lipophilic metabolites, 
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including compounds 5 and 6, from hydrophilic molecules such as proteins, 
carbohydrates and nucleic acids, which instead split up into the aqueous phase. The 
butanol phase was combined with the chloroform extracts and concentrated under 
vacuum obtaining a crude extract, then subjected to reverse phase chromatography 
on silica gel RP-18. Fraction A5 (MeOH/H2O 9:1) of the column chromatography 
was shown to be the fraction of interest, containing compounds 5 and 6. Due to the 
high content in known alkaloids, fraction A5 undergone an acid partition between 
chloroform, methanol and acidic water (1% v/v of acetic acid), in order to remove 
the alkaloids from the organic phase. The latter was hence subjected to two 
subsequent reverse phase HPLC separations, affording 5 (225 μg) and 6 (47 μg) as 
pure compounds (Figure 4.3).  
 
Figure 4.3. Structures of conulothiazoles A (5) and B (6). 
 
4.2 Structural determination of compound 5 and 6 
The structural elucidation of natural compounds, which are often isolated and 
purified in exiguous amounts, is undoubtedly the most fascinating aspect of the 
work of natural products chemists. The interest towards natural products increased 
in parallel with the technological progress and the development of new powerful 
analytical tools. The combined use of the most modern spectroscopic (NMR, IR, 
UV) and spectrometric (MS) techniques led to the isolation of conulothiazoles A 
(5) and B (6). Despite the small amount of the compounds isolated from the sponge, 
it was possible to record a complete series of two-dimensional homonuclear and 
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heteronuclear NMR spectra (COSY, HSQC, HMBC), which allowed the complete 
assignment of its structure. All 13C chemical shifts were assigned using the 2D 
NMR spectra, therefore one-dimensional NMR 13C spectra were not recorded. 
The positive ion mode high-resolution ESI mass spectrum of conulothiazole A 
(Figure 4.4) showed the presence of a [M + Na]+ pseudomolecular ion peak at m/z 
411.1270 and a M+2 isotopic peak, whose intensity (38%) suggested the presence 
in the structure of the molecule of both a chlorine (37Cl , 32%) and a sulfur atom 
(34S, 4%). These data are in perfect agreement with the molecular formula, which 
was determined as C21H25ClN2OS. 
 
Figure 4.4. Positive ion mode high-resolution ESI MS spectrum of compound 5. 
 
From the molecular formula it was possible to establish the number of 
unsaturations, which is equal to 10. 
The analysis of the 1H NMR spectrum (Figure 4.5) of 5, evidenced a certain 
similarity of this compound with the smenothiazole A (3, Figure 4.2). Both 
compounds share indeed a benzyl-vinyl chloride function and a thiazole ring.  
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These data were confirmed by the analysis of 13C NMR spectrum and by the main 
correlation peaks provided by the homonuclear and heteronuclear 2D-NMR spectra 
(Table 4.1 and Figure 4.6). 
The elucidation of central portion of the molecule could not be determined by the 
comparison with known compounds, and instead required a detailed analysis of 
one- and two-dimensional NMR spectra. 
The presence of an α-methyl, α,β-unsaturated amide function was demonstrated by 
the analysis of the HMBC spectrum (Figure 4.14), in which three correlations peaks 
of the methyl singlet (H3-8) at δ1.83 with the carbonyl carbon at δ 172.3 (C-6) and 
with the two olefinic carbons at δ 132.5 (C-7) and 137.7 (C-9) are present. This 
function is directly linked to a carbon chain constituted by three methylene groups, 
as confirmed by the vicinal couplings in the COSY spectrum (Figure 4.11). The 
allylic coupling of protons at δ 2.20 (H2-12) with the proton H-14 at (δ 6.02) 
allowed to demonstrate that the chlorovinyl function is linked to the three 
methylene-chain.  
The correlations peaks of the methyl protons at δ1.63 (H3-5) with the proton at δ 
5.39 (H-4) in the COSY spectrum suggested the presence of a single α-amino acid 
CH, deriving from an alanine residue [δH5.39 (H-4) and δC48.9 (C-4)]. The presence 
in the HMBC spectrum of two correlation peaks of proton H-4 at δ 5.39 with both 
carbon C-3 at δ 176.7 of the thiazole ring and the carbonyl carbon at δ 172.3 (C-6), 
allowed to understand that the thiazole ring was directly linked to the alanine-
derived residue.  
At that point, the only possible connection between the polyketide and the peptide 
moiety of the molecule was an amide bond between the carbonyl carbon C-6 (δ 
172.3) and the amino group at δ 48.9 (C-4). 
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These data completed the determination of planar structure of conulothiazole A (5, 
Figure 4.3). 
 
 
Pos. δH [mult., J (Hz)] δC (mult.) COSY HMBC 
1 7.71 (d, 3.4)  142.9 (CH) 2  
2 7.48 (d, 3.3) 120.5 (CH) 1 1, 3 
3 - 176.7 (C)   
4 5.39 (quartet, 7.1)   48.9 (CH) 5 3, 5, 6 
5 1.63 (d, 7.1)   20.9 (CH3) 4 3, 4 
6 - 172.3 (C)   
7 - 132.5 (C)   
8 1.83 (br. s)   12.8 (CH3) 9, 10 6, 7, 9 
9 6.34 (t of quartets, 7.4, 1.4) 137.7 (CH) 8, 10 6, 8 
10 2.16 (quartet, 7.5)   29.1 (CH2) 8, 9, 11 7, 9, 11, 12 
11 1.55 (quintet, 7.7)   27.2 (CH2) 12 9, 10, 12, 13 
12 2.20 (br. t, 7.9)   30.5 (CH2) 11, 14 10, 11, 13, 14, 15 
13 - 143.5 (C)   
14 6.02 (br. s) 115.4 (CH) 12, 15 12, 13, 15 
15 3.42 (br. s)   42.0 (CH2) 14, 17/21 12, 13, 14, 16, 17/21 
16 - 139.9 (C)   
17/21 7.19 (br. d, 7.8) 130.1 (CH) 15, 18/20 15, 19, 21/17 
18/20 7.28 (br. t, 7.8) 129.7 (CH) 17/21, 19 16, 20/18 
19 7.20 (br. t, 7.8) 127.7 (CH) 18/20 17/21 
 
Table 4.1. NMR data of conulothiazole A (5) (700 MHz, CD3OD. 
 
 
The molecular formula C22H27ClN2OS of compound 6 was established by the 
analysis of the high resolution ESI mass spectrum (Figure 4.5), in which a [M+Na]+ 
pseudomolecular ion peak at m/z 425.1426. In comparison with conulothiazole A 
(5) (Figure 4.3), the molecular formula of 6 accounts for 14 additional amu. This 
suggested the presence in compound 6 of an additional methyl group, which was 
indeed confirmed by the analysis of 1H NMR spectrum of compound 6 (Figure 4.15 
and table 4.2). 
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Figure 4.5. Positive ion mode high-resolution ESI MS spectrum of compound 6. 
 
As for conulothiazole A (5), a full set of homonuclear and heteronuclear two-
dimensional NMR spectra were recorded to elucidate the planar structure of 
compound 6. The only difference, from the spectroscopic point of view, between 
compounds 5 and 6 resides in the presence in the COSY spectrum (Figure 4.16) of 
a correlation between methyl protons H3-22 (δ 1.01) with the allylic methine proton 
H-10 (δ 2.47), and the absence of the allylic methylene proton signal at δ 2.16 (H2-
10), which allowed to understand that the additional methyl group is located in 
position 10. These data confirmed the structure of conulothiazole B (6). 
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Pos.  δH [mult., J (Hz)] δC (mult.) COSY HMBC 
1  7.71 (d, 3.4)  145.3 (CH) 2  
2  7.48 (d, 3.3) 120.5 (CH) 1 1, 3 
3  - 176.8 (C)   
4  5.40 (quartet, 7.1)   49.3 (CH) 5 3, 5, 6 
5  1.64 (d, 7.2)   21.7 (CH3) 4 3, 4 
6  - 172.3 (C)   
7  - 131.6 (C)   
8  1.84 (d, 1.4)   13.6 (CH3) 9 6, 7, 9 
9  6.14 (dq, 9.8, 1.4) 144.2 (CH) 8, 10 8 
10  2.47 (dddq, 9.8, 7.9, 5.9, 6.7)   34.4 (CH2) 9, 11a, 11b, 22  
11 a 1.48 (dddd, 13.2, 10.7, 5.9, 
5.9) 
  35.5 (CH2) 10,11b,12a, 12b 13 
 b 1.38 (dddd, 13.2, 10.7, 7.9, 
5.5) 
 10, 11a, 12a, 
12b 
10, 12, 13 
12 a 2.15 (ddd, 13.2, 10.7, 5.9)   29.8 (CH2) 11a, 11b, 12b, 14 11, 13, 14, 
15 
 b 2.10 (ddd, 13.2, 10.7, 5.5)  11a, 11b, 12a, 14 10, 13, 14, 
15 
13  - 143.8 (C)   
14  5.99 (br. s) 115.5 (CH) 12a, 12b, 15 12, 13, 15 
15 
 
3.40 (br. s)   42.5 (CH2) 14, 17/21, 18/20 
12, 13, 14, 
16, 17/21 
16  - 140.3 (C)   
17/21 
 
7.17 (br. d, 7.8) 130.5 (CH) 15, 18/20 
15, 19, 
21/17 
18/20  7.27 (br. t, 7.2) 129.9 (CH) 15, 17/21, 19 16, 20/18 
19  7.20 (br. t, 7.0) 127.7 (CH) 17/21, 18/20  
22  1.01 (d, 6.7)   20.4 (CH3) 10 9, 10, 11 
Table 4.2. NMR data of conulothiazole B (6) (700 MHz, CD3OD). 
 
 
4.3 Stereostructural determination of the two double bonds of conulothiazole 
A and B 
The correlations peaks present in the NOESY spectrum (Figure 4.12) allowed the 
assignment of the configuration of the two double bonds of compound 5 and 6. The 
configuration of both double bonds in conulothiazole A was determined as E, 
thanks to the presence in the NOESY spectrum of the correlation peaks between the 
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proton H-14 (δ 6.02) and the protons H2-15 (δ 3.42) and between protons H3-8  (δ 
1.83) and the protons H2-10 (δ 2.16). 
Conulothiazole B (6) possess the same configuration at both double bonds of 
conoulothiazole A (5). The configurations were determined as E through the 
analysis of ROESY spectrum (Figure 4.6 and Figure 4.17). 
 
 
Figure 4.6. The most significant correlations provided by the COSY, HMBC, and 
NOESY/ROESY 2D NMR spectra of conulothiazoles A (5) and B (6). 
 
4.4 Determination of the absolute configuration of the amino acid residues of 
conulothiazoles A and B 
As for smenamide A (chapter 1, paragraph 2.4), the absolute configuration of the 
amino acid residues of both compound 5 and 6 was determined by using a modified 
procedure of Marfey’s method. The sample was subjected to ozonolysis prior to 
hydrolysis with HCl to prevent racemisation which is reported to occur during 
hydrolysis at the carbon in α position to a thiazole ring (Figure 4.7). 
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Figure 4.7. Ozonolysis, hydrolysis and derivatization of conulothiazole A (5) with L-enantiomer 
of Marfey’s reagent. 
 
The absolute configuration of the alanine residue of conulothiazole A (5) and B (6) 
was determined as S for both compounds, on the basis of the retention times of their 
respective Marfey’s derivatives (Figure 4.8). 
 
 
 
Figure 4.8. HR-ESI-MS-HPLC analysis of Marfey’s derivatives from conulothiazole A (5) and B 
(6). Extracted-ion chromatograms at m/z 342.1044 of (a) authentic L-1-fluoro-2-4-dinitrophenyl-5-
alanine amide L-alanine (L-FDAA-L-Ala); (b) authentic D-FDAA-L-Ala; (c) L-FDAA-Ala from 
5; and (d) L-FDAA-Ala from 6. 
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4.5 Biogenetic studies 
The biogenetic studies on these new metabolites were carried out in collaboration 
with the research group of Prof. Alfonso Mangoni. Since I was not directly involved 
in this part of the project, I will only discuss the most significant results.  
Although smenamides, smenothiazoles and conulothiazoles do not have analogues 
in the field of natural products, they share some structural features with different 
known molecules, belonging to the class of hybrid peptides/polyketides compounds 
(Figure 4.9). 
 
Figure 4.9. Structural analogies of Smenospongia metabolites with cyanobacteria metabolites. 
 
The dolapyrrolidinone eastern terminus of smenamides is also present in dolastatin-
15 (a depsipeptide of probable cyanobacterial origin isolated for the first time from 
the sea hare Dolabella auricolaria) and in other cyanobacterial metabolites, known 
as mycapolyols A–F.4 The chlorovinyl function, present in the structure of all the 
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three smenamides, smenothiazoles and conulothiazoles, is an intriguing structural 
feature shared with jamaicamides, isolated from the cyanobacterium Lyngbia 
majuscula5 ( recently renamed as Moorea producens).6 Moreover, the peptide 
moiety of both smenothiazole A and B (3 and 4, respectively, Figure 4.2) is very 
similar to the eastern part of apramide G.7  
The secondary metabolites isolated from sponges can be either produced through 
the secondary metabolism of the sponge itself or through the symbiotic relationship 
of the sponge with microorganisms, such as bacteria or cyanobacteria. Although it 
has not yet been possible to establish whether compounds 1-6 (Figure 4.2 and 4.3), 
isolated from Smenospongia aurea and conulosa, are produced in one or the other 
way, comparable amounts of smenamides (1 and 2, Figure 4.2) were found in three 
samples of S. aurea collected in different moments and in different geographical 
areas. This observation, strengthened by the structural similarity of the smenamides 
with products of the metabolism of cyanobacteria, suggests their probable 
cyanobacterial origin. 
Recently, biogenetic studies were performed in order to detect the presence in the 
metagenome of S. aurea of cyanobacterial sequences.3 PCR experiments were 
performed by using the metagenome of the sponge as a template, while specific 
primers were used to reveal the presence of 16S rRNA cyanobacterial sequences. 
The production of clear bands of the expected length of 670 bp, confirmed the 
presence of cyanobacteria in S. aurea. Therefore, a gene library of the 16S rRNA 
sequences was build up from amplicons and 24 clones were sequenced. Except for 
three sequences not related to cyanobacteria, all the sequences match at 99% and 
were assigned to the Candidatus Synechococcus spongiarum, a "sponge-specific" 
line of unicellular symbiont cyanobacteria. The latter are considered the most 
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prevalent and widespread symbiotic cyanobacteria in tropical and temperate reef 
sponges.8 
Despite the presence of Ca. Synechococcus spongiarum in S. aurea was confirmed, 
this is not a sufficient condition to affirm that this cyanobacterium is the real 
producer of compounds 1-4 (Figure 4.2).  The isolation of metagenomic DNA from 
a complex and heterogeneous matrix, including marine sponges tissues, is a delicate 
procedure which involves the risk of overlooking underrepresented microbial taxa 
present among the symbiont microorganisms of the sponge. Morever, the genome 
of Ca. Synechococcus spongiarum from the sponge Carteriospongia foliascens was 
recently sequenced,9 providing no clue with the presence of NRPS or PKS 
pathways.10 This evidence further weakened the hypothesis according to which 
Synechococcus spongiarum may be the  real producer of smenamides (1, 2) and 
smenothiazoles (3, 4). 
Envisioning different approaches to metagenomic screening in order to detect the 
microbial source of these compounds, cell separation has emerged as a valid 
alternative approach.11,12,13 The latter was shown to be valuable technique used for 
the identification of symbionts microorganism producing secondary metabolites 
and the isolation of the relevant biosynthetic gene clusters. 
Therefore, a cell separation, using density gradient centrifugation (to prepare 
fractions enriched with bacteria of different cell densities), was performed on a 
freshly collected sample of S. conulosa, in order to gain a preliminary idea of the 
cellular distribution of the chlorinated peptide/polyketide hybrids of interest. 
The cell fractions were analysed by high resolution LC-MS revealing that these 
metabolites are mainly localised in two high-density fractions. In addition, the 
microscopically examination of these fractions showed that they are principally 
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constituted by a highly enriched population of large filamentous and branched green 
microorganisms, which could represent the producers of our compounds. 
Moreover, the unicellular cyanobacterium Synechococcus spongiarum  is mostly 
localized in low-density cell fractions. The latter evidence allows the exclusion of 
this bacterium as the producer of the chlorinated compounds from Smenospongia 
spp. 
Further studies are in progress to gain a better insight in the biogenesis of these 
metabolites, using the metagenomic DNA from the filamentous cell fractions, and 
to identify and isolate their biosynthetic gene clusters, with the future perspetive of 
heterologous expression. 
 
4.6 Conclusions 
The analysis of the lipophilic extract of the Caribbean sponge Smenospongia 
conulosa led to the isolation of two new hybrid peptide/polyketide compounds, 
conulothiazoles A (5) and B (6). Despite the scarce amount of these compounds 
isolated from the marine source, a full set of one- and two-dimensional NMR 
spectra were recorded, which allowed the structural elucidation of the molecule. 
The absolute configuration of the amino acidic  carbon of the alanine residue of 
both molecules was established by using Marfey’s method. Recent biogenetic 
studies on the metagenome of S. aurea showed the presence of Ca Synechococcus 
spongiarum as symbiont bacterium of the sponge. Unfortunately, further studies 
demonstrated that this microorganism is not the real producer of the chlorinated 
compounds isolated from S. aurea. Due to the little amount of these metabolites 
isolated from the sponge, the evaluation of their cytotoxic activity was not carried 
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out in order to avoid the massive collection of the sponge preserving the marine 
ecosystem. 
 
4.7 Experimental section 
4.7.1 Collection  
A sample (615 g wet weight) from the sponge Smenospongia conulosa (Order 
Dictyoceratida, Family Thorectidae) was collected on 10 July 2013 at 15 m depth 
by Scuba-diving along the coast of Little Inagua Island, Bahamas (GPS coordinates 
21°27.041' N 73°03.483' W) during a ship-board research expedition. The sample 
(a relatively small portion of a much larger sponge) was excised with a sharp scalpel 
to minimally affect the remaining sponge tissue and allow recovery and regrowth. 
After collection, the sample was unambiguously identified onboard using a web-
based photographic and taxonomic key, The Sponge Guide 
(www.spongeguide.org), with subsequent confirmation by sponge taxonomist Dr. 
Sven Zea. The sample was frozen immediately after collection and stored at −20 °C 
until extraction. A voucher specimen of the organism is stored at Dipartimento di 
Farmacia, Università degli Studi di Napoli “Federico II” with the reference number 
24713.  
  
4.7.2 Extraction and Isolation  
The sponge (615 g wet weight) was homogenized and extracted with MeOH (4 × 4 
L), MeOH and CHCl3 in different ratios (2:1, 1:1, 1:2) and then with CHCl3 (2 × 4 
L). The MeOH extracts were partitioned between H2O and n-BuOH; the BuOH 
layer was combined with the CHCl3 extracts and concentrated in vacuo. The total 
organic extract (15.31 g) was chromatographed on a column packed with RP-18 
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silica gel. The fraction eluted with MeOH/H2O (9:1, 293.5 mg) was partitioned into 
a two-phase system composed of H2O (160 mL), MeOH (260 mL), CHCl3 (140 
mL), and AcOH (5 mL); (see chapter 4) the organic layer, containing 
conulothiazoles, was subjected to reversed-phase HPLC separation [column 250 × 
10 mm, 10 μm, Luna (Phenomenex) C18; eluent A: H2O; eluent B: MeOH; 
gradient: 55→100% B, over 60 min, flow rate 5 mL min–1], thus affording a fraction 
(tR = 31 min) containing conulothiazole A and a fraction (tR = 33 min) containing 
the conulothiazole B. The two fractions were each separated on reversed-phase 
HPLC [C18, 5 μm, 250 × 4.6 mm; eluent A: H2O; eluent B: ACN; gradient: 
50→100% B, over 35 min, flow rate 1 mL min–1], which gave 36 µg of pure 
conulothiazole A  (tR = 20 min) and 41 µg of pure conulothiazole B (tR = 22 min). 
The weights were determined using an NMR quantitation method (QSCS)14 based 
on integration of solvent 13C satellite peaks.  A solution of pyridine in CD3OD (1.47 
mg/600µL) was used as external calibration. 
 
4.7.3 Conulothiazole A (5) 
Colorless amorphous solid, UV (MeOH): λmax (ε) 244 nm (15900) 216 nm 
(50900); HRESIMS (positive ion mode, MeOH) m/z 411.1270 [M+Na]+ (calcd. for 
C21H25ClN2NaOS
+ 411.1268); MS isotope pattern: M (100%), M + 1 (24%, calcd. 
22.7%), M + 2 (39%, calcd. 38.0%), M + 3 (8.3%, calcd. 8.3%); 1H and 13C NMR: 
see Table 5.1. 
 
4.7.4 Conulothiazole B (6)  
Colorless amorphous solid, UV (MeOH): λmax (ε): 244 nm (15600), 215 nm 
(48200); HRESIMS (positive ion mode, MeOH) m/z 425.1426 [M+Na]+ (calcd. for 
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C22H27ClN2NaOS
+ 425.1425); MS isotope pattern: M (100%), M+1 (24%, calcd. 
23.8%), M+2 (38%, calcd. 39.2%), M+3 (11%, calcd. 8.7%); 1H and 13C NMR: see 
Table 5.2.  
 
4.7.5 Ozonolysis and Hydrolysis 
 A small amount of compound 5 (4 µg) or 6 (4 µg) was separately suspended in 
ozone-saturated MeOH (300 μL) at  –78 °C for 5 min. The samples were dried 
under a N2 stream to remove ozone, then treated with 6 N HCl and heated in a sealed 
glass tube at 180 °C for 2 h. The residual HCl fumes were removed in vacuo. 
 
4.7.6 Marfey’s Derivatization with D- and L-FDAA  
The hydrolysate of 5 or 6 was dissolved in TEA/acetone (2:3, 100 µL) and the 
solution was treated with 100 µL of 1% 1-fluoro-2,4-dinitrophenyl-5-l-alaninamide 
(L-FDAA) in ACN/acetone (1:2). The vial was heated at 50 °C for 1 h. The mixture 
was dried, and the resulting L-FDAA-Ala derivatives were redissolved in 
ACN/H2O (5:95, 500 μL) for LC-MS analysis. An authentic L-Ala standard was 
treated with L-FDAA and D-FDAA as described above and yielded, respectively, 
the L-FDAA-L-Ala and D-FDAA-L-Ala standards used in the subsequent LC-MS 
analysis. 
 
4.7.7 High-resolution LC-MS Analysis of Marfey's derivatives  
Marfey’s derivatives were analyzed by LC-HRESIMS. A 5 μm Kinetex C18 
column (50 × 2.10 mm), maintained at 25 °C was eluted at 200 μL min−1 with H2O 
and CH3CN, using a gradient elution. The gradient program was as follows: 5% 
CH3CN 3 min, 5–60% MeOH over 20 min, 90% CH3CN 5 min. Mass spectra were 
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acquired in positive ion detection mode and the data were analyzed using the suite 
of programs Xcalibur. The retention times of L-FDAA-L-Ala and D-FDAA-L-Ala 
standards were determined as 15.36 and 16.37 min, respectively, on the basis of the 
extracted-ion chromatograms at m/z 342.1044. The retention times measured in the 
same way for the L-FDAA-Ala samples obtained from compounds 5 and 6 were, 
respectively, 15.32 min and 15.31 min, and were indicative of the L configuration 
of Ala in both compounds. 
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4.8 Supplementary spectroscopic data 
 
 Figure 4.10. 1H NMR spectrum of conulothiazole A (5) (CD3OD, 700MHz). 
 
Figure 4.11. COSY spectrum of conulothiazole A (5) (CD3OD, 700MHz). 
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Figure 4.12. NOESY spectrum of conulothiazole A (5) (CD3OD, 700MHz). 
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Figure 4.13. HSQC spectrum of conulothiazole A (5) (CD3OD, 700MHz). 
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Figure 4.14. HMBC spectrum of conulothiazole A (5) (CD3OD, 700MHz). 
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Figure 4.15. 1H NMR spectrum of conulothiazole B (6) (CD3OD, 700MHz). 
 
 
Figure 4.16. COSY spectrum of conulothiazole B (6) (CD3OD, 700MHz). 
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Figure 4.17. ROESY spectrum of conulothiazole B (6) (CD3OD, 700MHz). 
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Figure 4.18. HSQC spectrum of conulothiazole B (6) (CD3OD, 700MHz). 
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Figure 4.19. HMBC spectrum of conulothiazole B (6) (CD3OD, 700MHz). 
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 Chapter 5 
Evaluation of the antiproliferative activity of the 
organic extract of Geodia cydonium 
 
It is well known that marine sponges are one the of most prolific source of bioactive 
compounds, with about 4851 metabolites identified to date which correspond to 
nearly 30% of MNPs so far discovered.1 Currently, several studies have been 
conducted on most of the marine sponges, except for the Mediterranean sponge 
Geodia cydonium (Demospongiae, Astrophorida, Geodidae), for which only 
studies leading to the isolation of steroidal ketones have been reported.2  
 
Figure 5.1. A specimen of the Mediterranean sponge Geodia cydonium. 
 
A recent study3 on G. cydonium showed the anti-inflammatory effect of its 
methanol extract on human breast cancer MCF-7 cell line. Since inflammatory 
processes are often involved in the development, progression and metastasis of 
malignant tumours, the present study aimed to the evaluation of the anticancer 
162 
 
 
activity of the organic extract of G. cydonium.4 Since this was a multidisciplinary 
project, it was carried out in collaboration with the Istituto Nazionale per lo Studio 
e la cura dei Tumori “Fondazione G. Pascale”,  the “Stazione Zoologica Anton 
Dohrn”, the Department of Biology of University of Naples Federico II, and the 
Institute of Biomolecular Chemistry-CNR. As for my contribution to this project, I 
was involved in the analysis of the chemical content of the methanol extract of the 
sponge and its purification, as well as in the dereplication strategy. More precisely, 
the methanol extract of the sponge was subjected to chromatography and the three 
most abundant fractions obtained were tested on MCF-7, MDA-MB231 and MDA-
MB468 human breast cancer cell lines. Fraction 3 (Figure 5.3) was shown to have 
an antiproliferative activity on all of three cell lines, without interfering with the 
cell proliferation of the MCF-10A normal breast cell line, used as a control. Cellular 
studies were then carried out to understand whether the fraction is able to induce 
apoptosis and/or to block the cell cycle. Moreover, metabolomic studies have been 
performed on the cells treated with the fraction 3 in order to identify the metabolic 
pathways modulated by this fraction, whereas the increasing/decreasing of 
cytokines levels were analysed to evaluate the role of the active fraction in anti- or 
pro-inflammatory processes. Finally, the combined use of high resolution LC-MS, 
tandem mass spectrometry (MS/MS) and the molecular networking technique 
allowed to indentify the known as well as the new metabolites present in the fraction 
of interest. 
 
5.1 Bioguided fractionation of G. cydonium extracts 
A sample of the Mediterranean sponge G. cydonium  was collected on July 2015 at 
20 m depth by Scuba in the “Parco Sommerso di Baia” (Gulf of Naples, Italy). After 
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collection, the sponge was immediately frozen and stored at -20 °C until its arrive 
to the Department of Pharmacy. The sponge (509 g, wet weigh) was properly 
homogenized and extracted with CH3OH, mixtures of CH3OH/CH3Cl and CH3Cl. 
The methanol extract was partitioned between water and butanol. The butanol phase 
was then combined with the chloroform extracts and concentrated under vacuum 
obtaining a crude extract (3.9 g). The latter was then subjected to Droplet 
CounterCorrent Chromatography (DCCC) using CH3Cl/CH3OH/H2O (7:13:8) in 
the ascending mode. 6 mL fractions were collected and combined on the basis of 
their similar TLC profile. The most abundant fractions (fraction 1, 2 and 3) were 
tested on MCF-7, MDA-MB231 and MDA-MB468 human breast cancer cell lines 
and on MCF-10A normal breast cell line. Data showed that only fraction 3 has an 
antiproliferative activity on all the three cancer cell lines, while it has no effects on 
the healthy breast cell line. 
 
5.2 Combined use of LC-HRMS, LC-HRMS/MS and molecular networking 
as a novel dereplication strategy 
Molecular networking was recently introduced as a captivating dereplication 
strategy, allowing the identification of known metabolites as well as new 
compounds, which are present in an organic extract.5 The latter are analysed by LC-
HRMS and LC-HRMS/MS and the data obtained are used to generate a molecular 
network using the Global Natural Product Social Molecular Network (GNPS).6 
More precisely, the mass spectra obtained from one or more LC-HRMS/MS 
analyses are compared pairwise. Moreover, each spectrum is compared with 
MS/MS spectra of all of the natural compounds present in GNPS libraries. As a 
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result, a two-dimensional network is obtained, in which a node represents a single 
molecule, and each node is related to another through an edge. 
The molecular network obtained from the active fraction 3 is depicted in Figure 5.2. 
The network is characterized by six clusters, which are in turn constituted by two 
to thirteen nodes. 
 
 
Figure 5.2. (Left) Two-dimensional molecular network of the active fraction from the sponge 
Geodia cydonium. In the clusters indicated with (a–f), nodes are labeled with parent m/z ratio 
[M+H]+ ions; edge thickness is related to cosine similarity score; (Right) Liquid chromatography-
high resolution mass spectrometry (LC-HRMS) profile of the active fraction; the most abundant ions 
are represented by colored bold contour squares. 
 
Although molecular networking significantly reduces the dereplication efforts, a 
more traditional approach, based on the search against databases of marine natural 
compounds, is required when the molecular formula found does not match any 
compound name. A match within GNPS’ libraries gives indeed valuable 
information on the structure of the molecule but sometimes does not allow 
immediately the identification of a compound. Moreover, even though the MS/MS 
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spectra libraries contain a large number of known natural compounds, this number 
is still limited.  
Therefore, the results obtained from the molecular network of fraction 3 combined 
with the search of the traditional databases (Metlin at https://metlin.scripps.edu/ and 
MarinLit at http://pubs.rsc.org/marinlit/) gave the following information. Cluster 
a), consisting of thirteen nodes (Figure 5.2), was shown to contain nucleosides and 
nucleobases. Data obtained show the presence in this cluster of methyladenosine 
(m/z 282) and methyladenine (m/z 150), which were in turn connected to two nodes 
(m/z 268 and m/z 136 respectively). Although these compounds were also 
recognized by GNPS as methyladenosine and methyladenine, they possess a mass 
difference of 14 amu (atomic mass unit) with the library compounds, which 
indicates a missing methyl group. To confirm the identity of these compounds the 
HRMS spectra were analysed. Their molecular formulas were determined as 
C10H13O4N5 and C5H5N5, therefore confirming the identity of the compounds as 
adenosine and adenine, respectively. In addition, HRMS/MS spectra were recorded, 
confirming the characteristic fragmentation pattern of these nucleosides.7 More 
specifically, by cleavage of the glycosidic bonds, protonated bases (adenine and 
methyladenine) and a sugar moiety as the neutral fragment are obtained. According 
to LC-HRMS, the relative abundance of methyladenosine is 20-fold higher than 
adenosine, whereas methyladenine is double than adenine.  
Cluster b) contained instead two nodes: one with m/z 166 corresponded to 
phenylalanine, as confirmed also by the molecular formula. The second node (m/z 
132) was a compound related to pipecolinic acid (C6H11O2N) but with 2 additional 
amu. The molecular formula C6H14O2N for the [M+H]
+ pseudomolecular ion peak 
was consistent with a molecule  possessing two more hydrogens than pipecolinic 
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acid. This evidence suggested the presence in the compound of an open ring, 
corresponding therefore to a leucine. Both amino acids were found in comparable 
amounts in the active fraction, with Phe more abundant than Leu.  
GNPS6 identified the node with m/z 190.0498 in cluster c) as 5-aminosalycilic acid 
(5-asa). The compound actually had 36 amu more than 5-asa, corresponding to an 
additional C3 unit. The molecule containing 3 carbon atoms more as well as 3 
additional unsaturations, could not be therefore 5-asa. The molecule was then 
identified as 3-hydroxyquinaldic acid (3-HQA) in Metlin. A further confirmation 
was provided by the analysis of the HRMS/MS spectrum of the molecule, in which 
the ions at m/z 172.0390 and 144.0440 were present, showing the loss of water and 
formic acid (HCOOH), but not the loss of ammonia as expected by 5-asa.  
Finally, cluster d) included phosphatidylethanolamine (PE) and its analogues, while 
clusters e) and f) comprised unknown molecules, the structure of which could not 
be determined due to the small amount of the networked compounds. 
Each of the molecules found in the active fraction 3 was shown to be involved in 
one or more biological functions. Nucleosides (methyladenine and 
methyladenosine) and nucleotides (adenine and adenosine), found in cluster a), are 
essential metabolites of the living cells and are involved in fundamental biological 
processes, such as the synthesis of nucleic acids. Moreover, it is well known the 
antiviral, anticancer, vasodilator, muscle relaxant, and hypertensive activity of 
many marine nucleosides, which makes them promising lead compounds in drug 
design.8 The amino acids, such as leucine and phenylalanine found in cluster b), are 
molecules that are frequently found in the organic extracts of marine organisms, 
occurring both in the free-state and as basic structural units of proteins and peptides. 
Many marine amino acids derivatives and peptides possess captivating biological 
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activities, including a high specificity against cancer cell lines.9 3-HQA in cluster 
c) was identified as one of the two key chromophores (together with quinoxalinic 
acid) in many bisintercalator natural products of marine origin (such as thiocoraline, 
triostin, SW-163 and echinomycin/quinomycin),10 which are able to bind to duplex 
DNA by insertion between the bases allowing the proper placement of the peptidic 
core into the DNA minor groove.11 As for phosphatidylethanolamine (PE), present 
to cluster d), it belongs to the family of phospholipids and glycolipids that are the 
main constituents of sponge cell membranes, 12,13 and were shown to have immune-
modulating and antitumor activity.14,15 
 
5.3 Biological studies 
The biological studies on the three most abundant fractions obtained from the 
purification of the methanol extract of G. cydonium were performed in 
collaboration with the SC Farmacologia Sperimentale of Istituto Nazionale per lo 
Studio e la cura dei Tumori “Fondazione G. Pascale”,  the Department of Biology 
and Evolution of Marine Organisms (Stazione Zoologica Anton Dohrn), the 
Department of Biology of University of Naples Federico II, and the Bio-Organic 
Chemistry Unit of the Institute of Biomolecular Chemistry-CNR. Here the main 
results of these activities are reported. 
The antiproliferative activity of the three most abundant fractions obtained from the 
DCCC of the methanol extracts of G. cydonium was evaluated on three breast 
cancer (MCF-7, MDA-MB231, and MDA-MB468) cell lines through the 
sulforhodamine B (SRB) assay. After 24 and 48 hour of treatment, two of the three 
fractions (fraction 1 and 2) were not able to block cell proliferation in all three 
cancer cell lines. Fraction 3 blocked instead the cell proliferation in all three cancer 
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cell lines. The half minimal (50%) Inhibitory Concentration (IC50) of fraction 3 
were calculated for each cell line after 24 and 48 h: 
 MCF-7 cells: 72 and 67 g/mL after 24 and 48 h, respectively (Figure 5.3a); 
 MDA-MB231 cells: 73 and 44 g/ml after 24 and 48 h, respectively (Figure 
5.3b); 
 MDA-MB468 cells: 80 and 70 g/ml after 24 and 48 h, respectively (Figure 
5.3c). 
IC50 values are lower after 48 h than those observed after 24 h. 
 
Figure 5.3. Cell proliferation. Cell viability rate (CR) related to breast cancer cells: (a) MCF-7; (b) 
MDA-MB231; and (c) MDA-MB468, after treatment with fraction 3 for 24 (blue line) and 48 (red 
line) hours. 
 
On the basis of the results showed above, the Muse Annexin V and Dead Cell 
Assay was performed using the IC50 obtained after 48 h of treatment,  in order to 
evaluate the pro-apoptotic mechanism of the active fraction 3. An increase in the 
number of apoptotic cells (51.2% for MCF-7, 63.1% for MDA-MB231 and 56.6% 
for MDA-MB468 cell line) respect to the control (untreated cells), as shown in 
Table 5.1. 
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 LIVE (%) APOPTOSIS (%) DEAD (%) 
MCF-7 UNTREATED 94.8±2.4 3.8±2.6 1.4±0.8 
MCF-7 TREATED 47.8±1.8 51.2±1.1 0.9±0.4 
MDA-MB231 UNTREATED 97.7±3.2 2.1±2.3 0 
MDA-MB231 TREATED 36.4±3.9 63.1±2.5 0 
MDA-MB468 UNTREATED 96.3±2.4 3.5±2.3 0.30±0.05 
MDA-MB468 TREATED 38.7±3.2 56.6±3.1 3.9±0.9 
Table 5.1. Apoptosis. Percentage of live, apoptotic and dead cells expressed as mean ± 
standard deviation by the Muse Annexin V and Dead Cell assay in MCF-7, MDA-
MB231 and MDA-MB468 cells at IC50 concentration after 48h of treatment.  Untreated 
cells were used as the control. 
 
The difference in percentage of apoptotic cells revealed that the three cancer cell 
lines respond differently to the apoptosis assay. This phenomenon may be due to 
the different nature of cell lines. These differences in the percentage of apoptotic 
cells for the three breast cancer cell lines may be attributed to their different nature. 
MCF-7 cells are indeed estrogen-receptor-positive, while MDA-MB231 and MDA-
MB468 cells are estrogen-receptor-negative. In addition, MCF-7 cell line possess 
the wild-type tp53, a gene that codes for the protein  p53, which is a transcription 
factor that regulates the cell cycle acting as a tumour suppressor. The triple-negative 
human breast cancer cells, MDA-MB231 and MDA-MB468, have instead a 
mutated p53 gene, expressing therefore a more malignant phenotype.16,17 
To gain a better insight in the cell death mechanism the mRNA expression of some 
genes involved in the intrinsic (p53, Bax, p38 and caspase-3) and extrinsic 
(caspase-3 and caspase-8) pathways involved in the apoptotic process was 
evaluated through the RT-qPCR analysis (Figure 5.4). 
The expression of p53, Bax, p38, caspase-3 and caspase-8 increased significantly 
after 48 hour of treatment with fraction 3 in all the three breast cancer cell lines, 
indicating that both intrinsic and extrinsic pathways are involved in the apoptotic 
process.  
170 
 
 
 
Figure 5.4. RT-qPCR analysis: mRNA fold changes were evaluated as ratios between the expression 
levels of five genes in three breast cancer cell lines, MCF-7, MDA-MB231 and MDA-MB468, after 
treatment with the active fraction compared to the control (untreated cells). 
 
Cell cycle analysis was performed with the aim of understanding whether the active 
fraction was able to block the cell cycle. The effects of fraction 3 on the cell cycle 
were evaluated by treatment of the tumour cells with the IC50 obtained after 48 h. 
Negligible effects were observed for all the three cell lines (see Table 5.2), 
suggesting that the active fraction was able to induce apoptosis without interfering 
with the progression of the cell cycle. 
 
 G0/G1 S M 
MCF7 UNTREATED  51.7±2.3 17.3±2.7 30.7±1.7 
MCF7 TREATED  45.3±2.1 14.2±3.4 31.2±2.3 
MDAMB231 UNTREATED 59.1±3.2 16.9±3.9 21.8±2.4 
MDAMB231 TREATED  63.7±1.4 15.2±4.3 18.8±2.3 
MDAMB468 UNTREATED 47.1±3.9 16.9±4.5 33.7±1.8 
MDAMB468 TREATED  39.2±4.9 14.2±2.9 39.1±2.2 
Table 5.2. Cell percentages in the different cell cycle phases (G0/G1, S, G2 and M) 
expressed as mean ± standard deviation after Muse Cell cycle assay in MCF-7, MDA-
MB231 and MDA-MB468 cells at IC50 concentration after 48h of treatment. Untreated 
cells were used as the control. 
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Further studies were performed through 1H NMR analysis of the polar extracts of 
MCF-7, MDA-MB231 and MDA-MB468 cells before and after treatment with 
fraction 3 in order to identify the metabolomic pathways modulated by the active 
fraction. The Orthogonal Projections to Latent Structures discriminant analysis 
(OPLS-DA) revealed that the spectra recorded for the three cell lines clustered in 
different groups (Figure 5.5a). As depicted in Figures 5.5b-d (variable importance 
in projection (VIP) score plots), each of the cell lines showed statistically different 
proton signals and metabolites after treatment respect to the control (untreated 
cells). Fraction 3 essentially modulated the metabolites involved in glycolysis and 
in the metabolism of lipids and amino acids. More precisely, the level of lactate 
increased after treatment in all three cell lines whereas the levels of alpha- and beta-
glucose, choline, glycerophosphocholine, glutamine, glutamate and lipids 
decreased. A decreasing in the level of other metabolites differently decreased in 
the three cell lines: proline in MCF-7 cells, threonine in MDA-MB231 cells, 
asparagine and lysine in MDA-MB468 cells, while glycine in both MDA-MB231 
and MDA-MB468 cell lines. It is well known the key role of the glucose as a 
bioenergetic support in the development of most tumours. Cancer cells are indeed 
haracterised by a greater consumption of glucose through a different glycolysis 
pathway in comparison with normal cells, in which the pyruvate obtained by 
glycolysis is converted to lactate.18 The deprivation of glucose in cancer cells can 
therefore induce their death.19,20  
Fraction 3 was able to induce a decrease in glucose levels and an increase in lactate, 
that is turn due to the unbalanced conversion of glucose to lactate, in all three breast 
cancer cells. Since glutamine, glycine and glutamate originate from glycolysis 
intermediates,  a decrease in their levels may be correlated to a decrease of glucose. 
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In addition, lower levels of choline were observed after treatment of the three cancer 
cell lines with the active sponge fraction. Choline is an essential molecule in the 
formation of cellular membrane, being the head group of 80% of phospholipids 
(phosphatidylcholine and sphingomyelin) in the extrarnal part of the membrane. 
The alteration of choline metabolism is considered a metabolic marker associated 
to oncogenesis and tumor progression.21 Choline levels decreased after treatment, 
suggesting that fraction 3 was able to block tumour progression. 
 
  
(a) (b) 
  
 
Figure 5.5. OPLS-DA plot. (a) OPLS-DA and variable importance in projection (VIP) 
analysis where the metabolites increased or decreased in the endo-metabolome of (b) 
MCF-7, (c) MDA-MB231 and (d) MDA-MB468 cells after treatment with the active 
fraction from the sponge Geodia cydonium, compared to untreated cells.  
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Oncogenesis and tumour progression are often related to inflammatory processes. 
The methanol extract of G. cydonium, from which fraction 3 was obtained, 
previously showed an anti-inflammatory activity on the human breast cancer MCF-
7 cell line.3 Further studies were therefore carried out in order the establish whether 
fraction 3 was also able to modulate cytokines levels. After incubation of MCF-7, 
MDA-MB231 and MDA-MB468 cells with the IC50 of the active fraction obtained 
after 48 h, the cytokines levels were evaluated in the cellular supernatants (Figure 
5.6). Data showed that the levels of the pro-inflammatory cytokines VEGF, 
CXCL10, and IL-8 decreased. These three cytokines were shown to be related to 
tumours development.22,23,24 Moreover, a slight increase in levels of IL-4 and IL-10 
was observed. IL-4 and IL-10 are anti-inflammatory cytokines  which were proven 
to be involved in antitumor response.25 These data are in agreement with the 
previous results showing that the methanol extract of the sponge induced decrease 
in  pro-inflammatory cytokine levels in MCF-7 human breast cancer cell line.3 
 
Figure 5.6. Cytokine levels in breast cancer cells. Scheme reporting the cytokines 
modulated by the active fraction  obtained from the sponge Geodia cydonium. In 
particular, anti-inflammatory cytokines that are increased after treatment are reported in 
red and pro-inflammatory and pro-angiogenic cytokines that are decreased after treatment 
are reported in green. 
 
5.4 Conclusions 
The chromatografic purification of the methanol extract of the Mediterranean 
sponge G. cydonium yielded three most abundant fractions (fractions 1-3), which 
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were tested on three human breast cancer cell lines (MCF-7, MDA-MB231 and 
MDA-MB468). Among them, only fraction 3 was able to block the proliferation of 
the three cancer cell lines, but without interfering with the progression of the cell 
cycle. Moreover, this fraction showed any effect on the healty MCF-10A breast cell 
line. The combined use of LC-HRMS, LC-HRMS/MS and molecular networking 
as a dereplication strategy allowed to identify most of the compounds contained in 
the active fraction. These metabolites were shown to be involved in pro- or anti-
tumor processes, as confirmed by the analysis of the metabolomic profiling and 
cytokine levels observed in the three cancer cell lines after treatment with the active 
fraction. These results open up the possibility to use it for therapeutic purposes. 
Further studies are necessary to understand the mechanism of action of each 
compound present in fraction 3 and to evaluate the possible synergistic effect of a 
pool of compounds.  
 
5.5 Experimental section 
5.5.1  Collection, extraction, and separation 
A sample of the sponge Geodia cydonium (Order Tetractinellida, Family 
Geodiidae) was collected on July 2015 at 20 m depth by scuba diving in the “Parco 
Sommerso di Baia” (Gulf of Naples, Italy). After collection, the sample was 
immediately frozen and stored at −20 °C until extraction. The sponge (509 g wet 
weight) was homogenized and extracted with MeOH (2 × 2 L), MeOH and CHCl3 
in different ratios (2:1, 1:1, 1:2) and then with CHCl3 (2 × 2 L). The MeOH extracts 
were partitioned between H2O and n-BuOH; the BuOH layer was combined with 
the CHCl3 extracts and concentrated in vacuo. The resulting organic extract (3.9 g) 
was chromatographed by DCCC using CHCl3/CH3OH/H2O (7:13:8) in the 
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ascending mode; 6 mL fractions were collected and combined in ten fractions on 
the basis of their similar TLC retention times. The most abundant fractions were 
tested to evaluate their antiproliferative activity on three human breast cancer cell 
lines, MDA-MB231, MDA-MB468 and MCF-7, and the normal human breast 
epithelial cell line MCF-10A.  
5.5.2 LC-HRMS and LC-HRMS/MS and Molecular Networking Analyses 
Experiments were performed using a Thermo LTQ Orbitrap XL high-resolution 
ESI mass spectrometer coupled to an Agilent model 1100 LC system, which 
included a solvent reservoir, in-line degasser, binary pump, and refrigerated 
autosampler. A 5 μm Kinetex C18 column (50 × 2.1 mm), maintained at 25 °C, was 
operated using a gradient elution of H2O and MeOH running at 200 μL/mim. The 
gradient program was as follows: 10% MeOH for 5 min, 10%-100% MeOH over 
25 min, 100% MeOH for 13 min. All the mass spectra were recorded in the positive-
ion mode. MS parameters were a spray voltage of 4.8 kV, a capillary temperature 
of 285 °C, a sheath gas rate of 32 units N2 (ca. 320 mL/min), and an auxiliary gas 
rate of 15 units N2 (ca. 150 mL/min). Data were collected in the data-dependent 
acquisition (DDA) mode, in which the first and second most intense ions of a full-
scan mass spectrum were subjected to tandem mass spectrometry (MS/MS) 
analysis. MS/MS scans were obtained for selected ions with CID fragmentation, 
isolation width 2.0, normalized collision energy 36, Activation Q 0.250, and 
activation time 30 ms. Mass data were analyzed using the Thermo Xcalibur 
software. 
A molecular network was created using the online workflow at GNPS. The data 
was then clustered with MS-Cluster with a parent mass tolerance of 2.0 Da and a 
MS/MS fragment ion tolerance of 0.5 Da to create consensus spectra. Further, 
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consensus spectra that contained less than 2 spectra were discarded. A network was 
then created where edges were filtered to have a cosine score above 0.6 and more 
than 6 matched peaks. Further edges between two nodes were kept in the network 
if and only if each of the nodes appeared in each other's respective top 10 most 
similar nodes. For dereplication purposes the spectra in the network were then 
searched against GNPS' spectral libraries. All matches kept between network 
spectra and library spectra were required to have a score above 0.6 and at least 6 
matched peaks. Analog search was enabled against the library with a maximum 
mass shift of 100.0 Da. The data were then imported into Cytoscape 3.2.1 
(http://www.cytoscape.org/) and displayed as a network of nodes and edges. The 
network was organized with the preferred layout plug-in. 
 
5.5.3 Cell culture 
Three human breast cancer cell lines, MDA-MB231, MDA-MB468 and MCF-7, all 
derived from adenocarcinoma metastasis and on normal human breast epithelial 
cells MCF-10A were used. In particular, MCF-7 and MCF-10A cells were 
expanded at 37oC in a humidified atmosphere of 5% CO2 in culture medium 
DMEM (Dulbecco’s Modified Eagle’s Medium, Lonza), whereas MDA-MB-231 
and MDA-MB-468 in RPMI 1640 (Lonza), supplemented with FBS (Invitrogen, 
Camarillo, CA, USA) at 10%, Penicillin/Streptomycin 100x (Euroclone, Devon, 
UK), Glutamax 100x (Invitrogen) non-essential amino acids 100x (Invitrogen). 
Moreover, in the case of MCF-10A the DMEM was supplemented also with human 
insulin 10µg /mL (Life Technologies Corporation, Carlsbad, CA, USA), human 
epidermal growth factor 20ng/mL (Life Technologies), and hydrocortisone 
0.5µg/mL (Sigma-Aldrich) according to the procedure reported in Rothwell et al. 
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(2014), while for MDA-MB468 the medium was implanted with Ham’s F-12 
medium (1:1 mixture). Phosphate buffer (PBS phosphate buffered saline Ca2+ and 
Mg2+ free) and trypsin (Ca2+ and Mg2+ free) were supplied by Euroclone. Finally, 
the cells were kept in an incubator at a humidified atmosphere of 95% air and 5% 
CO2 at 37°C. 
 
5.5.4 Cell treatment and cell proliferation assay 
Cell proliferation of cancer cells was assessed in the presence and absence of the 
methanol extract from G. cydonium by colorimetric assay with sulforhodamine B 
(SRB, Sigma Aldrich). This extract was first dissolved in dimethyl sulfoxide 
(DMSO 100mM, Sigma-Aldrich) at concentrations < 0.1%, so as not to induce toxic 
effects on cells. Thus, a stock solution (100 mg/mL) and its serial dilutions had a 
final concentration of DMSO of 0.05%.  
Cancer cells were plated in 96 well tissue culture plates at a concentration of 15x103 
cells per well and allowed to attach for 24h. Cells were then treated with different 
concentrations of the methanol extract (2.5 µg/mL, 5 µg/mL, 10 µg/mL, 25 µg/mL, 
50 µg/mL, 100 µg/mL, 200 µg/mL) and incubated for 24h and 48h. These 
concentrations were selected on the basis of a recent paper.3  After 48h of treatment, 
cells were fixed with trichloroacetic acid (Sigma Aldrich, St. Louis, MO, USA) for 
1h at 4°C.  Subsequently they were stained for 30 min with 0.4% (wt/vol) 
sulforhodamine B (SRB, Sigma Aldrich) dissolved in 1% acetic acid. The number 
of viable cells was directly proportional to the amount of protein bound-dye which 
was then solubilized with 10mM Tris base solution (pH10.5) and measured at 
540nm using the ELISA fluorometric assay (Bio-Rad, Hercules, CA, USA; 
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Microplate Reader). All experiments were performed in duplicate and repeated 
three times. The IC50 was assessed from the dose-response curves. 
 
5.5.5 Apoptosis evaluation  
After counting, 3 x 105 cells were harvested and washed twice with ice-cold PBS. 
Cells were labeled with an Annexin V and Dead Cell Assay kit according to the 
manufacturer’s instructions (Merck Millipore, Darmstadt, Germany).  The kit 
detects the externalization of phosphatidylserine (PS) in apoptotic cells using 
fluorescently-labeled Annexin V in combination with the dead cell marker 7-
aminoactinomycin D (7-AAD). We identified four populations of cells: (1) viable 
cells that did not undergo detectable apoptosis: Annexin V (-) and dead cell marker 
(-); (2) early apoptotic cells: Annexin V (+) and dead cell marker (-); (3) late 
apoptotic cells: Annexin V (+) and dead cell marker (+); and (4) cells that died via 
non-apoptotic pathways: Annexin V (-) and dead cell marker (+). Cells were 
counted using the Muse™ Cell Analyzer (Merck Millipore) and analyzed using a 
software provided by Merck Millipore. 
 
5.5.6 Cell cycle assay 
1x106 cells were counted for the Muse™ Cell Cycle Assay that consisted in the use 
of the nuclear DNA intercalating stain RNAse A and propidium iodide (PI) in a 
proprietary formulation. The latter was used to discriminate cells in different phases 
of the cell cycle, based on differential DNA content in the presence of RNAse to 
increase the specificity of DNA staining. After treatment with the active G. 
cydonium fraction, cells were washed with Phosphate buffered saline (PBS) and 
centrifuged. The supernatant was removed and 1mL of ice cold 70% ethanol was 
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added to the re-suspended cell pellet. Samples were capped and frozen at -20°C for 
at least 3h prior to staining. Ethanol-fixed cells were washed with PBS and 
incubated with 200μL of Muse™ Cell Cycle Reagent for 30 min at room 
temperature, in the dark. After staining, cells were processed for cell cycle analysis. 
 
5.5.7 Extraction of the polar fractions in untreated and treated cancer cells 
All cancer cell lines were plated in cell culture flasks (~2x106cells/flask) and treated 
with the active fraction at the IC50 concentration obtained after 48h treatment. After 
incubation time (48h), cellular supernatants were collected and stored at -80 °C for 
further investigation. Cell pellets obtained by trypsin digestion were washed twice 
in Phosphate buffered saline and deuterated water (PBS-D2O) and refrigerated at -
80 °C. Subsequently they were re-suspended in 170µL of H2O and 700µL of 
methanol and were sonicated for 30 s. 350µL of chloroform was added and cell 
pellets were shaken on ice in an orbital shaker for 10 min. H2O/chloroform (350µL, 
1:1, v/v) was added to each cell suspension and centrifuged at 10,000 rpm for 10 
min at 4°C. Thereafter, the aqueous (polar) and lipophilic (apolar) phases were 
collected separately and evaporated by SpeedVac system.  
 
5.5.8 1H-NMR Metabolomic Analysis of the cellular polar fractions 
A 600-MHz BrukerAvance DRX spectrometer with a TCI probe was used to 
acquire 1H spectra on the cellular polar fractions. They were dissolved in 630 µLof 
PBS-D2O with the pH adjusted to 7.20, and 70 µL of sodium salt of 3-
(trimethylsilyl)-1-propanesulfonic acid (1% in D2O) used as the internal standard.  
All 1H-NMR spectra were acquired at 300 K with the excitation sculpting pulse 
sequence to suppress water resonance. A double-pulsed field gradient echo was 
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used, with a soft square pulse of 4 ms at the water resonance frequency and with 
gradient pulses of 1 ms duration, adding 128 transients of 64 k complex points, with 
an acquisition time of 4 s/transient. Time domain data were all zero-filled to 256 k 
complex points and an exponential amplification of 0.6 Hz was applied prior to 
Fourier transformation. 
 
5.5.9 Statistical and Pathway Analysis 
The spectral 0.50–8.60 ppm region of 1H-NMR spectra was integrated in buckets 
of 0.04 ppm by the AMIX package (Bruker, Biospin GmbH, Rheinstetten, 
Germany). The water resonance region (4.5–5.2 ppm) was excluded during the 
analysis and the bucketed region was normalized to the total spectrum area using 
Pareto scaling. Orthogonal Projections to Latent Structures discriminant analysis 
(OPLS-DA) was used to compare the spectra obtained on the polar phases from 
three breast cancer cell lines before and after treatment because OPLS-DA can more 
effectively cope with chemical shift variation in full-resolution 1H NMR datasets26 
without requiring binning or alignment steps. Pathway analysis on the metabolites 
that were modulated after treatment was performed using Metabo Analyst tool.27  
 
5.5.10 Bio-Plex Assay 
Several cytokines, chemokines, and growth factors levels were evaluated 
concurrently with the Bio-Plex assay that containing dyed microspheres conjugated 
with a monoclonal antibody highly specific for a target protein. The method was 
carried out according to the manufacturer’s instructions (Bio-Plex Bio- Rad) to 
assess the cytokines levels. The Bio-Plex Pro Human Cytokine 27-Plex 
Immunoassay has been used on supernatants of the three lines of human breast 
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cancer after treatment with sponge extract concentrations. This panel consists of: 
IL-1𝛽, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, CCL2, CCL11, CXCL10, CXCL8, IFN-
𝛾, IL-9, IL-10, IL-12 (p70), IL-13, IL-15, IL-17, basic FGF, G-CSF, GM-CSF, 
MIP-1𝛼, MIP-1𝛽, PDGF-𝛽𝛽, RANTES, TNF-𝛼, and VEGF. Protein levels were 
determined using a Bio-Plex array reader (Luminex, Austin, TX, USA) that 
quantifies multiplex immunoassays in a 96-well format with very small fluid 
volumes. The analyte level was calculated using a standard curve, with software 
provided by the manufacturer (Bio-Plex Manager Software). A Bio-Plex array 
reader (Luminex, Austin, TX, USA) that quantifies multiplex immunoassays in a 
96-well format with very small fluid volumes, has been used for protein level 
determination. The levels of the analytes were calculated using a standard curve, 
with the Bio-Plex Manager Software provided by the manufacturer.  
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 Conclusion 
 
Today the synthesis of new bioactive compounds is the key step of the biomedical 
research, enabling chemists and biologists to advance their researches to higher 
levels. During my PhD I pursued both the advanced synthesis of new compounds 
and the investigation of pharmacological properties of new metabolites isolated 
from marine sponges. 
The asymmetric convergent total syntheses of 16-epi- and ent-smenamide A, two 
structural analogues of the cytotoxic smenamide A, were carried out in 23 steps 
with a 2.5% and 2.6% overall yield, respectively. Afterwards, eight shorter-chain 
“functional analogues” of 16-epi-smenamide A were designed and prepared using 
a flexible synthetic route in order to gain a better insight in the biological activity 
of smenamides family.  
On the other hand, I was involved in the study of the chemical composition of two 
marine sponges, the Caribbean Smenospongia conulosa and the Mediterranean 
Geodia cydonium. Two new chlorinated compounds, namely conulothiazole A and 
B, were isolated from the organic extract of S. conulosa. At the same time, using a 
novel dereplication strategy, involving the use of LC-HRMS and LC-HRMS/MS 
coupled with a bioinformatic technique, e.g. Molecular Networking, an active 
subfraction of the organic extract of G. cydonium was identified. This fraction 
showed moderate antiproliferative activity on three human breast cancer cell lines 
(MCF-7, MDA-MB-231 and MDA-MB-468) and no toxicity on the healty MCF-
10A human breast cell line. 
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Although the study of the chemical composition of marine organisms is an 
intruiguing research field, I was totally fascinated by the challenges posed by the 
total synthesis, “the endeavour of synthesizing the molecules of living nature in the 
laboratory”.1 
 
  
186 
 
 
References 
1 K. C. Nicolaou, Proc. R. Soc., 2014, A 470: 20130690. 
                                                          
